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Summary 
 
Human essential hypertension is a substantial public health problem with greater 
than 25% of the adult population affected worldwide.  It is a complex disorder 
and a major risk factor for various cardiovascular diseases such as heart disease, 
renal disease and stroke.  The stroke-prone spontaneously hypertensive rat 
(SHRSP) is a commonly used model of human essential hypertension.  Previous 
studies identified a quantitative trait locus (QTL) for blood pressure regulation 
on rat chromosome 2.  To further enhance the investigation of this QTL, rat 
chromosome 2 congenic strains were generated by transferring regions of 
chromosome 2 from the normotensive WKY onto the genetic background of the 
SHRSP.  Congenic strains exhibited significantly lower blood pressure than the 
SHRSP parental strain indicating that genes within the congenic region are 
important for blood pressure regulation.  Renal microarray analysis of congenic 
2c* and parental strains led to the identification of glutathione s-transferase mu 
type 1 (Gstm1) as a positional and possible functional candidate gene for 
hypertension in the SHRSP.  Expression of Gstm1 was significantly lower in the 
SHRSP kidney than in 2c* and WKY and renal oxidative stress was increased in 
SHRSP.  Glutathione s-transferase mu type 1 is part of a large family of 
antioxidant enzymes and may play a role in hypertension by modulating levels of 
oxidative stress. 
 
This study has utilised small RNAs to examine the role of Gstm1 in cellular 
oxidative stress and also investigated microRNA (miRNA) expression in the rat 
congenic strains.  RNA interference (RNAi) was utilised to knock-down expression 
of Gstm1 in a rat kidney tubular epithelial cell line (NRK-52E).  Three different 
short interfering RNA (siRNA) sequences designed to target Gstm1 were 
evaluated.  Each sequence significantly reduced expression of Gstm1 and was 
confirmed at both mRNA and protein level.  Off-target effects on other Gstm 
isoforms and the interferon response gene, oligoadenylate synthetase 1 were 
prevented by reducing the concentration of siRNA used.  To take knock-down of 
Gstm1 expression into an in vivo setting, local delivery to the kidney via the 
renal artery was assessed but was found to cause significant kidney damage.  
Instead, kidney targeted vectors that can be delivered systemically were 
evaluated in the SHRSP.  Immunohistochemistry confirmed specific targeting of 
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kidney tubules.  Plasmid vectors were then generated that express Gstm1 
specific short-hairpin RNA (shRNA) molecules based on the sequences that 
successfully knocked down Gstm1 expression in vitro.  Transfection of these 
plasmids into NRK-52E cells was poor and knock-down of Gstm1 could not be 
confirmed.   
 
The role of Gstm1 in protection against cellular oxidative stress was evaluated in 
NRK-52E cells by measuring markers of oxidative stress following knock-down of 
Gstm1 expression.  Total GST activity was not reduced in cells transfected with 
Gstm1 specific siRNA however activity was increased following over-expression 
of Gstm1.  No change in the levels of reduced glutathione was observed in cells 
following knock-down of Gstm1.  Oxidative stress was determined by measuring 
8-isoprostane (a marker of lipid peroxidation), 8-hydroxy-2-deoxyguanosine (8-
OH-dG) (a marker of oxidative DNA damage) and by the comet assay (DNA 
damage).  No significant difference in the levels of 8-isoprostane or 8-OH-dG was 
observed in cells treated with Gstm1 specific siRNA compared to control siRNA.  
However a small but significant increase in ‘comet’ tail length was observed in 
cells with reduced Gstm1 expression indicating greater DNA damage in these 
cells. 
 
Two miRNAs that map to the chromosome 2 congenic regions were investigated 
(miR-137 and miR-9-1).  The expression of each miRNA was investigated in 
kidney from SHRSP, WKY and congenic rat strains at 5, 16 and 21 weeks of age.  
Expression of miR-9-1 was unchanged in the SHRSP but was significantly reduced 
in 16 week 2c* and WKY compared to 5 week.  Expression of miR-137 was 
unchanged in both WKY and 2k but was significantly increased in 21 week old 
salt-loaded SHRSP compared to 21 week old SHRSP without salt.  Successful 
over-expression of each miRNA was demonstrated in NRK-52E cells but inhibition 
of each miRNA could not be confirmed.  MicroRNA target prediction methods 
were employed to identify potential gene targets for each miRNA.  A list of 
predicted targets for each miRNA was generated and combined with gene 
expression datasets generated from 5 week, 16 week, 21 week and 21 week plus 
salt  kidney microarray analysis carried out previously.  Using Ingenuity Pathway 
Analysis software, predicted target genes were identified according to patterns 
of expression.  Analysis of predicted miR-137 targets failed to find any genes 
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that followed the correct pattern of expression (down-regulated in SHRSP but 
unchanged in both WKY and 2k).  Of the targets predicted for miR-9-1, seven 
were identified that were up-regulated in both WKY and 2c* but not SHRSP.   
The expression levels of each of the seven genes were assessed in kidney and 
NRK-52E cells over-expressing miR-9-1 however none of the predicted targets 
could be validated. 
 
In summary, a wide range of techniques have been employed in an attempt to 
investigate the function of Gstm1 and the possible role of miRNA that map to the 
congenic regions implicated in blood pressure regulation.  Although a specific 
role for Gstm1 in protection against oxidative stress has yet to be fully 
determined, the integration of targeted vectors and modulation of Gstm1 
expression will allow the role of Gstm1 to be investigated more fully in vivo.   
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Chapter 1: Introduction 
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1.1 Cardiovascular Disease 
 
The Global Burden of Disease Study carried out by the World Health Organisation 
(WHO) identified cardiovascular disease (CVD) as the leading cause of death in 
the world, accounting for ~32% of all deaths in women and ~27% in men in 2004 
(1). Cardiovascular diseases are disorders of the heart and vascular system 
serving the heart, brain, kidney and other vital organs and include coronary 
heart disease, heart failure, stroke, peripheral vascular disease and renal 
disease.  Of these disorders, ischaemic heart disease and cerebrovascular 
disease are responsible for the majority of deaths worldwide with 12.2% and 
9.7% of total deaths attributed to each cardiovascular disorder respectively.  In 
2004, CVD was responsible for 17.1 million deaths globally and this has been 
projected to increase to 23.4 million by 2030 (1).  According to the British Heart 
Foundation Statistics Website, CVD is responsible for ~40% of deaths in the UK 
with coronary heart disease (CHD) as the most common cause.  In terms of 
economic costs, CVD is a substantial problem.  It is estimated that CVD costs the 
UK economy ~£30.7 billion a year, with CHD alone costing ~£9 billion (2).  It is 
clear that investigation into the causes of CVD is of great benefit to public 
health. 
 
1.1.1 Risk Factors 
 
There are various modifiable risk factors for CVD including being overweight or 
obese, smoking, dyslipidaemia, type 2 diabetes and hypertension.  Mortality 
from CHD is approximately 60% higher in smokers than non-smokers and this is 
increased to 80% in heavy smokers.  Passive smoking is also detrimental to CV 
health, with an approximate 25% increased risk of CHD in those regularly 
exposed to second hand smoke.  Estimates from the INTER-HEART case control 
study suggest that smoking is responsible for ~30% of heart attacks in Western 
Europe.  As well as smoking, abdominal obesity has also been identified as a 
major cause of heart attacks and is deemed to be a more significant risk factor 
than body mass index (BMI) (3).  Studies on obesity and weight gain have 
demonstrated increased incidence of CV events.  Being overweight or obese is 
also a risk factor for raised blood cholesterol, hypertension and type 2 diabetes, 
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further contributing to CVD risk (4).  Increased total blood cholesterol is 
estimated to be responsible for ~60% of cases of CHD and ~40% of strokes in 
developed countries.  Abnormal lipids have also been identified as a major 
contributing factor to heart attack risk (3).  Cardiovascular disease is a major 
cause of death in people with type 2 diabetes accounting for approximately 50% 
of all diabetic fatalities.  Those with type 2 diabetes are 2 times more likely to 
suffer a heart attack or stroke.  Coronary heart disease risk is 2 to 4 fold greater 
in men and 3 to 5 fold greater in women with diabetes (5).                
 
1.1.1.1 Hypertension 
 
Hypertension is responsible for approximately 6% of adult deaths worldwide and 
is a major contributing factor to cardiovascular disease. Hypertensive patients 
present an increased risk of developing various cardiovascular complications 
such as stroke, heart disease, heart failure and end-stage renal disease (6-10).  
Many studies have been carried out that show that even mild increases in blood 
pressure can dramatically increase the risk of a cardiovascular event.  For every 
20mmHg increase in SBP and 10mmHg increase in DBP, the mortality rate from 
cardiovascular disease doubles (11).  It has also been shown that having high 
normal blood pressure, defined as systolic BP 130-139mmHg and diastolic BP of 
85-89mmHg (see Table 1.1), can result in an increased risk of developing 
cardiovascular disease in both men and women (12).  
 
Table 1.1: Blood Pressure Classification  
Blood Pressure Category Systolic BP (mmHg) Diastolic BP (mmHg) 
NORMAL <120 <80 
HIGH NORMAL  130-139 85-89 
HYPERTENSION >140 >90 
STAGE 1 140-159 90-99 
STAGE 2 >160 >100 
 
Adapted from (11) 
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Clinical trials investigating the efficacy of antihypertensive therapies 
demonstrate that even small reductions in blood pressure can quite considerably 
reduce incidence of stroke, heart disease and other CV events (13). 
 
Hypertension is often found in conjunction with other cardiovascular risk factors 
such as, insulin resistance, dyslipidaemia and obesity (14).  These features 
together comprise what is commonly described as the metabolic syndrome.  
Data collected from the Framingham Heart Study found that hypertension is 
present as a single CVD risk factor in less than 20% of cases (15).  The presence 
of a single risk factor at age 50 is associated with increased risk of 
cardiovascular disease, this risk increases substantially when 2 or more risk 
factors are present.  As well as a greater likelihood of developing CVD, risk 
factor clusters also substantially reduce survival.  
  
1.1.1.2 Blood Pressure Regulation 
 
Normal blood pressure is defined as systolic blood pressure less than 120mmHg 
and diastolic pressure less than 80mmHg and can be described as the product of 
cardiac output and total peripheral resistance (11).  Blood pressure is 
determined by many, complex regulatory mechanisms including the sympathetic 
nervous system, various chemical and hormonal controls that affect vascular 
resistance (see Figure 1.1) and local controls such as flow auto-regulation with 
the kidneys playing a major role in blood pressure control by regulating sodium 
and fluid balance (Figure 1.2).  The importance of the kidney in blood pressure 
regulation was demonstrated in rat kidney transplant studies.  Young 
hypertensive rats receiving kidneys from a normotensive rat strain did not 
develop hypertension, conversely, when kidneys from young hypertensive rats 
(before the onset of hypertension) were transplanted into normotensive rats, 
blood pressure was found to increase (16;17).  
 
The renin-angiotensin system (RAS) is an important regulator of blood pressure 
and fluid balance.  This system comprises an enzymatic cascade that results in 
the production of the potent vasoconstrictor angiotensin II (Ang II) (18).  The 
cascade begins with the synthesis and release of the enzyme renin from the 
juxtaglomerular cells in response to various stimuli.   
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Figure 1.1 Factors regulating vascular tone 
Vascular tone is subject to various hormonal, local and neuronal controls 
contributing to both vasoconstriction and vasodilation. 
α1-AR: alpha 1-adrenergic receptor, β2-AR: beta 2-adrenergic receptor, NO: 
nitric oxide   
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Figure 1.2 Factors contributing to blood pressure regulation 
Arterial pressure can be defined as the product of cardiac output and total 
peripheral resistance and is affected by a range of complex regulatory 
mechanisms. 
 
Adapted from (19)  
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Figure 1.3 Renin-Angiotensin System 
ACE: angiotensin converting enzyme, ACE2: ACE-related carboxypeptidase, AT1: 
angiotensin II type 1 receptor, AT2: angtiotensin II type 2 receptor 
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Angiotensinogen, produced in the liver, is the substrate for renin and is 
converted to the inactive angiotensin I.  Angiotensin I is then cleaved to produce 
the active angiotensin II by angiotensin converting enzyme (ACE).  Angiotensin 
converting enzyme can also cleave bradykinin, a vasodilator and in doing so, 
further contributes to vasoconstriction.  Angiotensin II mediates its actions 
through two receptors; AT1 and AT2 (20).   Binding of Ang II to the AT1 receptor 
leads to vasoconstriction and increased retention of sodium in the kidneys.  Ang 
II also stimulates secretion of aldosterone leading to further re-absorption in the 
kidney resulting in increased blood pressure. The AT2 receptor when bound by 
Ang II counteracts the effects produced via the AT1 receptor by stimulating 
vasodilation.  More recently, a human homologue of ACE has been discovered.  
This ACE-related carboxypeptidase (ACE2) acts on Ang I and catalyses its 
cleavage to produce angiotensin 1-9 (Ang 1-9) and subsequent generation of 
angiotensin 1-7 (Ang 1-7) (21).  Ang 1-7 has also been shown to interact with the 
G protein coupled receptor Mas.  Deletion of this receptor in mouse kidney 
completely abolished Ang 1-7 binding and receptor deficiency in aortas resulted 
in diminished dilatory response, indicating that Ang 1-7 interacts with the Mas 
receptor and in doing so induces vasodilation (22) (Figure 1.3). 
 
1.2 Essential Hypertension 
 
Human essential hypertension is a substantial public health problem, with 
greater than 25% of the adult population affected (23).  It is commonly defined 
as systolic pressure greater than 140mmHg and diastolic pressure greater than 
90mmHg (11).  Most cases of hypertension (>90%) are of unknown cause with 
many possible contributing factors.  Hypertension is a complex disorder that is 
subject to both environmental and genetic factors.  Non-modifiable risk factors 
such as gender, age and race have been shown to influence blood pressure.  
Blood pressure is sexually dimorphic where men tend to have higher blood 
pressure than women and systolic pressure is found to increase with age (24).  
Diastolic pressure also increases progressively in both men and women until 
approximately sixty years of age, after which time it begins to decrease.  
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1.2.1 Environmental Factors 
 
Environmental factors such as diet, salt intake and weight all have an impact on 
blood pressure and it has been shown that by modifying diet or losing weight, 
blood pressure can be reduced (25-28).  The DASH (Dietary Approaches to Stop 
Hypertension) trial investigated the blood pressure lowering effects of adopting 
a diet rich in fruits and vegetables and placed emphasis on low fat dairy 
products to help reduce total fat and saturated fat consumption.  By modifying 
diet in this way a significant reduction in both systolic and diastolic pressure was 
observed (25). A minimal increase in age related blood pressure has been 
observed in populations where a very low sodium diet is consumed.  However, in 
those populations consuming greater than 20g of salt per day, there is a much 
higher prevalence of hypertension (17).  Alcohol consumption has also been 
associated with hypertension and studies have shown that by decreasing alcohol 
intake, blood pressure can be reduced (29;30).   
 
Within the general population being overweight (assessed by BMI) is a major 
contributor to the onset of hypertension with greater than 40% of new onset 
hypertension attributable to being overweight.  Increased body fat has also been 
found to be associated with hypertension, particularly centrally located body fat 
(4;11).   
 
1.2.2 Genetics and Hypertension 
 
Genetics play an important role in hypertension with approximately 30% 
attributed to genetics in combination with the environmental issues mentioned.  
Population studies found that blood pressure varied less within families than 
between families (31) and the NHLBI twin study identified greater genetic 
heritability of blood pressure in monozygotic twins than dizygotic twins (32).   
 
1.2.2.1 Mendelian Forms of Hypertension 
 
Most genetic studies of hypertension have focused on the Mendelian forms of the 
disorder, which are characterised by altered renal salt handling.  Glucocorticoid-
remediable aldosteronism (GRA) is an autosomal dominant disorder that results 
 28 
in hypertension due to aberrant aldosterone synthesis and can be inhibited by 
treatment with glucocorticoids.  It is characterised by low plasma renin activity 
and normal or raised aldosterone levels (33).  Those with GRA have a form of 
salt sensitive hypertension, often associated with metabolic alkalosis and 
hypokalaemia.  The disorder is caused by unequal crossing over between two 
closely related genes.  These genes are CYP11B1, which encodes 11 β-
hydroxylase and CYP11B2, which encodes aldosterone synthase.  This crossing 
over results in the production of a chimeric gene where aldosterone synthase is 
under the control of an adrenocorticotropic hormone (ACTH) dependent 
promoter.  Instead of responding to Ang II, which normally regulates aldosterone 
synthase, aldosterone synthesis is stimulated by ACTH and is continuously 
produced.  This increase in aldosterone causes salt retention leading to 
increased plasma volume and suppression of renin excretion.     
 
Liddle’s syndrome is an autosomal dominant hypertensive disorder characterised 
by low renin levels and suppressed aldosterone secretion.  It is caused by gain of 
function mutations in the β or γ subunits of the epithelial Na+ channel (ENaC) so 
that the channel remains activated allowing for continued sodium re-absorption 
(34).  This increase in salt retention leads to hypertension.  
 
Pseudohypoaldosteronism type II (PHAII) or Gordon’s syndrome is caused by 
mutations in two genes belonging to the WNK family of kinases.  These genes are 
WNK1 and WNK4 and are expressed in the distal part of the nephron (35).  
Gordon’s syndrome is associated with increased renal salt absorption, 
hyperkalaemia and low plasma renin and aldosterone levels.  
 
Apparent mineralocorticoid excess (AME) is an autosomal recessive disorder that 
is associated with hypokalaemia, metabolic alkalosis and suppressed plasma 
renin activity with almost no circulating aldosterone present.  It is caused by the 
absence of 11β-hydroxysteroid dehydrogenase (11βHSD), the enzyme responsible 
for conversion of cortisol to cortisone.  Studies involving the use of antagonists 
of the mineralocorticoid receptor (MR) resulted in reduced blood pressure in 
patients with AME suggesting that a mineralocorticoid other than aldosterone 
can activate MR (36).  Further investigation did not indentify another circulating 
mineralocorticoid but instead found that patients with AME do not produce 
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11βHSD thereby reducing their ability to convert cortisol to cortisone.  
Subsequent in vitro studies and cloning of MR found that cortisol can bind and 
activate MR to a similar degree as aldosterone so that in the absence of 
aldosterone in these patients, MR can still be activated and result in increased 
ENaC activity.       
 
1.2.2.2 Genetics of Essential Hypertension 
 
These studies have identified various mechanisms by which hypertension can 
occur but do not provide the answer to the problems posed by the more complex 
and polygenic nature of essential hypertension.  Monogenic forms of 
hypertension are very rare and account for less than 1% of all human 
hypertension.   
 
1.2.2.3 Candidate Gene Analysis 
 
Many candidate gene studies have been carried out to assess the association of 
genes that are implicated in BP variation with essential hypertension.  Such 
genes fall into five broad categories: renin angiotensin aldosterone system 
(RAAS), adrenergic, vascular, metabolic and those with miscellaneous roles.  
However results within each category are conflicting and no candidate gene has 
shown consistent association with hypertension.  This lack of reproducibility 
demonstrates the difficulty of trying to identify the genetic causes of complex 
disease.   
 
The angiotensinogen gene (AGT) has been extensively studied in an attempt to 
identify an association with essential hypertension.  Sib-pair linkage analysis 
identified significant linkage of the AGT gene locus to hypertension in two 
separate populations.  However, in one of these populations, only a subset of 
participants with more severe hypertension demonstrated linkage.  A common 
variant in this gene (M235T) was identified and found to be significantly more 
frequent in hypertensive subjects than controls (37).  This variant has been 
shown to associate with hypertension in several but not all populations studied 
(38;39).  A meta-analysis of combined case-control studies found that the T 
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allele associated with risk of hypertension in Caucasians but not Blacks or Asians 
(40).  However this association found in Caucasians may be due to a publication 
bias with a lack of studies with negative results present in the meta-analysis.   
 
Another candidate gene related to RAAS is the gene encoding angiotensin 
converting enzyme (ACE).  Much work has been done to identify an association 
between ACE and essential hypertension but again the results have been 
conflicting.  Jeunemaitre et al reported that there is no linkage between the 
ACE locus and essential hypertension following sib-pair linkage analysis of a 
marker linked to the ACE locus. The total population was then split into sub-
groups to try and reduce heterogeneity in the population, but still no linkage 
with hypertension was found (41).  However, a further two population studies 
identified association of ACE with hypertension in men but not women 
suggesting that ACE may be a sex specific candidate gene for hypertension 
(42;43).  Again, no definitive conclusion can be drawn as results are not 
consistent (44).  
 
The cytoskeletal protein adducin has also been implicated in hypertension.  
Adducin is composed of three subunits; α, β and γ encoded by ADD1, ADD2 and 
ADD3 respectively and may play a role in sodium re-absorption in the renal 
tubule.  Studies in the Milan hypertensive rat strain identified point mutations in 
α and β-adducin coding sequence resulting in amino acid substitutions.  The 
Add1 gene mutation was found to associate with blood pressure and when a 
region encompassing the Add1 locus was transferred from a hypertensive donor 
to a normotensive rat strain, blood pressure in the recipient increased (45-47).  
Several human studies have sought to establish a relationship between the α-
adducin gene (ADD1) and blood pressure (17;45).  A case control study 
performed in 190 hypertensive patients and 126 control subjects found 
significant linkage of markers surrounding the ADD1 locus to hypertension.  The 
greatest association was found with the marker closest to the adducin locus 
however this does not exclude the possibility that another gene in this region 
contributes to the blood pressure variation observed (48).  Linkage of 
hypertension to the ADD1 locus was confirmed in another population and cDNA 
analysis identified a mutation causing an amino acid substitution (G460W).  This 
polymorphism was found to significantly associate with hypertension in both 
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populations used in this study (49).  However, a more recent study found no 
association of the G460W polymorphism with hypertension (50).  The ADD2 gene 
encoding the β-adducin subunit has also been investigated for its association 
with hypertension, with conflicting results.  A study of the C1797T polymorphism 
in three European populations found that presence of the T allele was associated 
with increased blood pressure in two out of the three populations (51).         
 
1.2.2.4 Genetic Linkage and Association Studies 
 
Various genome wide linkage and association studies have been undertaken to 
attempt to identify genetic regions that are responsible for blood pressure 
phenotype in essential hypertension.  One advantage of such studies is that no 
prior information of genetic function is required.    
 
1.2.2.5 Linkage Analysis 
 
Genome wide linkage studies are possible due to the vast number of 
microsatellite and single nucleotide polymorphism (SNP) markers spread 
throughout the genome.  This combined with recent technological advances 
allow the location of chromosomal regions or quantitative trait loci (QTLs) linked 
to hypertension to be identified.  By finding markers that associate with blood 
pressure phenotype, the location of a QTL can be determined.   Using this 
approach, numerous QTLs relating to hypertension or blood pressure have been 
found throughout the human genome.  However these studies have been poorly 
replicated due to the polygenic and multi-factorial nature of hypertension. 
Multiple loci have been found on some chromosomes suggesting that it is unlikely 
that a single genomic region is responsible for predisposition to hypertension 
(19;52).   
 
In an attempt to improve the likelihood of detecting QTLs for essential 
hypertension, the MRC British Genetics of Hypertension (BRIGHT) study was 
performed on sibling pairs from families with severe early onset hypertension.  
Individuals were only selected for the study if non-diabetic, non-obese with no 
history of secondary hypertension and with blood pressure in the top 5% of the 
 32 
blood pressure distribution in the UK.  Linkage analysis identified a locus on 
chromosome 6 and 3 further regions that have suggested linkage on 
chromosomes 2, 5 and 9 (53).  Further analysis of this data with additional 
microsatellite markers reinforced support for linkage of essential hypertension 
with chromosome 5 (54).  However, analysis supporting linkage to chromosome 6 
should be regarded with care as the locus is present near the end of the 
chromosome.  Analysis of such regions by linkage computer programs can 
produce misleading results (55).  The Family Blood Pressure Program (FBPP) 
study was a meta-analysis of four separate family studies designed to identify 
linkage to hypertension through genome wide linkage scans.  The study involved 
over 6000 individuals but failed to identify any hypertension related QTLs, 
indicating that blood pressure is not subject to control by single genomic regions 
but by many loci imparting small effects on phenotype (56). 
 
1.2.2.6 Genome Wide Association Studies 
 
Genome wide association studies utilise the availability of SNP markers to carry 
out large scale association mapping and involve comparisons of allele frequency 
throughout the genome in a case-control design.  This approach is unbiased as no 
assumptions are made regarding the genomic location of genetic variants that 
may have an affect on phenotype.  Such studies have been made possible due to 
the availability of high throughput technologies and genome wide determination 
of genetic variation by the HapMap project (52;57).   
 
The Welcome Trust Case Control Consortium (WTCCC) carried out a large scale 
genome wide association study in an attempt to identify genes involved in 7 
common human diseases, including hypertension (58).  For each disease 2000 
individuals were examined with a shared set of 3000 controls all of whom 
identified themselves as white Europeans.  Following analysis, 24 independent 
association signals were identified at p<5x10-7, the genome wide significance 
level set for this experiment.  The association signals included 1 in bipolar 
disorder, 1 in coronary artery disease, 9 in Crohn’s disease, 3 in rheumatoid 
arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes.  For hypertension, none 
of the previously suggested associated variants were identified and no further 
SNPs were discovered with significance below the set threshold level.  There are 
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many reasons that may explain why no significant associations were detected for 
hypertension, such as poor gene coverage in the Affymetrix chip used in the 
study.  For example, WNK1, which has been previously identified as a candidate 
gene for hypertension but is poorly tagged on the Affymetrix chip.  Another issue 
with this study is the use of a shared set of common controls, as this increases 
the likelihood that a proportion of controls may have hypertension or may go on 
to develop it in the future.  This could significantly reduce the power of the 
study for identifying associations with hypertension.  It has been estimated that 
“if 5% of controls would meet the definition of cases at the same age, the loss of 
power is approximately the same as that due to a reduction of sample size by 
10%” (58).         
 
1.3 Animal Models 
 
In order to better understand the mechanisms contributing to complex human 
disease, such as hypertension, animal models can be studied.  The rat is the 
most commonly used model for investigating hypertension.  There are various 
non genetic models of hypertension that are useful for investigation of secondary 
hypertension.  These include the 2 kidney, 1 clip rat and DOCA salt rats for 
investigating renovascular and endocrine causes of hypertension. 
 
1.3.1 Genetic Models of Hypertension 
 
The spontaneously hypertensive rat or SHR is an example of a selectively bred 
animal model that can be utilised for the genetic analysis of hypertension.  
Other genetic models of hypertension include the stroke-prone SHR, the 
genetically hypertensive rat, Sabra model, Lyon hypertensive rat, Milan 
hypertensive rat and Dahl salt sensitive rats.  The SHR was generated from the 
Wistar rat strain.  Male Wistar rats exhibiting spontaneous hypertension (SBP 
>150mmHg) were mated with female rats with above average blood pressure 
(SBP >130mmHg).  Pairs of rats from the F1 generation with spontaneous 
hypertension were then mated.  This process was repeated so that in subsequent 
generations, spontaneous hypertension was observed approximately 100% of the 
time.  In this strain, blood pressure increases with age, as is the case in human 
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hypertension.  Blood pressure rises steadily from ~140mmHg SBP at about 5 
weeks of age to ~200mmHg at 25 weeks (59).  The stroke prone spontaneously 
hypertensive rat (SHRSP) is a sub-strain of the SHR that displays extremely high 
blood pressure and has a high incidence of stroke.  Both strains are excellent 
genetic models of human hypertension as they exhibit many features that are 
common to the human disorder, such as endothelial dysfunction, cardiac 
hypertrophy, renal dysfunction and heart failure (60;61).  The high blood 
pressure phenotype observed in the SHR and SHRSP models is independent of 
dietary salt or other environmental influence unlike Dahl salt sensitive rats 
which develop high blood pressure following a high salt diet.  However, when 
fed a 1% salt solution, spontaneously hypertensive rats do have increased blood 
pressure (62).  Both SHR and SHRSP exhibit salt sensitivity. 
 
1.3.2 Congenic Strains 
 
Genetic linkage studies carried out in rat models of hypertension have led to the 
identification of numerous QTLs for blood pressure regulation across many 
chromosomes.  However QTLs usually encompass regions that are too large to 
yield a small number of genes that can easily be investigated.  To overcome this, 
congenic strains can be generated to narrow down the region for investigation.  
This involves the transfer of one chromosomal region from one rat strain to 
another.  A donor and recipient strain are crossed and the progeny containing 
the region of interest are then backcrossed to the recipient strain.  Backcrossing 
is carried out until the progeny are entirely of recipient genetic background with 
the exception of the region transferred (63).  It is estimated that following eight 
generations of back-crossing that more than 99% will be from the recipient.  This 
process can be accelerated by using a speed congenic strategy, where back-
crossed male rats are screened for genetic markers allowing for rats with the 
least donor genetic background to be selected for future crosses (Figure 1.4).  By 
narrowing down the congenic region, the possibility of identifying causative 
genes is increased. 
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Figure 1.4 Traditional and speed congenic breeding 
Construction of congenic strains demonstrating the differences between 
traditional and marker-assisted speed congenic breeding.  Decreasing shades of 
grey represent dilution of the donor genome.  D: donor strain alleles, R: 
recipient strain alleles, B: backcross, F1: first filial generation 
 
Taken from (60).  Permission to reproduce this figure has been granted by John 
Wiley & Sons, Inc. 
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The congenic strategy to discover candidate genes as described above was 
successfully utilised by Aitman et al to identify Cd36 as an insulin resistance 
gene.  Previous studies identified a QTL on chromosome 4 in spontaneously 
hypertensive rats for defective glucose and fatty acid metabolism in adipocytes 
(64).  In order to further investigate the QTL region, Aitman and colleagues 
generated a congenic strain where the SHR QTL on chromosome 4 was replaced 
with the equivalent region from the Brown Norway (BN) rat.  The congenic strain 
showed improved insulin mediated glucose uptake and complete restoration of 
the normal lipid metabolism phenotype, thus confirming that genes with the QTL 
are responsible.  To further dissect which genes may be responsible, cDNA 
microarray analysis was performed to identify genes that are differentially 
expressed across strains.  In this way Cd36 was identified and pursued as a 
candidate gene.  This gene maps to the chromosome 4 QTL region and encodes a 
fatty acid translocase with expression in adipose tissue and in skeletal and 
cardiac muscle.  However, in the SHR, Cd36 protein was undetectable in 
adipocyte plasma membrane.  A transgenic mouse over-expressing Cd36 in heart 
and skeletal muscle was found to have lower blood triglycerides.  This 
investigation identified that Cd36 deficiency is responsible for insulin resistance 
and defects in fatty acid metabolism in the SHR (65).  Further studies involving 
transgenic overexpression of Cd36 in the SHR found that Cd36 decreases serum 
fatty acid levels, increases sensitivity to insulin and improves glucose tolerance 
but has no effect on mean arterial blood pressure (66).  More recently, renal 
expression of Cd36 has been shown to have an inverse correlation with blood 
pressure.  Renal transplantation experiments have demonstrated that rats 
receiving kidneys expressing wild type Cd36 result in reduced blood pressure 
compared to those receiving kidneys lacking Cd36 (67). 
 
A similar congenic strategy has been utilised in our own laboratory to identify 
candidate genes for hypertension.  Genome wide linkage analysis of the SHRSP 
led to the identification of 2 QTL for blood pressure regulation within rat 
chromosome 2 (68).  In order to further dissect the contribution of the QTL 
region of rat chromosome 2 to blood pressure regulation, congenic strains were 
generated.   
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Figure 1.5 Rat chromosome 2 congenic strain SP.WKYGla2c* 
The 2c* congenic strain was generated by transferring a chromosomal region 
from WKY onto the SHRSP background.  This region, between markers D2Wox9 
and D2Mgh12, encompasses a blood pressure quantitative trait locus (QTL). 
 
Adapted from (69) 
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Figure 1.6 Day and night-time average systolic and diastolic blood pressure 
Blood pressure measured by radiotelemetry in SHRSP, WKY and congenic 2c*.  
SBP: systolic pressure (top panel), DBP: diastolic pressure (bottom panel) 
 
Adapted from (69) 
 
 
 
 
 
 
 
 
 39 
In this case, a region encompassing the lower QTL on chromosome 2 from a 
normotensive strain (WKY) was transferred onto the genetic background of the 
SHRSP using a marker assisted breeding strategy (70) to generate the 
SP.WKYGla2c* (2c*) (Figure 1.5).  Initial studies with the congenic SP.WKYGla2c* 
found that blood pressure was significantly lower in the congenic when 
compared to the SHRSP (Figure 1.6). This indicates that genes found within the 
congenic region are indeed responsible for blood pressure regulation.  To further 
examine which genes may be playing a role, microarray analysis was carried out 
on the congenic strains.  Of the many probe sets that were found to be 
differentially expressed, three mapped to the congenic region.  All three probes 
corresponded to the gene encoding glutathione S-transferase mu type 1 (Gstm1) 
(69).  Gstm1 was found to have significantly lower expression in the SHRSP 
compared to the congenic and WKY.  As the congenic strain has lower blood 
pressure than the SHRSP, genes within the congenic region appear to be 
important and due to its position and differential expression, Gstm1 has been 
identified as a positional candidate gene for rat and possibly human 
hypertension. 
 
The microarray analysis that led to identification of Gstm1 was performed in 
kidney tissue from SHRSP, WKY and 2c* congenic strains.  The kidney was chosen 
for investigation of candidate genes in hypertension as it is the major organ 
responsible for long term blood pressure control and evidence from kidney 
transplant studies in rats have shown that blood pressure phenotype follows the 
kidney (71).  In experimental models of hypertension, the induction of 
hypertension involves some reduction of renal function (72).  It has been well 
documented that the kidney plays an important role in blood pressure regulation 
where control of sodium and water excretion has been suggested as the main 
mechanism contributing to pressure control (73).  As described in section 
1.1.1.2, the renin-angiotensin system contributes to blood pressure control and 
in the kidney stimulates retention of sodium and water, thereby raising blood 
volume and consequently raising blood pressure.  The activation of AT1 receptors 
by angiotensin II leads to vasoconstriction and a study has shown that the 
absence of kidney AT1 receptors in mice was enough to enable a blood pressure 
reduction of almost 20 mmHg even with normal expression of the receptor in 
other tissues (74).  Another action of angiotensin II is to stimulate release of 
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aldosterone from the adrenal cortex.  Aldosterone promotes sodium and water 
retention in the kidney via the epithelial sodium channel (ENaC).  Elevated 
levels of circulating aldosterone in Sprague Dawley rats led to an increased 
abundance of the α subunit of ENaC and caused redistribution of ENaC subunits 
to the apical region of principal cells of the collecting duct (75).   
The absorption of sodium and water by the collecting duct is important as it is 
here that sodium and water excretion is subjected to ‘fine tuning’ by the kidney 
(76).  Studies performed to identify where Gstm1 was expressed found that 
Gstm1 expression was present in kidney tubular epithelium and in particular was 
found in the principal cells of the collecting duct (77).  Due to the localisation of 
Gstm1 expression to kidney tubules and its reduced expression in renal tissue 
from hypertensive rats, the focus of the work presented in this thesis has been 
the kidney and in particular has utilised a rat kidney tubular epithelial cell line 
(NRK-52E). 
At present very little is known about the specific role of Gstm1 in the rat 
however a gene mapping study in the mouse identified Gstm1 as a positional 
candidate gene for susceptibility to renal vascular injury.  A study of a genetic 
model of angiotensin II type 1A receptor deficiency found that the genetic 
background of these mice could modify their susceptibility to renal vascular 
hypertrophy (78).  Those with a C57BL/6 genetic background were found to be 
more susceptible to renal vascular hypertrophy and linkage analysis identified a 
locus on chromosome 3 with significant linkage to the vascular phenotype.  
Screening for candidate genes found that Gstm1 mapped to this region and was 
differentially expressed between C57BL/6 susceptible and 129 resistant strains 
suggesting that Gstm1 may play a role in vascular homeostasis (79).  Expression 
of Gstm1 was significantly lower in aortic VSMCs isolated from C57BL/6 
compared to VSMCs from 129 mice.  The C57BL/6 VSMCs also exhibited a higher 
cell proliferation rate and increased reactive oxygen species when compared to 
129 VSMCs.  Transfection of VSMCs with Gstm1 siRNA to reduce Gstm1 expression 
resulted in a significant increase in VSMC proliferation, migration and superoxide 
levels.  It may be that Gstm1 modulates VSMC proliferation and migration by 
protecting cells from products of oxidative stress which could influence VSMC 
proliferation, although the exact mechanism is not yet known (79). 
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1.4 Oxidative Stress 
 
The term oxidative stress refers to a state where cellular antioxidants are 
overwhelmed by pro-oxidants resulting in an increased production of reactive 
oxygen species (ROS).  Reactive oxygen species are produced by all cells of the 
vasculature and play an important role in cellular homeostasis and signalling.  
Reactive oxygen species include non-radical molecules such as hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO
-) and free radicals such as superoxide 
(O2
-), nitric oxide (NO) and hydroxyl radical (OH-). 
 
There is much evidence available that suggests a role for oxidative stress in the 
development of hypertension (80).  Increased levels of ROS can cause 
remodelling of the vasculature due to inflammation and cellular damage (Figure 
1.7).  This leads to an increase in total peripheral resistance thus causing blood 
pressure to become elevated (81).  Oxidative stress, induced by depletion of 
glutathione, has been shown to cause normotensive Sprague-Dawley rats to 
become hypertensive (82).  Treating pre-hypertensive spontaneously 
hypertensive rats (SHR) with Tempol, a SOD mimetic, prevents rats from 
becoming hypertensive.  This indicates that by lowering levels of oxidative 
stress, hypertension can be prevented (83). 
 
1.4.1 Superoxide and Vascular NAD(P)H Oxidase 
 
Superoxide is a key molecule in the production of oxidative stress as it is a 
precursor for various other reactive oxygen species.  Superoxide is produced 
from the one electron reduction of molecular oxygen.  There are many sources 
of superoxide such as xanthine oxidase and the mitochondrial respiratory chain 
but within the vasculature, the principal source is NAD(P)H (nicotinamide 
adenine dinucleotide phosphate) oxidase (84).  Vascular NAD(P)H oxidase is 
similar in structure to the phagocytic type oxidase but instead of producing 
superoxide in short bursts, it is generated at a much lower level over a longer 
period of time.  NAD(P)H oxidase is a multi-subunit enzyme comprising 2 
membrane associated and 3 cytosolic components, see Figure 1.8.   
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Figure 1.7 Oxidative stress   
Increased production of superoxide can lead to endothelial dysfunction by 
diminishing nitric oxide bioavailability. Superoxide also results in the generation 
of various other reactive oxygen and nitrogen species that can inflict cellular 
damage and vascular remodelling contributing to increased peripheral resistance 
and blood pressure. 
O2
-: superoxide, H2O2: hydrogen peroxide, NO: nitric oxide, ONOO
-: 
peroxynitrite, SOD: superoxide dismutase, eNOS: endothelial nitric oxide 
synthase, BP: blood pressure 
Adapted from (81) 
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The membrane associated subunits are p22phox and Nox, a homologue of the 
gp91phox found in phagocytic NAD(P)H oxidase.  Together, the 2 subunits form the 
cytochrome b558.  Studies carried out in vascular smooth muscle cells identified 
p22phox as a critical factor in NAD(P)H oxidase mediated superoxide production.  
Cells transfected with p22phox antisense cDNA have reduced Ang II stimulated 
NAD(P)H oxidase activity, producing less superoxide thus indicating the 
importance of p22phox for enzyme function (85).  The 3 cytosolic components are 
p40phox, p47phox and p67phox all of which reside in the cytosol and translocate to 
the membrane upon activation.  When cells are stimulated, p47phox becomes 
phosphorylated allowing interaction with the cytochrome b558 complex.  The G 
protein, Rac1, is also required for enzyme activation through its interaction with 
p67phox.  When all of the components assemble at the cell membrane, the active 
enzyme complex is formed (86).  Evidence from studies in endothelial and 
vascular smooth muscle cells suggests that NADH is the preferred substrate for 
superoxide generation with NADPH used to a lesser degree (87). 
 
Increased NAD(P)H oxidase activity has been implicated in the development of 
hypertension (86;88).  Chabrashvili et al reported that expression of p47phox was 
greater in SHR kidney than kidneys from WKY rats; this increased expression was 
also found in younger, pre-hypertensive rats (89).  NAD(P)H oxidase activation 
has been observed in Sprague Dawley rats infused with Ang II to induce 
hypertension.  Following Ang II infusion, superoxide production and SBP increase 
but when infused with NE, only SBP increases indicating that Ang II activates 
NAD(P)H oxidase and is associated with the onset of hypertension (90).  In mice 
treated with an NAD(P)H oxidase inhibitor that prevents assembly of the enzyme 
complex, superoxide production was attenuated and SBP was significantly lower 
further adding support to a role for increase NAD(P)H oxidase activity and 
subsequent superoxide production in the development of hypertension (91). 
 
1.4.2 Nitric Oxide 
  
Superoxide readily reacts with the free radical nitric oxide (NO).  First described 
as endothelium derived relaxing factor, NO is a potent vasodilatory signalling 
molecule that plays an important role in the regulation of platelet aggregation 
and vascular tone.       
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Figure 1.8 Active NAD(P)H oxidase complex structure  
NAD(P)H oxidase is composed of 5 subunits, comprising 2 membrane bound (Nox 
and p22phox) and 3 cytosolic subunits (p40phox, p47phox and p67phox).  The 
activation of the enzyme complex is regulated by Rac1.  
NAD(P)H: nicotinamide adenine dinucleotide phosphate, O2: oxygen, O2
-: 
superoxide,  Phox: phagocytic oxidase, Nox: NAD(P)H oxidase (gp91phox 
homologue) 
 
Adapted from (92) 
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Nitric oxide is produced by nitric oxide synthase of which there are three 
isoforms; neuronal, inducible and endothelial (NOSI, NOSII and NOSIII 
respectively).  Endothelial nitric oxide synthase (eNOS) produces nitric oxide 
during the conversion of L-arginine to L-citrulline and requires various co-
factors.  Enzyme activity is Ca2+/calmodulin dependent and also requires NADPH, 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and 
tetrahydrobiopterin (BH4).   
 
Endothelial NOS is activated in response to increased intracellular Ca2+ resulting 
in NO generation.  Nitric oxide can then diffuse from the endothelium and exert 
its vasodilatory effects on nearby smooth muscle cells via cyclic guanosine 
monophosphate (cGMP).  Nitric oxide activates soluble guanylate cyclase (sGC) 
by binding to its haem group which in turn converts GTP to cGMP.  Accumulation 
of cGMP leads to activation of cGMP dependent protein kinase (PKG) triggering a 
decrease in [Ca2+]i through various mechanisms (93).  PKG mediated 
phosphorylation of K+ ion channels results in membrane hyperpolarisation and 
inhibition of Ca2+ influx (94).  PKG can also inhibit Ca2+ channels directly to 
reduce [Ca2+]i.  Reduced Ca
2+ levels result in diminished myosin light chain kinase 
(MLCK) activity and subsequent reduction of myosin light chain phosphorylation 
leading to smooth muscle relaxation (Figure 1.9).   
 
 
1.4.2.1 eNOS Uncoupling and Endothelial Dysfunction 
 
As well as producing NO, eNOS can also generate superoxide.  Elevated levels of 
superoxide are present in SHRSP aorta but can be attenuated by removing the 
endothelium or by adding NOS inhibitors, indicating that in the aortas of these 
animals superoxide is being produced by eNOS (95). This phenomenon, known as 
eNOS uncoupling occurs when L-arginine or BH4 levels are depleted.  The 
production of superoxide by uncoupled eNOS leads to diminished bioavailability 
of nitric oxide, which has been associated with endothelial dysfunction in the 
vasculature.   
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Figure 1.9 Nitric oxide signalling in vascular smooth muscle 
Nitric oxide regulates vascular smooth muscle relaxation through activation of 
soluble guanylate cyclase and accumulation of cGMP resulting in decreased 
intracellular calcium concentration.   
VSMC: vascular smooth muscle cell, EC: endothelial cell, eNOS: endothelial nitric 
oxide synthase, NO: nitric oxide, sGC: soluble guanylate cyclase, cGMP: cyclic 
guanosine monophosphate, guanosine triphosphate, PKG: cGMP dependent 
protein kinase, P: phosphorylation 
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Endothelial dysfunction is characterised by impaired endothelium dependent 
vasorelaxation due to reduced bioavailability of nitric oxide and is a feature of 
many cardiovascular risk factors such as hypertension and atherosclerosis.  
Coronary endothelial dysfunction has been associated with atherosclerosis 
progression and subsequent coronary artery disease (96).  Impaired 
vasorelaxation is also found in rat models of hypertension (97) and hypertensive 
patients (98).  In rat models of hypertension, superoxide levels are elevated and 
this contributes to the reduced NO bioavailability observed.  Nitric oxide rapidly 
interacts with superoxide resulting in the production of the highly reactive 
peroxynitrite (ONOO-).  Peroxynitrite can cause damage to DNA, protein and 
lipids and can also oxidise the co-factors required by eNOS, contributing further 
to eNOS uncoupling.   
 
1.4.3 Antioxidant Systems 
 
In order to counteract the production of ROS there are many antioxidant systems 
in place to help prevent oxidative damage (99;100).  These defences include 
small non-protein antioxidants such as vitamins and glutathione and enzymes 
such as superoxide dismutase (SOD), catalase (CAT), glutathione transferases 
(GST) and glutathione peroxidase (GPx). 
 
1.4.3.1 Antioxidant Vitamins 
 
Vitamin E (α-tocopherol) effectively scavenges lipid peroxides but in doing so 
can become a radical itself.  Data from epidemiological studies suggests an 
inverse association between vitamin E intake and risk of cardiovascular disease 
(101).  However, studies designed to test the effect of vitamin E 
supplementation on cardiovascular risk have shown no significant decrease in the 
number of CV events and in some cases increased intake of vitamin E was 
associated with a greater risk of heart failure (102;103).  Vitamin C (ascorbate) 
can reduce oxidative stress by scavenging ROS directly and by recycling α-
tocopherol, preventing its radical formation thus helping to prevent lipid 
oxidation (104).  It has also been shown to be effective in the reduction of 
endothelial dysfunction in patients with coronary artery disease (105;106) and 
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hypertension (107).  Studies in endothelial cells show that treatment with 
ascorbate leads to increased production of nitric oxide and stabilisation of the 
eNOS co-factor BH4, preventing eNOS uncoupling and maintaining bioavailability 
of NO (108;109).  
 
1.4.3.2 Superoxide Dismutase 
 
Superoxide can be scavenged by SOD by catalysing the conversion of superoxide 
to oxygen and H2O2.  The reaction involves the binding of two superoxide anions 
and two protons by SOD leading to the production of hydrogen peroxide and 
oxygen.  Three SOD isoforms have been identified in mammals, encoded by three 
distinct genes.  SOD1 encodes a dimeric copper-zinc (Cu/Zn) SOD that is located 
in the cytoplasm.  The second isoform, manganese (Mn) SOD, is found in the 
mitochondria as a tetrameric enzyme and is encoded by SOD2.  SOD3 encodes a 
tetrameric Cu/Zn SOD isoform that is found mainly in extracellular spaces and is 
commonly described as ecSOD.  
 
Superoxide dismutase helps to increase NO bioavailability and improve 
endothelium dependent vasodilatation in a rabbit model of diabetes.  In afferent 
arterioles from diabetic rabbits, acetylcholine induced vasodilatation is inhibited 
but when treated with the SOD mimetic Tempol, the dilatory response is 
restored (110).  Gene transfer studies have shown that ecSOD can cause a 
decrease in arterial blood pressure in SHR and improve carotid artery relaxation 
in response to acetylcholine (111).  The benefits of SOD activity are clear, 
superoxide mediated cytotoxicity is reduced and NO bioavailability is increased. 
However, SOD generates H2O2, a stable molecule with oxidising properties that in 
turn can lead to production of the highly reactive OH-. 
 
Hydrogen peroxide has been shown to function in vascular smooth muscle cell 
(VSMC) proliferation and hypertrophy, features that are common to vascular 
disease.  Upon stimulation with phenylephrine, the level of H2O2 in VSMC is 
increased and proliferation is induced.  However, when H2O2 is inhibited by 
catalase, phenylephrine induced proliferation is also inhibited (112). Hydrogen 
peroxide itself can be scavenged by enzymes such as catalase and glutathione 
peroxidase.  In the presence of metal containing molecules, H2O2 can be reduced 
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to form hydroxyl (OH-) radical another reactive species that can inflict local 
damage (113).   
 
1.4.3.3 Catalase 
 
Catalase is a tetrameric enzyme that reacts with H2O2 and generates water and 
molecular oxygen.  The protective benefit of catalase has been demonstrated in 
the cardiovascular system.  Catalase transgenic mice were generated to 
investigate the role of H2O2 in vascular hypertrophy.  Angiotensin II induced 
aortic wall hypertrophy was attenuated by the increased expression and activity 
of catalase specifically in vascular smooth muscle (114).  Over-expression of 
catalase in ApoE-/- mice has also been shown to have protective properties by 
inhibiting the development of atherosclerosis and reducing markers of oxidative 
stress (115). 
 
1.4.3.4 Glutathione 
 
Glutathione is a small tripeptide molecule (γ-glutamyl-cysteinyl-glycine) that is 
used by various detoxifying enzymes such as GPx and GST and plays an important 
role in antioxidant defence.  Glutathione exists in a reduced state and acts as an 
electron donor.  It can be oxidised to produce glutathione disulphide (GSSG) by 
various electrophilic substances including ROS leading to lower levels of reduced 
glutathione.  The GSH:GSSG ratio is often used as an indicator of cellular 
oxidative stress status.  Upon stimulation by oxidative stress glutathione 
reductase is stimulated and converts glutathione back to its reduced form. 
 
The liver is a major producer of GSH, the most abundant low molecular weight 
thiol.  Glutathione is synthesised in a two step reaction in the presence of ATP 
by two cytosolic enzymes; γ-glutamylcysteine synthetase (γGCS) and GSH 
synthetase, see Figure 1.10.     
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Figure 1.10 Glutathione synthesis 
Glutathione is synthesised in a 2 step reaction by GCS and GSH synthetase.  It 
can be oxidised to GSSG by various electrophilic substrates and reduced by GSH 
reductase. 
GSH: glutathione, GCS: glutamyl-cysteine synthetase, GSSG: glutathione 
disulphide, GPx: glutathione peroxidase 
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Firstly, γ-glutamyl-cysteine is produced by γGCS which catalyses the reaction of 
the γ carboxyl of glutamate with the amino group of cysteine.  This first step is 
rate limiting for GSH synthesis as is the availability of L-cysteine.  The second 
step involves the interaction of glycine with γ-glutamyl-cysteine to produce GSH 
which is catalysed by GSH synthetase. 
 
Glutathione can exert its antioxidant effect either independently or through 
enzymatic activity such as GPx or GST.  Glutathione can non-enzymatically 
interact with and detoxify OH- and can also detoxify products of nitrosative 
stress such as peroxynitrite.    
 
1.4.3.5 Glutathione Peroxidase 
 
Glutathione peroxidases are able to catalyse the reduction of hydroperoxides 
including H2O2 by utilising glutathione as a reducing agent.  In mammals, there 
are 4 known selenocysteine containing isoforms of GPx.  GPx-1 and GPx-2 are 
both tetrameric proteins and share similar activities.  Each is capable of 
metabolising H2O2 but cannot reduce phospholipid hydroperoxides.  GPx-1 was 
discovered first and is also known as classic or cytosolic GPx (cGPx).  GPx-2 is 
found predominantly in the epithelium of the gastrointestinal tract and is also 
known as GPx-GI.  GPx-3 is a tetrameric glycoprotein that is present in plasma.  
The main source of this enzyme is the kidney, with mRNA expression found 
particularly in epithelial cells of the proximal tubules.  GPx-4 is a monomeric 
enzyme that is able to metabolise phospholipid hydroperoxides. 
 
The effect of adenosine mediated over-expression of GPx-1 on human primary 
endothelial cell sensitivity to H2O2 was assessed by Zhang et al.  Increased 
expression of GPx-1 reduced H2O2 cellular toxicity, confirming its protective role 
against oxidative stress (116).  GPx-1 deficiency in mice has been associated 
with endothelial dysfunction and structural abnormalities in the vasculature and 
has been shown to increase levels of isoprostanes, indicating increased oxidative 
stress in these animals (117).  
 
 52 
1.4.3.6 Glutathione Transferases 
 
Glutathione S-transferase mu type 1, identified as a positional and functional 
candidate gene for hypertension in the rat, is one of a large family of phase II 
detoxifying enzymes that play a role in the cellular defence against oxidative 
stress, by catalysing the conjugation of glutathione to various electrophilic 
substrates (118).  The effectiveness of glutathione transferases (GST) as 
antioxidant enzymes is limited by the enzymes responsible for GSH synthesis and 
those responsible for transporting the GSH conjugates out of the cell.  Once 
conjugated to GSH, substrates can be removed from the cell by various ATP 
dependent transport mechanisms including multi-drug resistance associated 
proteins (MRP) (119) and glutathione S-conjugate export pumps (GS-X) (120).  
 
The GSTs are dimeric enzymes and can exist as homodimers or heterodimers but 
can only be formed from subunits from the same class.  Members of the same 
class share greater than 40% identity and between classes share less than 25%.  
Each GST subunit is composed of two distinct domains.  The N-terminal domain 1 
or G site is highly conserved between classes and is responsible for binding 
glutathione through its interaction with cysteine.  It is connected to domain 2 or 
the H site by a short linker sequence.  Domain 2 is less well conserved and is 
responsible for binding hydrophobic substrates.  The diversity in the H site 
between classes may account for the broad substrate specificities of the various 
GSTs.  Once bound to the G site, GSH is activated and becomes deprotonated.  
By doing so, GSH becomes a strong nucleophile and facilitates its interaction 
with an electrophilic substrate (121). 
 
GSTs have been shown to detoxify the breakdown products of oxidative damage 
to protein, DNA and lipids such as base propenals and 4-hydroxyalkenals (118).  
Oxidative stress can lead to oxidation of nucleotides and DNA degradation and 
subsequently generate base propenals.  GSTs have been shown to protect cells 
against cytotoxicity mediated by adenine and thymine propenal generation, 
particularly Pi class GSTs (122).    Peroxynitrite induced protein nitrotyrosine 
production can be inhibited by incubation with GST, leading to denitration of 
proteins (123).  .   
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Alpha class GSTs also demonstrate glutathione peroxidase activity against lipid 
hydroperoxides generated from damage to cell membranes.  Although 
endogenous systems are in place to counteract ROS, if superoxide production is 
increased, these systems can be overwhelmed causing damage to DNA, proteins 
and lipids. 
 
In mammals there are at least seven classes of cytosolic GST including, alpha, 
mu, pi, theta, sigma, omega and zeta.  There are eight possible members of the 
mu class in the rat that have been reported to date.  The rat mu family includes, 
Gstm1, 2, 3, 4, 5 and 6.  A further 2 genes are designated Gstm6l (Gstm6-like) 
and Gstm7 (GSTM7-7 like).  All eight genes map to chromosome 2q34 and form a 
cluster in the order m7-m1-m2-m4-m6l-m3-m6 followed by m5 (inverted).  There 
are five members of the mu class in humans (GSTM1-5) all of which map to 
chromosome 1p13.3 (124).  The genes are arranged in the following order: M4-
M2-M1-M5 and M3 (inverted).     
 
1.4.3.7 Glutathione S-Transferase Mu Type 1 
 
Polymorphisms in various genes encoding glutathione transferases have been 
implicated in carcinogenesis (125).  In humans, 50% of the population is GSTM1 
null and as such do not express GSTM1 protein.  The GSTM1 null allele has been 
associated with an increased risk of developing various cancers, particularly lung 
cancer (126).  At present, little work has been done to investigate the role of 
GSTM1 in cardiovascular disease.  A recent study aimed to assess the association 
between various GSTM variants and hypertension.  Individuals with and without 
hypertension were screened for SNPs in GSTM1, 2, 3, 4 and 5.  In the initial 
screen a SNP in the 3' region of GSTM5 was found to be associated with 
hypertension.  However this result was not replicated in a second cohort and 
suggests that GSTM gene variants are not associated with hypertension (127).   
Although an association between human GSTM1 and hypertension could not be 
confirmed, it is not yet known which human GSTM is the true orthologue of rat 
Gstm1. 
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The reduced expression of Gstm1 in 16 week old SHRSP kidneys was found in 
parallel with increased renal oxidative stress and blood pressure compared to 
the 2c* and WKY strains (69;77).  Expression of Gstm1 was found to be 
significantly lower in 5 week old SHRSP before the onset of severe hypertension 
indicating that the differential expression of renal Gstm1 may be a contributing 
factor to the development of hypertension and is not an adaptive response to 
long term increased blood pressure (77).  It may be that increased renal 
oxidative stress in the SHRSP is contributing to the development of hypertension.  
Increased renal oxidative stress has been demonstrated to contribute to 
hypertension in various rat models.  In Sprague Dawley rats, oxidative stress was 
induced in the renal medulla by infusion of the CuZn-SOD inhibitor 
diethyldithiocarbamic acid (DETC).  Following infusion of DETC, increased 
superoxide levels were found in the renal medulla and blood pressure was 
significantly increased (128).  The addition of TEMPOL prevented the DETC-
induced increase in superoxide but did not prevent the DETC-induced 
hypertension.  However, when catalase was co-infused with TEMPOL, DETC-
induced hypertension was blocked.  This suggested that removal of superoxide 
from the renal medulla alone was not sufficient to prevent the development of 
hypertension but by limiting TEMPOL induced H2O2 production, hypertension 
could be prevented. Direct renal infusion of H2O2 alone was also found to 
produce hypertension, possibly as a result of oxidative injury to renal medullary 
cells (129).  Hypertensive Dahl S rats on a high salt diet exhibited significantly 
lower SOD activity levels and increased excretion of urinary isoprostanes (a 
marker of lipid peroxidation), indicating increased oxidative stress in the kidneys 
of these rats (130).  The reduction of Gstm1 expression in kidney tubular 
epithelium may result in reduced protection against the products of oxidative 
stress and subsequently lead to oxidative DNA, protein or lipid damage in these 
cells.  This is in turn may contribute to the development of hypertension due to 
an impaired ability of tubular cells to properly regulate the sodium-fluid 
balance.  
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1.5 RNA Interference 
 
RNA interference (RNAi) is a naturally occurring mechanism that results in post-
transcriptional gene silencing (PTGS) in response to double stranded RNA 
(dsRNA) molecules that are homologous to a target gene. By exploiting this 
mechanism experimentally it is possible to reduce the expression of a particular 
gene of interest to further investigate its function.  Post-transcriptional gene 
silencing was first observed by Napoli et al. during transgenic experiments in 
plants.  They found that introducing a chimeric chalcone synthase (CHS) gene 
(responsible for petunia petal pigmentation) generated white flowers lacking 
pigmentation resulting from suppression of both the endogenous and introduced 
CHS genes.  This unexpected effect was described as co-suppression (131;132).  
Experiments carried out in Neurospora crassa identified a related mechanism for 
gene inactivation, termed quelling (133;134).  Both of these mechanisms are 
related to RNAi which was first described in C.elegans by Fire et al. 
Investigations into the role of RNA structure in genetic silencing found that 
dsRNA mediates RNAi, as dsRNA directed against a luciferase reporter gene had a 
much stronger silencing effect than either sense or antisense strand alone (135).  
Tushl and colleagues then reported that the strong silencing observed in 
response to dsRNA is not just due to the longer half life of dsRNA as single 
stranded RNA modified with a 7-methyl guanosine cap to increase stability is still 
unable to inhibit gene expression (136). 
 
1.5.1 RNA Interference: Mechanism  
  
The mechanism by which RNAi works has been elucidated through various studies 
with C.elegans and Drosophila (137).  This mechanism is outlined in Figure 1.11.  
RNA interference is induced by dsRNA sequences that are 21-22 nucleotides (nt) 
long and have 2nt 3’overhangs.  The 5’ end of the sequence contains a 
phosphate group and the 3’ end contains a hydroxyl group (138).  These short 
interfering RNAs (siRNAs) are generated from long dsRNA molecules by Dicer, an 
ATP dependent RNase III like enzyme that is specific for dsRNA (139).   
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Figure 1.11 Mechanism of RNA interference  
Double stranded interfering RNA molecules (siRNA/shRNA) are introduced to the 
cell.  Duplex RNA dissociates and one strand is incorporated into the RNA 
induced silencing complex.  The target mRNA and siRNA strand anneal and the 
target is then degraded via nuclease activity.  Part of this RNAi pathway is also 
utilised by microRNAs.  
RISC: RNA induced silencing complex, siRNA: short interfering RNA, shRNA: short 
hairpin RNA, mRNA: messenger RNA, miRNA: microRNA, pri-miRNA: primary 
miRNA, pre-miRNA: precursor miRNA 
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Dicer is found in complex with R2D2, a dsRNA binding protein that facilitates 
siRNA binding.  Although R2D2 is involved in binding the siRNA duplex it is not 
required for production of siRNA as R2D2 mutant flies are no different to wild 
type in their ability to generate siRNAs (140).  However, R2D2 is necessary for 
siRNA incorporation into the RNA induced silencing complex (RISC), the effector 
complex responsible for sequence specific degradation of the mRNA (141;142).  
R2D2 has been found to bind to the more stable end of the siRNA duplex whereas 
Dicer binds to the less stable end; this binding of siRNA by Dicer/R2D2 produces 
the RISC loading complex (RLC) (143).  It is RISC that is responsible for mRNA 
cleavage and for this to take place; RISC must associate with the siRNA duplex 
and incorporate the guide strand.  Active RISC is composed of the Argonaute 
family of proteins and siRNA.  Argonaute proteins are composed of 4 domains: an 
N-terminal, PAZ domain (also found in Dicer), Mid domain and PIWI domain 
(144).  Prior to incorporation of siRNA, RISC is inactive and is termed holo-RISC.  
To become active, the Argonaute complex interacts with the RISC loading 
complex allowing association with the siRNA duplex.  The duplex is cleaved by 
the Argonaute protein allowing it to unwind and the guide strand becomes part 
of the now active RISC (145).  RISC can now interact with the target mRNA 
through complementary base pairing with the siRNA.  The endonuclease activity 
provided by RISC results in cleavage of mRNA every 21-23 nucleotides, reflecting 
the size of the siRNA (146).   
 
1.5.2 MicroRNAs 
 
MicroRNAs (miRNAs) are another class of small RNA that regulate gene 
expression, in part, through the RNAi pathway (147).  Unlike siRNAs that are 
generated via viral replication or through introduction of chemically synthesised 
molecules or expression vectors, miRNAs are produced from endogenously 
expressed transcripts.  Genes encoding miRNAs generate primary miRNAs (pri-
miRNAs) that form long stem loop structures.  The hairpin region is then cut out 
by the RNase III family enzyme Drosha to generate a stem loop precursor miRNA 
(pre-miRNA) of ~70nt long (148;149).  The pre-miRNA is then exported from the 
nucleus to the cytoplasm where Dicer cleaves the stem loop structure to form 
the 21-25nt long mature miRNA (150;151).  The mature miRNA associates with 
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RISC and binds to the target 3'UTR and in doing so results in translational 
repression. 
 
1.5.3 In Vitro RNAi 
 
Elbashir et al. were the first to demonstrate siRNA induced RNA interference in 
cultured mammalian cells.  They found that transfecting cells with 21nt siRNA 
duplexes resulted in knock-down of genes expressed endogenously and from 
reporter constructs (152).  To utilise RNAi for in vitro experimental purposes, 
double stranded RNA molecules first have to gain access to cells expressing the 
gene of interest.  This can be achieved in a variety of ways.  Chemically 
synthesised short interfering RNA (siRNA) molecules of 21 nucleotides in length 
can be incorporated into lipid or amine based complexes and introduced using 
various transfection methods.  As well as transfection, siRNA can be introduced 
via electroporation (153).  By using synthetically generated siRNA, the need for 
processing by Dicer is avoided.  As described previously, Dicer is responsible for 
cleaving long dsRNA into short sequences that can initiate RNAi.  However, 
introduction of dsRNA molecules greater than 30nt can result in activation of the 
interferon response in mammalian cells (152).  Therefore, using short sequences, 
the possibility of adverse activation of interferon response genes can be limited.    
Alternatively, plasmid or viral vectors can be used that are engineered to 
express short hairpin RNAs (shRNA) that are complementary to the target mRNA.  
Once in the cytoplasm, the siRNA/shRNA molecules can then associate with RISC.  
Once incorporated into RISC the siRNA associates with the target mRNA, leading 
to its degradation and subsequent knockdown of gene expression. 
 
1.5.4 In Vivo RNAi 
 
As previously mentioned, RNAi requires the introduction of dsRNA molecules 
directly to those cells expressing the gene that is to be silenced.  This can be 
readily achieved in vitro (136;152) however; in vivo RNAi poses a greater 
challenge. It is possible to introduce naked siRNA molecules in vivo.  McCaffrey 
et al was able to demonstrate luciferase reporter gene silencing in the livers of 
adult mice following the delivery of naked siRNA via hydrodynamic tail vein 
 59 
injection (154).  Hydrodynamic delivery involves the rapid injection of nucleic 
acid in a large volume of fluid (155).  This method of delivery can elicit a quick 
silencing response, as the molecule need only gain access to the cytoplasm 
where it can interact with RISC and carry out its function.  However, the 
stability of these 21nt sequences within an in vivo environment is an issue, as 
well as factors such as the half-life of the target protein (156;157).  By 
introducing siRNA in this way the silencing effect would be short lived and 
although introducing large concentrations of siRNA may help to prolong the 
effect, excess siRNA could result in off-target effects.  While siRNA is designed 
to be specific to a target mRNA, excess molecules could cause aberrant silencing 
of unintended genes (158).  High specificity will also help to ensure that no non-
specific binding occurs, thus helping to prevent off-target effects. 
 
To further facilitate in vivo delivery, siRNA molecules can be introduced in 
complex with cationic lipids.  A liposome-based method was utilised by Sorensen 
et al, to induce gene silencing in adult mice (159).  More recently, Santel et al 
have demonstrated the use of lipoplexes for in vivo delivery of siRNA molecules 
targeted against genes expressed in the vascular endothelium of mice.  
Following intravenous injection of the lipoplex (cationic lipid, helper lipid and 
siRNA), reduced expression of endothelial specific genes was observed (160).   
This method of liposomal delivery has since been utilised to silence gene 
expression in the liver of cynomolgus monkeys (161).  
 
Alternatively, interfering RNA fragments can be introduced via expression 
vectors, such as plasmids or viral vectors.  Viral vectors such as adeno-associated 
viral (AAV) vectors can be manipulated to express short-hairpin RNA molecules 
(shRNA), that can target host cell mRNA for destruction.  For this method to be 
effective the virus must gain entry to the nucleus, thus enabling the expression 
of the shRNA molecule and although this may take more time to produce an 
effect, the silencing obtained would be more stable.  Once expressed, the shRNA 
is processed and exported to the cytoplasm where it can associate with RISC, 
thereby allowing its interaction with the target mRNA. Wang et al have 
demonstrated gene silencing in rats following intravenous delivery of AAV 
vectors engineered to express shRNA (162). 
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1.5.5 Therapeutic Potential 
 
RNA interference has more recently shown promise as a potential therapeutic for 
the treatment of disease.  Synthetically generated siRNAs have been shown to 
inhibit hepatitis C virus production in cultured cells (163).  Mice treated with 
siRNA targeted to the Fas receptor gene are shown to have greater resistance to 
liver disease.  Following intravenous injection of siRNA, hepatocytes isolated 
from treated mice were resistant to apoptosis (164).  DiFuglia et al 
demonstrated the potential use of RNAi as a treatment for the neurological 
disorder Huntington’s disease (HD).  A virus mediated transgenic model of HD 
was utilised to test the efficacy of anti-htt (HD gene) siRNA.  Striatal neurons in 
siRNA treated mice had a prolonged survival and presented fewer abnormalities 
that are associated with HD. 
 
RNA interference has also been evaluated as a potential antiviral therapy for 
respiratory syncytial virus (RSV) infection.  Bitko et al demonstrated inhibition of 
RSV following nasal administration of anti-RSV siRNA in mice.  Antiviral effects 
were observed before and after RSV infection indicating the potential of siRNA 
as a therapy that can be delivered locally to combat RSV infection (165).  This 
siRNA has since gone on to be tested in a phase II clinical trial to evaluate its 
safety as an antiviral therapeutic.  The siRNA was delivered to the respiratory 
tract via a nasal spray and was found to be well tolerated with few side effects 
(166).  Another disorder where clinical trials are underway for a therapeutic 
siRNA is age-related macular degeneration (AMD).  Studies have shown that 
siRNAs targeted against vascular endothelial growth factor (VEGF) or VEGF 
receptor 1 (VEGFR1) have beneficial effects in mouse models of AMD.  In these 
models, reducing expression of VEGF or VEGFR1 inhibited choroidal 
neovascularisation (CNV), a common cause of vision loss in people suffering with 
AMD (167;168).  Following on from these and other studies, siRNA targeting 
VEGFR1 (siRNA-027) has since been taken forward to phase II clinical trials (169).  
Another siRNA (REDD14NP) is also being evaluated for AMD in a phase I clinical 
trial (170).       
 
RNA interference provides an excellent tool for elucidating gene function both in 
vitro and in vivo.  Using various means of delivery it is possible to reduce 
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expression in animal models of human disease and as such may prove beneficial 
in the identification of the function of glutathione S-transferase mu type 1 in 
both oxidative stress and hypertension.  In vivo delivery of Gstm1 specific 
interfering RNA molecules would allow for a more accurate investigation into the 
role of Gstm1 in rat hypertension, with a view to finding similar blood pressure 
regulatory mechanisms in human. 
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1.6 Hypothesis 
 
Due to the role of GSTs in defence against oxidative stress and the involvement 
of oxidative stress in the development of hypertension, we hypothesise that 
depleted renal expression of Gstm1 may contribute to development of 
hypertension by reducing the capacity of renal cells to protect themselves 
against the damaging products of oxidative stress.  In addition to the differential 
expression of Gstm1 observed between the parental and congenic strains, it may 
be that microRNAs mapping to the chromosome 2 congenic region are 
responsible for regulating the expression of genes which could contribute to the 
blood pressure phenotypes observed in these strains. 
 
  
1.6.1 Aims 
 
A combination of congenic breeding and microarray analysis has identified Gstm1 
as a positional and functional candidate gene for hypertension in the stroke-
prone spontaneously hypertensive rat (SHRSP).  This aims of this study are to 
investigate the role of Gstm1 using an RNAi mediated approach and develop 
molecular tools that could be used for targeted modulation of gene expression in 
vivo.  In addition to this, another aim is to investigate microRNAs that map to 
the chromosome 2 congenic regions. 
 
The specific aims of this study are: 
1. To assess the ability to knock-down Gstm1 expression specifically 
with siRNA and develop tools for in vivo kidney targeted knock-
down 
2. To assess the contribution of reduced Gstm1 expression to markers 
of oxidative stress  
3. To investigate expression of microRNAs in kidney from parental and 
chromosome 2 congenic strains and assess expression levels of 
potential microRNAs targets 
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Chapter 2: Materials and Methods 
 64 
2.1 General Laboratory Practice 
 
This chapter outlines general materials and methods that are common to more 
than one chapter.  Where necessary, more details are given in the appropriate 
chapters.   
 
All laboratory equipment and reagents used throughout the project were of the 
highest available grades.  A laboratory coat and latex powder-free gloves were 
worn during all procedures.  Handling of hazardous reagents was carried out in 
accordance with Control of Substances Hazardous to Health regulations. 
 
Laboratory glassware was cleaned in Decon 75 detergent, rinsed with distilled 
water and dried in a 37°C cabinet.  Sterile, disposable plastic-ware was also 
used, including 0.5 ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio-One), 
15 ml and 50 ml Corning centrifuge tubes and 5 ml and 20 ml Universal 
containers (Sterilin).  Glass-ware and reagents requiring sterilisation were 
autoclaved in a Priorclave Tactrol 2. 
 
To weigh out reagents an Ohaus Portable Advanced balance (sensitive to 0.01 g) 
or a Mettler HK160 balance (sensitive to 0.0001 g was used).  To dispense 
volumes from 0.1 µl to 1000 µl, Gilson pipettes were used (Gilson Medical 
Instruments.  For larger volumes from 1 ml to 25 ml, sterile disposable pipettes 
(Corning) were used with a Gilson battery-powered pipetting aid.  When 
preparing solutions, distilled water (dH20) was used unless otherwise stated and 
to aid dissolving and mixing a Jenway 1000 hotplate and stirrer was used.  The 
pH of solutions was determined using a Mettler Toledo digital pH meter.  The 
meter was calibrated before use with solutions of pH 4, 7 and 10 prepared from 
buffer tablets (Sigma-Aldrich).  Vortexing was carried out using an FSA 
Laboratory Supplies WhirliMixer.  For experiments requiring incubations between 
37°C and 90°C, a Julabo TW8 water bath utilised and for temperatures up to 
100°C a Grant SBB14 boiling water bath was used.  For centrifugation of samples 
up to 2 ml, an Eppendorf 4515 microcentrifuge was used.  Larger volume 
samples were centrifuged in a Sigma 4K15, compatible with 15 ml and 50 ml 
centrifuge tubes, 20 ml Universal containers and carriers for standard reaction 
plates.  
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For all experiments involving RNA, certified nuclease-free reagents and plastic-
ware were used, including nuclease-free water, 0.5 ml, 1.5 ml and 2 ml RNase-
free microcentrifuge tubes (Ambion) and nuclease-free pipette tips for volumes 
between 0.2 µl and 1 ml (RAININ).  Prior to beginning RNA work, all pipettes and 
bench space were wiped with RNaseZap (Ambion) and rinsed with nuclease-free 
water.   
 
 
2.2 Cell Culture 
 
All in vitro RNA interference experiments were carried out in the rat renal 
tubular epithelial cell line NRK-52E.  Cells were obtained from the European 
Collection of Cell Culture (ECACC).  The details of other cell lines used are 
described in the methods section of the relevant chapters.  NRK-52E cells were 
grown in 150 cm2 flasks containing Dulbecco’s modified Eagle’s medium plus 
GlutaMAX supplemented with 10% (v/v) foetal calf serum (FCS), 100 U/ml 
penicillin and 100 mg/ml streptomycin.  Cells were maintained at 37°C in a 5% 
CO2/95% air atmosphere incubator. 
 
2.2.1 Cell Passage 
 
Cell culture medium, sterile PBS (Lonza) and 1X TE (0.05% trypsin; 0.2% 
ethylenediamine tetraacetic acid (EDTA)) were warmed to 37°C in a water bath.  
Culture medium was removed from the flask and cells were rinsed twice with 10 
ml sterile PBS.  To detach cells, 5 ml 1X TE was added to the flask and incubated 
at 37°C for 5 minutes.  Once cells had detached from the flask, 15 ml of culture 
medium containing 10% (v/v) FCS (to inactivate trypsin) was added and the cell 
mixture was transferred to a 50 ml centrifuge tube (Corning).  Cells were 
centrifuged at 1500 rpm for 5 minutes to pellet cells.  The supernatant was 
removed and cells were re-suspended in fresh culture medium.  Of this 
suspension, 1/20-1/10 was transferred to a fresh 150 cm2 flask containing 25 ml 
culture medium.  
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2.2.2 Cell Counting 
 
Cells were counted using a haemocytometer (Hausser Scientific).  A cell 
suspension was prepared by detaching cells with 1X TE as described in section 
2.3.  A cover-slip was placed on the haemocytometer counting surface and 10 µl 
of the cell suspension was applied to the grid under the coverslip.  The number 
of cells in a 1 mm square was determined by counting the number of cells in 
each quadrant.  The average number of cells in each 1mm square was 
determined and multiplied by 104 to give the number of cells per ml.     
 
 
2.3 Transfection of NRK-52E Cells with siRNA  
 
Cells were cultured in 6 well plates until ~70% confluent and then transfected 
with 30 to 100nM Silencer® Pre-designed Gstm1 specific siRNA (Applied 
Biosystems).  Three different sequences were evaluated, designated A (ID# 
200597), B (ID# 200598) and C (ID# 200599).  The siRNA sequences were as 
follows: 
 
Sequence A: GCUCAUCAUGCUUUGUUACtt (sense) 
         GUAACAAAGCAUGAUGAGCtg (antisense)  
 
Sequence B:  CCUAUAUUUUCGAAGUUGGtt (sense) 
          CCAACUUCGAAAAUAUAGGtg (antisense) 
 
Sequence C:  CCUCACAGUCCUUUUCUGUtt (sense) 
     ACAGAAAAGGACUGUGAGGtt (antisense) 
 
Each sequence was 19nt long with 2nt 3’overhangs.  A Silencer® Cy™ 3 labelled 
control siRNA that has no known homology to any expressed genes was also used, 
allowing for an assessment of transfection efficiency by fluorescence 
microscopy.  In each experiment, three controls were used: untransfected cells 
(UTF), cells with transfection reagent only (TFC) and cells transfected with 
labelled control siRNA (siCTL).  RNase free micro-centrifuge tubes and pipette 
tips were used throughout.  Each transfection was carried out in triplicate using 
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siPORT™ Amine transfection reagent (Applied Biosystems) according to 
manufacturer’s instructions.  Briefly, 12 µl of siPORT™ Amine was diluted to a 
final volume of 197 µl (per well) in Opti-MEM® Reduced Serum Medium 
(Invitrogen) and incubated at room temperature for 15 minutes.  The volume of 
growth medium in each well was reduced to 800 µl.  Chemically synthesised 
siRNA was added to the transfection reagent mix (to give a final concentration of 
30 or 100nM siRNA) and incubated at room temperature for 15 minutes.  The 
transfection reagent and siRNA complexes were added drop-wise to each well.  
Plates were gently rocked back and forth to disperse the transfection complex 
and incubated at 37°C for 5 hours.  The medium in each well was then topped 
up with 2 ml of normal growth medium and incubated at 37°C for a further 48 
hours.  After 48 hours, cells or medium were collected for further analysis. 
2.4 Protein Extraction 
 
Protein was collected from cells cultured in tissue culture plates.  Culture 
medium was removed and cells were rinsed twice with sterile PBS.  Adherent 
cells were made permeable with 0.2% Triton X-100/PBS and samples were 
collected by scraping the cells with a pipette tip. Protein samples were then 
passed through a 25 gauge needle 5 times and briefly centrifuged to remove cell 
debris.  The supernatant containing protein was then transferred to a fresh 1.5 
ml centrifuge tube and stored at -20°C.  
 
2.4.1 Measuring Protein Concentration 
 
The total protein concentration of each lysate was determined using a 
bicinchoninic acid (BCA) assay kit (Pierce) according to the manufacturer’s 
instructions.  A set of 9 albumin protein standards ranging from zero to 2000 
µg/ml were prepared by diluting each standard in PBS and used to generate a 
standard curve. The BCA working reagent (WR) was prepared by mixing BCA 
Reagent A with BCA Reagent B at a ratio of 50:1 (A:B).  The total volume of 
working reagent required was calculated as follows: (no. of standards + no. of 
unknown samples) x (no. of replicates) x (volume of WR per sample).  Each 
standard and sample (25 µl) was assayed in duplicate in a 96 well plate and 200 
µl of the WR was added to each well.  The plate was then covered to protect 
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from light and incubated at 37°C for 30 minutes.  Following incubation the plate 
was cooled to room temperature and the absorbance from each well was read at 
560nm using a Wallac Victor2 plate reader.  Each standard and sample was 
measured in duplicate and average readings were taken.  A standard curve was 
generated and the protein concentration in each sample was determined from 
the curve using ‘Work-Out’ software (Wallac). 
 
2.5 Western Blot  
 
Western blotting was performed to assess levels of protein expression. 
 
2.5.1 Gel Electrophoresis 
 
Proteins were resolved by SDS PAGE (sodium dodecyl sulphate polyacrylamide 
gel electrophoresis) in a Hoefer SE 600 gel electrophoresis tank.  A 12% resolving 
gel was prepared and poured between 18 cm x 16 cm glass plates followed by a 
4% stacking gel poured on top.  The 12% resolving gel consisted of 40% (v/v) 
polyacrylamide (30%) (BIORAD), 0.375M Tris pH 8.8, 0.1% (v/v) SDS, 300 µl 
ammonium persulphate (APS) and 30 µl TEMED (N,N,N',N'-
tetramethylethylenediamine).  The 4% stacking gel consisted of 13.3% (v/v) 
polyacrylamide (30%), 0.125M Tris pH 8.8, 0.1% (v/v) SDS, 300 µl APS and 30 µl 
TEMED.   
 
Protein samples and controls were added to 2X Laemmli sample buffer (Sigma 
Aldrich) in a 1:1 ratio to a maximum volume of 60 µl and heated to 100°C for 10 
minutes.  Amersham low range rainbow molecular weight markers (GE 
Healthcare Life Sciences) were loaded (15 µl) to allow for determination of 
protein size.  Samples were loaded into the wells of the gel and subjected to 
electrophoresis at 100V for 1 hour in running buffer (0.025M Tris-HCl, 0.2M 
glycine and 0.001M SDS).  Once through the stacking gel, the voltage was 
increased to 200V for approximately 3 hours until proteins were sufficiently 
resolved as determined by the separation of the rainbow markers.   
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After electrophoresis the gel and six sheets of Whatman 3 mm chromatography 
blotting paper were prepared for transfer by placing in transfer buffer (0.025 M 
Tris, 0.2 M glycine, 20% (v/v) methanol and 0.01% (v/v) SDS) for 20 minutes.  
Hybond™-P nitrocellulose membrane (Amersham) was prepared by wetting with 
methanol for 5 seconds and then soaking in distilled water for 5 minutes 
followed by 10 minutes in transfer buffer.  A transfer cassette was then set up 
(cathode to anode) as follows: 3 sheets of blotting paper, gel, membrane and 
another 3 sheets of blotting paper Resolved proteins were transferred onto the 
nitrocellulose membrane overnight at 90mA in transfer buffer in a Hoefer TE 50X 
transfer tank.  
 
2.5.2 Antibody Probing  
 
Following transfer, the membrane was blocked for at least 6 hours (with shaking) 
in a 10% (w/v) milk solution (blocking buffer) prepared in Tris-buffered saline 
Tween buffer (TBS-T) (0.025 M Tris pH7.4, 0.14 M NaCl, 0.0027 M KCl, 0.1% (v/v) 
Tween 20 (Sigma)).  After blocking, the membrane was incubated in primary 
antibody solution at 4°C overnight, with shaking.  The membrane was then 
washed 6 times for 5 minutes with TBS-T and then incubated with a secondary 
antibody conjugated to horseradish peroxidase (Dako) for 1 hour at room 
temperature.  All antibodies were diluted to the required concentration in 
blocking buffer.  The membrane was washed again as described previously.   
 
2.5.3 Enhanced Chemiluminescence and Detection 
 
Bands were detected using Amersham ECL (enhanced chemiluminescence) 
western blotting detection reagents (GE Healthcare).  Equal quantities of the 
two reagents were mixed and poured over the membrane, ensuring the 
membrane was completely covered.  After 3 minutes at room temperature, the 
membrane was removed from the ECL reagents and any excess was drained off.  
The membrane was then wrapped in Saran wrap and placed in an 
autoradiography cassette.  Film exposure and development was carried out in a 
dark room.  Kodak general purpose medical X-ray film was used and films were 
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exposed for varying lengths of time from 5 seconds to overnight.  Films were 
developed in a Kodak X-Omat 1000 developer. 
 
2.5.4 Densitometry 
 
To ensure that any change in protein level was not due to unequal loading, 
membranes were stripped and re-probed for β-actin.  The membrane was 
incubated with stripping buffer (0.2 M glycine and 1% (v/v) SDS at pH 2.2) for 30 
minutes at room temperature then washed twice for 10 minutes in TBS-T.  The 
membrane was blocked as before and incubated at 4°C overnight with a mouse 
β-actin antibody (Abcam) used at a dilution of 1/1000.  Bands were detected on 
X-ray film as before.   
 
To normalise each band, the X-ray films were scanned using the BIORAD Fluor-S 
Multi-imager and bands were quantified using ‘Quantity One’ software (BIORAD).  
The intensity of each band was determined by the software using the global 
background subtraction method and expressed in units of optical density per 
mm2 (ODU/mm2).  The adjusted volume value for each band was divided by the 
equivalent value obtained for the β-actin band to give a final value corrected for 
loading.  
 
2.6 RNA Extraction 
  
RNA was extracted from NRK-52E cells using an RNeasy Mini Kit (Qiagen), 
according to the manufacturer’s guidelines.  Cell culture medium was removed 
and cells were rinsed twice with PBS.  Cells were lysed by scraping with a 
pipette tip in 350 µl buffer RLT containing guanidine isothiocyanate with the 
addition β-mercaptoethanol (10µl/ml).  The lysates were transferred to RNase 
free 1.5 ml centrifuge tubes and mixed with 350 µl 70% ethanol by pipetting.  
The samples were transferred to RNeasy mini columns allowing RNA to bind to 
the membrane and then centrifuged at 8000 g for 15 seconds and the flow-
through discarded.  The columns were washed with 700 µl Buffer RW1 and 
centrifuged at 8000 g for 15 seconds.  The columns were then washed with 500 
µl Buffer RPE and centrifuged at 8000 g for 15 seconds.  This wash step was 
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repeated but centrifuged at 8000 g for 2 minutes.  The flow-through was 
discarded and the column was centrifuged again for 1 minute at full speed to 
remove any residual buffer.  RNA was eluted in 40 µl nuclease free water, put 
through the column twice and centrifuged at 8000 g for 1 minute.  RNA samples 
were stored at -80°C.  
2.6.1 DNase Treatment of Extracted RNA 
 
To remove any contaminating DNA from RNA preparations, samples were 
subjected to TURBO DNA-free DNase treatment (Applied Biosystems).  Samples 
were transferred to 0.5 ml RNase free centrifuge tubes.  To each sample, 0.1 
volumes of 10X TURBO DNase buffer and 1 µl TURBO DNase were added and 
mixed gently followed by incubation at 37°C for 30 minutes.  Re-suspended 
DNase inactivation reagent was then added to each sample (0.1 volumes) and 
incubated for 2 minutes at room temperature with occasional mixing.  To 
remove the DNase inactivation reagent, samples were centrifuged at 10,000 g 
for 1.5 minutes.  This step pellets the DNase inactivation reagent and the 
supernatant containing the RNA can be transferred to a fresh RNase free tube.     
 
2.6.2 Nucleic Acid Quantification 
 
Total RNA or DNA concentrations were quantified using the NanoDrop ND-1000 
Spectrophotometer and ND-1000 v3.1.0 programme.  For each sample, 1.5 µl of 
either DNA or RNA was quantified.  An absorbance ratio (260nm/280nm) of 
approximately 2 for RNA and 1.8 for DNA indicated nucleic acid samples of high 
purity.   
 
 
2.7 Reverse Transcription   
 
TaqMan® Reverse Transcription Reagents (Applied Biosystems) were used to 
generate 1st strand cDNA from 1 µg of total RNA using random hexamer primers.  
Nuclease free water was added to 1 µg of total RNA to give a volume of 7.7 µl.  
The reverse transcription reaction mix was prepared as follows:  
• 2 µl 10X TaqMan RT buffer 
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• 4.4 µl 25mM magnesium chloride 
• 4 µl deoxyNTPs mixture 
• 1 µl random hexamer primers 
• 0.4 µl RNase inhibitor 
• 0.5 µl MultiScribe reverse transcriptase (50U/µl). 
 
This was added to the RNA sample to give a final reaction volume of 20 µl.  Two 
control samples were also run; 1 blank (no RNA in sample) and 1 no RT control 
(nuclease free water was added instead of reverse transcriptase).  Reverse 
transcription was carried out using the following thermal cycling parameters:  
• 10 minutes at 25°C 
• 30 minutes at 48°C 
• 5 minutes at 95°C 
 
cDNA samples were stored at -20°C until ready for use. 
 
2.7.1 TaqMan® Quantitative Real-Time Polymerase Chain Reaction  
 
Quantitative real-time PCR (qRT-PCR) was performed on cDNA using Applied 
Biosystems Gene Expression Assays and the ABI PRISM 7900ht Sequence Detection 
System.  The comparative CT method (2
-∆∆Ct)(171) was used to determine 
expression of the gene of interest relative to a β-actin house-keeping control 
gene.  Efficiency tests were performed for each gene of interest to determine 
whether the assays for both the control gene (β-actin) and gene of interest could 
be performed in the same well (duplex) or separate wells (simplex).  If the gene 
of interest amplified with equal efficiency to the control gene then both assays 
could be run in duplex, if not then they were run separately.  Serial dilutions of 
a cDNA template were prepared and set up in simplex and duplex reactions for 
each gene of interest and the β-actin control gene.  Efficiencies were calculated 
according to the manufacturer’s instructions (ABI PRISM 7700 Sequence 
Detection System User Bulletin #2).  The Ct values were plotted against log 
(dilution) for the gene of interest and β-actin and the gradient of each slope was 
compared.  If the absolute value of the slope was <0.1 then the efficiencies 
were considered to be equal.  
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For each gene of interest a 5µl duplex reaction was set up in a 384 well plate 
consisting of: 
• 0.25µl FAM labelled probe 
• 0.25µl VIC labelled probe 
• 2µl of template cDNA 
• 2.5µl of TaqMan® Universal PCR master mix 
 
The probes for the gene of interest were tagged to FAM labelled fluorescent dyes 
and β-actin probes were tagged to VIC labelled fluorescent dyes.  If the 
efficiency of the gene of interest was not equal to β-actin, then a simplex 
reaction was prepared with nuclease free water added in place of the second 
probe.  All samples were assayed in duplicate or triplicate and subjected to the 
following temperature cycling: 
• 50°C for 2 minutes 
• 95°C for 10 minutes 
• 35 cycles of 95°C for 15 seconds followed by 60°C for 1 minute 
 
 
2.8 Production of Short Hairpin RNA Expressing Plasmids 
 
The pShuttle-CMV vector (Stratagene) was used to generate Gstm1 targeting and 
control short-hairpin RNA (shRNA) expressing vectors (pShuttle-CMV-shRNA), see 
Figure 2.1. 
 
2.8.1 pShuttle-CMV Plasmid DNA Purification 
 
The pShuttle-CMV vector (Figure 2.1) was grown from a glycerol stock by 
streaking onto Luria agar (Sigma) plates containing kanamycin at 50 µg/ml.  
Plates were inverted and incubated at 37°C overnight.  A single colony was 
picked and added to 10 ml Luria broth (LB) plus kanamycin and incubated with 
shaking at 37°C for approximately 8 hours.  After this time, cells were 
transferred to 2 litre flasks containing 500 ml of LB and left to incubate at 37°C 
overnight with shaking. 
 
 74 
The following day, the culture was transferred to sterile bug pots and bacteria 
were harvested by centrifugation at 6000 g for 15 minutes at 4°C in a Beckman 
Coulter Avanti J-26XP.  Plasmid DNA was extracted using the Qiagen Plasmid 
Maxi Kit, according to kit instructions.  The bacteria pellet was re-suspended in 
10 ml buffer P1 (lysis buffer) until no clumps were visible and 10 ml buffer P2 
was added.  The pot was inverted 4-6 times to mix and then 10 ml chilled buffer 
P3 was added.  The pot was inverted again and then kept on ice for 20 minutes.  
The lysates were then subjected to centrifugation at 20,000 g for 30 minutes at 
4°C.  The supernatant was retained and transferred to equilibrated columns 
(equilibrated with 10 ml buffer QBT).  The supernatant was allowed to 
completely run through the column before the column was washed twice with 30 
ml buffer QC.  Plasmid DNA was eluted with 15 ml buffer QF into polypropylene 
centrifuge tubes and DNA was precipitated by the addition of 10.5 ml 
isopropanol and centrifuged at 15,000 g for 30 minutes at 4°C. The supernatant 
was carefully poured off and the pellet was re-suspended in 5 ml 70% ethanol 
and centrifuged at 15,000 g for 10 minutes at room temperature.  The ethanol 
was carefully removed by pipette and the DNA pellets were left to air dry for 
approximately 10 minutes before being re-suspended in 200 µl nuclease free 
water.  The plasmid DNA concentration was quantified as described in section 
2.5.2 and stored at -20°C 
 
2.8.2 Restriction Digest 
 
To enable cloning of the shRNA sequences into the pShuttle-CMV backbone, 
plasmid DNA was digested with restriction enzymes.  A total of 3 µg of DNA was 
digested in a reaction containing 4-CORE SYSTEM reaction buffer (Promega) and 
a 10-fold excess of enzyme over DNA, as per manufacturer’s instructions.  
Typically a 20 µl reaction was carried out, including 1.5 µg plasmid DNA, 2 µl 10X 
restriction buffer, 0.2 µl BSA and 1.5 µl of each restriction enzyme (10U/µl) so 
that there was a 10-fold excess of each enzyme per reaction.  The reagents were 
mixed gently, then centrifuged briefly and incubated in a water bath at 37°C 
overnight. 
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Figure 2.1 pShuttle-CMV vector and shRNA sequences 
A: Outline of the pShuttle-CMV vector map used to generate shRNA expressing 
plasmids (172).  B: Oligonucleotides encoding each shRNA as shown above were 
cloned into the pShuttle-CMV vector backbone. 
 
shRNA B CCTATATTTTCGAAGTTG
GTGGATATAAAAGCTTCAAC
T 
T C 
A 
A 
G 
A G 
A 
shRNA C CCTCACAGTCCTTTTCTG
TTGGAGTGTCAGGAAAAGAC
T 
T C 
A 
A 
G 
A G 
A 
shRNA SCR ACTACCGTTGTTATAGGT
TTTGATGGCAACAATATCCA
T 
T C 
A 
A 
G 
A G 
A 
A 
B 
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2.8.3 Agarose Gel Purification 
 
The digested plasmid DNA fragments were separated by agarose gel 
electrophoresis.  A 1% agarose gel (Eurogentec) was prepared in 1X Tris-Borate 
EDTA (TBE) (Fisher Bioreagents) containing 1µl ethidium bromide (Sigma) per 100 
ml of molten agarose.  Loading dye (6X) (50% glycerol and 0.05% bromophenol 
blue) was added to the DNA sample and to a control sample (linearised pShuttle-
CMV DNA).  Samples and a 1kb DNA ladder were subjected to electrophoresis at 
6 volts per cm length of gel.  Gels were visualised by UV transillumination on a 
BIO-RAD Fluor-S Multi-Imager.  Electrophoresis was stopped after clear resolution 
of bands was observed.  The band containing digested pShuttle-CMV DNA was cut 
out of the gel and DNA was extracted using the Wizard SV gel and PCR clean up 
system (Promega).  The gel band was weighed and stored in a 1.5 ml tube.  
Membrane binding solution was then added (10 µl per 10 mg of gel) and 
incubated at 65°C for 10 minutes until agarose had melted.  DNA was then 
extracted using the kit protocol provided and then eluted into 50 µl of nuclease 
free water. 
 
2.8.4 Annealing and Ligation 
 
Oligonucleotides encoding shRNA based on the siRNA sequences already 
evaluated were designed to include ends that were compatible with restriction 
sites present in the multiple cloning site of pShuttle-CMV (Figure 2.1).  The 
oligonucleotide concentration required for annealing was 1 µg/µl.  To achieve 
this, oligonucleotides were first diluted with nuclease free water to 2 µg/µl and 
then diluted to 1 µg/µl in 1X TE.  Oligonucleotides were annealed in a reaction 
containing 46 µl 1X DNA Annealing Solution (Ambion) and 2 µl of each 
oligonucleotide (top and bottom).  The reaction was incubated at 90°C for 3 
minutes followed by 1 hour at 37°C.  Annealed oligonucleotides were stored at -
20°C. 
 
The NEB Quick Ligation kit was used to ligate the different Gstm1 shRNA inserts 
into the pShuttle-CMV vector backbone.  A 100:1 insert to vector ratio was used 
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with 100 ng of vector in each ligation.  The following equation was used to 
calculate how much insert to add to each ligation reaction: 
 
((ng of vector x kb size of insert) / kb size of vector) x (molar ratio of insert to 
vector) 
 
The ligation reaction was then carried out according to the manufacturer’s 
instructions.  A reaction mix was prepared containing 100 ng vector and a 100-
fold molar excess of insert adjusted to 10 µl with water,  10 µl 2X Quick Ligation 
Buffer and 1 µl T4 DNA Ligase, this was mixed gently, centrifuged briefly and 
incubated at room temperature for 5 minutes.  After ligation, samples were kept 
on ice until required for transformation. 
 
2.8.5 Transformation of DH5α Cells 
 
MAX Efficiency DH5α competent cells (Invitrogen) were thawed gently on ice for 
approximately 5 minutes.  Once thawed, 50 µl of competent cells were 
transferred into pre-chilled 1.5 ml tubes and kept on ice.  Ligation reactions 
were diluted 5-fold in 10 mM Tris-HCL, 1 mM EDTA and then 1 µl of the dilution 
was added to one 50 µl aliquot of cells.  To determine transformation efficiency, 
a control transformation was carried out with 50 pg of control plasmid DNA 
(ampicillin resistant pUC19).  The cells were kept on ice for 30 minutes, heat 
shocked at 42°C for 45 seconds and then returned to ice for a further 2 minutes.  
Cells were removed from the ice and 0.9 ml of room temperature SOC media 
was added to each aliquot followed by 1 hour incubation at 37°C with shaking.  
The control plasmid transformation was diluted 1:100 and 100 µl was plated onto 
an agar plate containing ampicillin.  For all other transformations, 200 µl was 
spread onto agar plates with kanamycin (50 µg/ml).  The plates were kept in a 
37°C incubator overnight. 
 
2.8.6 Polymerase Chain Reaction (PCR) 
   
After overnight incubation, plates were removed from the incubator and the 
number of colonies on each plate was determined.  Single colonies were picked 
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and added to nuclease free water in a 96 well PCR plate.  A PCR master mix was 
then prepared containing:  
• 10X PCR buffer (plus 20mM MgCl2)  
• 2.5 µl forward primer (2µM)  
• 2.5 µl reverse primer (2µM)  
• 4 µl dNTPs (1mM) 
• 0.2 µl Taq (5U/µl). 
 
This was added to each well to give a final reaction volume of 20 µl.  Each 
sample was then subjected to: 
• 4 minutes at 95°C  
• 34 cycles of 30 seconds at 94°C 
• 30 seconds at 58°C 
• 1 minute at 72°C  
• 7 minutes at 72°C.   
 
A 1.5% agarose gel was prepared in 1X TBE containing 2µl ethidium bromide.  
Loading dye (6X) was added to 10 µl of each PCR reaction and subjected to 
electrophoresis at 150V for 1½ hours alongside a 50bp DNA ladder (Promega).  
Reactions that generated a band at the correct size were purified and 
sequenced. 
 
2.8.6.1 PCR Purification 
 
PCR samples were purified using an AMPure PCR purification kit (Agencourt) 
according to manufacturer’s instructions.  Briefly, 18 µl of AMPure reagent was 
added to each PCR reaction in a 96 well plate.  Reagents were mixed, 
centrifuged at 1000 rpm for 1 second and incubated for 4 minutes at room 
temperature.  The plate was then placed on a SPRI magnet plate for 8 minutes.  
With the plate on the magnet, the plate was inverted and the cleared solution 
was discarded.  Fresh 70% ethanol was prepared and 200 µl was added to each 
well and incubated for 30 seconds.  The plate was inverted onto tissue and 
centrifuged at 600 rpm for 1 second then left to air dry for 20 minutes.  Once 
dry, 40 µl of nuclease free water was added to each well, mixed and centrifuged 
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at 1000 rpm for 1 second.  Cleaned products were then transferred to a 96 well 
plate and stored at -20°C until required for sequencing. 
 
2.8.7 Sequencing 
 
Forward and reverse strand sequencing was carried out on each PCR sample 
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).  
The sequencing reaction was carried out in a 96 well plate and prepared as 
follows: 
• 10 µl of each PCR sample 
• 1 µl Ready Reaction Mix 
• 4µl of BigDye Terminator Sequencing Buffer (5X) 
• 2µl of forward or reverse primer (2µM) 
• Nuclease free water to a final volume of 20 µl   
 
Each reaction was then subjected to: 
• 25 cycles of 45 seconds at 96°C 
• 25 seconds at 50°C 
• 4 minutes at 60°C 
• 5 minutes at 12°C. 
 
 
2.8.7.1 Sequencing Clean-up 
 
Dye terminator removal was carried out on each sequencing reaction using the 
Agencourt CleanSeq Dye Terminator Removal Kit.  Briefly, 10 µl of room 
temperature CleanSeq was added to each sequencing reaction, followed by the 
addition of 62 µl of 85% ethanol.  The reagents were mixed and centrifuged to 
1000 rpm for 1 second.  The plate was then placed on a SPRI magnet plate for 3 
minutes.  With the plate on the magnet, the plate was inverted and the cleared 
solution discarded.  Then 150 µl of 85% ethanol was added to each well and 
incubated at room temperature for 30 seconds.  The plate was inverted on tissue 
paper, centrifuged to 600 rpm and then left to air dry for 20 minutes.  Once dry, 
40 µl of nuclease free water was added to each well and centrifuged to 1000 
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rpm.  The cleaned sequencing product (20 µl) was then transferred to a bar-
coded 96 well plate and analysed with the Applied Biosystems 3730 DNA Analyzer 
and SeqScape v2.5 software.  
 
2.9 Immunohistochemistry 
 
2.9.1 Rat Tissue Preparation 
 
Tissues were rinsed in PBS and cut into sections.  Each section was fixed in 10% 
formalin solution at 4°C overnight.  After overnight fixing, the formalin solution 
was removed and replaced with PBS.  The fixed tissues were then embedded into 
paraffin.  Using a microtome, 3 µm paraffin kidney sections were cut and baked 
onto microscope slides at 60°C for 3 hours followed by overnight incubation at 
40°C to ensure that the tissue section adhered to the slide. 
 
2.9.2 Deparaffinisation and Rehydration of Sections 
 
Slides were placed in racks then sections were deparaffinised and rehydrated 
through an alcohol gradient consisting of Histoclear, twice for 3 minutes, 
Histoclear and 100% ethanol (1:1 ratio) for 3 minutes, 100% ethanol, twice for 3 
minutes, 95% ethanol for 3 minutes, 70% ethanol for 3 minutes, 50% ethanol for 3 
minutes and a final rinse in running cold tap water. 
 
2.9.3 Primary Antibody  
 
Sections were washed twice for 5 minutes in TBS plus 0.025% Triton X-100.  The 
slides were then transferred onto humidified trays and a wax pen was used to 
draw around each section.  The sections were then blocked in 10% (v/v) normal 
goat serum in TBS for 2 hours at room temperature.  The blocking solution was 
drained off and sections were incubated with primary antibody or negative 
control IgG diluted in 1% goat serum in TBS overnight at room temperature.  
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2.9.4 Secondary Antibody 
 
Sections were washed twice for 5 minutes in TBS plus 0.025% Triton X-100, then 
incubated for 30 minutes in 0.03% H2O2 diluted in methanol to quench 
endogenous peroxidase activity.  The slides were returned to humidified trays 
and sections were incubated with biotinylated secondary antibody from the 
Vectastain ABC kit, for 30 minutes at room temperature.  Sections were washed 
with TBS, 3 times for 5 minutes and then ABC complex (pre-incubated for 30 
minutes) was added to each section and incubated at room temperature for 30 
minutes (according to manufacturer’s instructions). 
 
2.9.5 Staining 
 
Sections were washed 3 times for 5 minutes in TBS.  Sections were then 
incubated with DAB chromogen (3, 3’-diamionbenzidine, Vector Lab DAB 
Substrate Kit) plus nickel solution to produce black staining, for 5 minutes at 
room temperature in humidified trays.  Sections were washed for 5 minutes in 
distilled water and counter-stained with haematoxylin for 10 seconds followed 
by 5 minutes in running tap water.  The sections were then dehydrated by 
putting through an alcohol gradient as described before, in reverse.  Sections 
were cover-slip mounted using Histomount (National Diagnostics).  
 
2.10 Haematoxylin and Eosin Staining 
 
Following the removal of paraffin and rehydration of sections as described in 
section 2.9.2, sections were stained with haematoxylin for 2 minutes.  Slides 
were then washed in running tap water for 5 minutes and then transferred to 
eosin for 2 minutes.  Slides were washed again for 5 minutes in running tap 
water.  Sections were dehydrated through an alcohol gradient and cover-slip 
mounted using Histomount.  
2.11 Statistical Analysis 
 
Analysis of results for multiple groups was performed by one way analysis of 
variance (ANOVA) and Dunnet’s post-hoc test, comparing all results to a 
designated control group.  For comparisons between two groups, 2 sample t-
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tests were applied.  Statistical analysis was performed using Prism 4.0 Graph Pad 
Software.  Significance was determined as p<0.05.   
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Chapter 3: Development of Molecular Tools for Modulation of 
Gstm1 Expression 
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3.1 Introduction 
 
Glutathione S-transferase mu type 1 (Gstm1) has been identified as a positional 
and functional candidate gene for hypertension in the SHRSP (69).  At present 
there are no selective pharmacological inhibitors of Gstm1 making further 
investigation of its function difficult.  To overcome this, an approach involving 
RNA interference (RNAi) has been adopted.  RNA interference is an endogenous 
gene silencing mechanism that can be exploited to experimentally reduce the 
expression of a particular gene of interest (137).  In vitro knock-down of gene 
expression has been successfully achieved through the introduction of chemically 
synthesised gene specific siRNA (152).  To assess siRNA mediated silencing of 
Gstm1 expression in vitro an appropriate cell line had to be chosen.  Previous 
work carried out by our group found that Gstm1 expression was localised to the 
tubular epithelium of the kidney, particularly the collecting ducts (77).  For this 
reason, in vitro RNAi experiments have been carried out in the rat cell line NRK-
52E, a renal tubular cell line.  
 
3.1.1 Adenoviral Vectors 
 
To utilise RNAi for in vivo gene knock-down, adenoviral vectors have been used 
to drive the expression of short hairpin RNA molecules that mediate gene 
silencing (173).  Recombinant adenovirus serotype 5 (Ad5) vectors have been 
commonly used for delivery as they are able to infect both dividing and non-
dividing cells and have a broad cellular tropism.  However, Ad5 vectors have a 
high hepatic tropism so that when delivered systemically most vectors end up in 
the liver (174;175).  This characteristic means that Ad5 vectors are not practical 
for site specific delivery via systemic administration.  
 
The adenoviral capsid is composed of three main structural proteins; hexon, 
fiber and penton base.  The fiber is a major determinant of virus tropism and is 
composed of an N-terminal tail, a central shaft and a C-terminal knob domain 
(176).  The fiber knob domain interacts with the coxsackie virus and adenovirus 
receptor (CAR) to mediate cell binding and infection.  As mentioned previously, 
Ad5 vectors have a high hepatic tropism but recent studies have shown that 
following intravascular administration, CAR is not involved in liver transduction.  
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Following intravascular injection of mutant Ad5 vectors that are unable to bind 
CAR, liver transduction is the same as unmodified vectors that are able to bind 
CAR, indicating that another pathway is involved (177).  Ad5 vectors have been 
shown to bind blood coagulation factors and when mutations were introduced 
into the fiber domain to ablate blood factor binding, reduced liver cell 
transduction was observed (178).  It has since been shown that the Ad5 hexon 
protein interacts with the vitamin K dependent coagulation factor X (FX) and in 
doing so mediates liver transduction (179-181).   
 
3.1.1.1 Adenoviral Vector Tropism 
 
High hepatic tropism is problematic for site specific delivery but it has been 
shown that it is possible to modify tropism by pseudotyping Ad5 vectors with a 
fiber from another serotype.  To aid the re-targeting of Ad5 gene therapy 
vectors, a helper independent adenovirus vector expressing the β-galactosidase 
reporter gene and with E1, E3 and fiber genes deleted (Ad5.βgal.∆F) was 
developed (182).  This vector in combination with packaging cell lines that 
express the fiber gene of choice would allow for easier modification of virus 
tropism (183).   Previous work carried out by our group found that pseudotyping 
Ad5 with the fiber from serotype Ad19p (Ad5/19p) reduced hepatic tropism 
(184).  The ability of Ad5/19p to infect cultured rat, mouse and human 
hepatocyte cells was significantly reduced compared to unmodified Ad5 and 
following systemic administration in vivo a similar reduction in liver transduction 
was observed (184).  This Ad5/19p pseudotyped vector was further developed to 
enable it to target the kidney specifically.  In vivo phage display was utilised to 
identify the peptides HTTHREP (HTT) and HITSLLS (HIT) both of which selectively 
target the kidneys in rats.  The Ad19p fiber gene was genetically modified to 
allow peptide insertion and oligonucleotides encoding HTT and HIT were cloned 
into modified fiber expressing plasmids.  The plasmids were used to generate 
peptide modified vectors that when systemically delivered to WKY rats were 
found to localise to kidney tubular epithelium (Ad19p-HTT) and glomeruli 
(Ad19p-HIT) (185).  The use of such targeted vectors provides a powerful tool for 
site specific knock-down of Gstm1.  It has previously been shown that Gstm1 
expression is localised to the tubular epithelium, specifically in the collecting 
ducts (77).  Therefore Ad19p-HTT would be an appropriate choice of vector for 
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expression of Gstm1 shRNA to allow for the role of Gstm1 to be investigated 
more fully in vivo.  
 
 
3.1.2 RNA Interference and Immune System Activation 
 
The use of targeted adenoviral vectors for knock-down of gene expression may 
overcome the transduction issues associated with systemic delivery but there is 
still the possibility that delivery of dsRNA could activate the innate immune 
response (186).  Double stranded RNA is recognized by cells as a by-product of 
viral replication and so to counteract this, the interferon (IFN) system is induced 
and protein synthesis is inhibited.  Double stranded RNA longer than 30 bp has 
been found to stimulate the IFN response (152). 
 
3.1.2.1 Oligoadenylate Synthetase  
 
The 2'-5'-oligoadenylate synthetases (2'-5'OAS) have been characterised as IFN 
induced enzymes activated by dsRNA molecules longer than 15bp (187).  
Oligoadenylate synthetase 1 (OAS1) is one of four members of the mammalian 2'-
5'OAS family (186).  The enzyme is composed of two domains that when 
assembled form a dsRNA binding site and when bound by dsRNA result in enzyme 
activation (188).  Once activated, 2'-5'OAS uses ATP to form 2'-5' linked oligomers 
of adenosine (2'-5'oligoadenylates or 2-5A) which in turn bind and activate the 
endoribonuclease, RNase L.  This leads to degradation of both foreign and 
cellular RNA and a subsequent reduction in protein synthesis (189).  
 
Early studies carried out to investigate in vitro silencing of gene expression by 
dsRNA found that the introduction of long dsRNA (>30 bp) to rabbit reticulocyte 
lysates caused substantial non-specific mRNA degradation (136).  This was likely 
due to the activation of RNase L by the presence of long dsRNA as previously 
observed by Williams and colleagues (190).  However, it has been proposed that 
short dsRNAs would not activate 2'-5'OAS and it has been observed that dsRNA 
between 21 and 27 bp long are poor inducers of 2'-5'OAS in vitro (186;191). 
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3.2 Aims 
 
• To evaluate 3 different siRNA sequences designed to be specific for Gstm1 
for their ability to knock-down Gstm1 expression in vitro and quantify 
expression at both mRNA and protein level 
 
• To investigate non-specific effects on other members of the Gstm family 
in response to Gstm1 specific siRNA  
 
• To determine if introduction of Gstm1 specific siRNA into renal cells leads 
to induction of an interferon response  
 
• To generate plasmids expressing Gstm1 specific and control shRNAs and 
evaluate their function 
 
• To assess targeting of kidney tubules by modified adenoviral vectors 
 
• To assess methods for local delivery of siRNA/shRNA to renal cells in vivo   
 
 
3.3 Methods 
 
3.3.1 Transfection of NRK-52E Cells with siRNA 
 
Short interfering RNA sequences targeted against Gstm1 were evaluated for their 
ability to knockdown gene expression in NRK-52E cells.  Transfections were 
carried out as described in section 2.3.  Transfected cells were incubated at 
37°C for 48 hours and then protein or RNA was extracted for analysis by western 
blot or quantitative real-time PCR. 
 
3.3.2 Transfection of NRK-52E Cells with Plasmid DNA 
 
Each transfection experiment was performed in triplicate and included an 
untransfected control (UTF) and a mock transfection control (cells treated with 
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transfection reagent only) (TFC).  In experiments involving transfection of 
pShuttle-CMV-shRNA vectors, a control vector (SCR) that expresses a scrambled 
shRNA sequence (based on the negative siRNA control used previously that has 
no known homology to any expressed genes) was also used. 
 
3.3.2.1 FuGENE® 6 Transfection 
 
FuGENE® 6 (Roche) is a proprietary mix of lipids in 80% ethanol that facilitates 
the transfer of plasmid DNA across cell membranes.  NRK-52E cells were cultured 
in 6 well tissue culture plates until 70% confluent.  Transfection complexes were 
prepared at a ratio of 6:3 (µl FuGENE® reagent : µg of plasmid DNA).  Per well, 6 
µl FuGENE® reagent was added directly to 94 µl OptiMEM® Reduced Serum 
Medium in a 1.5 ml tube, mixed gently and incubated at room temperature for 5 
minutes.  To the transfection reagent mix, 3 µg of plasmid DNA was added and 
incubated for 25 minutes at room temperature.  The transfection reagent/DNA 
complex was added drop-wise to each well containing 2 ml normal growth 
medium.  Plates were gently rocked back and forth to disperse the transfection 
complex and then incubated at 37°C for 48 hours.  
 
3.3.2.2 Lipofectamine™ 2000 Transfection 
 
NRK-52E cells were cultured in 6 well tissue culture plates until 80%-90% 
confluent.  Lipofectamine™ 2000 (Invitrogen) is a proprietary cationic lipid 
formulation.  Transfection complexes were prepared at a ratio of 3:1 (µl 
Lipofectamine™ 2000 : µg plasmid DNA).  Per well, 5 µl Lipofectamine™ 2000 
reagent was added to 245 µl OptiMEM® Reduced Serum Medium, mixed gently 
and incubated for 5 minutes at room temperature.  A volume of plasmid DNA (2 
µg) was diluted to 250 µl with OptiMEM® Reduced Serum Medium.  The diluted 
DNA was then combined with the diluted Lipofectamine™ 2000 reagent and 
incubated for 20 minutes at room temperature.  The culture medium was 
removed from each well and cells were washed twice with 2 ml sterile PBS.  To 
each well, 500 µl OptiMEM® Reduced Serum Medium was added followed by 500 
µl of the Lipofectamine™ 2000/DNA complex, added drop-wise.  Plates were 
gently rocked back and forth to disperse the transfection complex and incubated 
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for 5 hours at 37°C.  After this time, 2 ml of normal growth medium containing 
20% (v/v) FCS was added to each well.  Cells were incubated at 37° for a further 
48 hours. 
 
 
3.3.3 β-galactosidase Expression Staining 
 
NRK-52E cells with transfected with the p-Shuttle-CMV-LacZ vector (Stratagene) 
to assess transfection efficiency.  Following transfection, cell culture medium 
was removed from each well and cells were washed twice with 2 ml sterile PBS.  
To fix cells, 2 ml 2% paraformaldehyde in 0.1M sodium phosphate (72 mM 
Na2HPO4, 23 mM NaH2PO4) was added to each well and cells were kept on ice for 
15 minutes.  The paraformaldehyde was removed and cells were washed again 
with PBS.  To each well, 2 ml X-Gal (5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside) stain (77mM Na2HPO4, 23mM NaH2PO4, 1.3mM MgCl2, 3mM 
K4Fe(CN)6, 0.05% (v/v) 20 mg/ml X-Gal dissolved in dimethyl formamide) was 
added and cells were incubated at 37°C overnight.  After overnight incubation, 
cells were examined under a microscope for blue staining. 
 
 
3.3.4 Gstm1 Western Blot Analysis 
 
Protein samples were prepared and quantified as described in sections 2.4 and 
2.4.1.  Gel electrophoresis and blotting were carried out on these samples as 
described in section 2.5.1  Into each lane, 30µg of protein sample prepared in an 
equal volume of 2x sample reducing buffer was loaded and a low range rainbow 
marker was used to determine band size.  A rat GSTM1 purified protein standard 
(Yb1) was also loaded as a positive control (Oxford Biomedical).  For immuno-
detection the membrane was incubated at 4°C overnight with a rabbit anti-rat 
GSTM1 polyclonal antibody (gift from Prof. John Hayes, University of Dundee) 
used at a dilution of 1/2000 followed by a goat anti-rabbit IgG secondary 
antibody conjugated to horseradish peroxidase (Dako) at 1/2000 for one hour at 
room temperature.  Bands were visualised using enhanced chemiluminescence, 
as described in section 2.5.3. 
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3.3.5 Gstm Family mRNA Expression 
 
RNA was extracted from NRK-52E cells and 1st strand cDNA was generated as 
described in sections 2.6 and 2.7.  Quantitative RT-PCR was performed on cDNA 
using TaqMan Gene Expression Assays (Applied Biosystems) for Gstm1 (Assay ID: 
Rn00755117_m1), Gstm2 (Rn00598597_m1), Gstm3 (Rn00579867_m1), Gstm5 
(Rn00597012_m1) and Gstm7 (Rn00579867_m1)  (FAM labelled probes) in duplex 
with β-actin (Assay ID: 4352340E) (VIC labelled probe).  Efficiency tests were 
carried out (section 2.7.1) to ensure that the β-actin housekeeper was 
compatible with each of the Gstm probes allowing each reaction to be carried 
out in duplex.  
 
3.3.6 OAS-1 mRNA Expression 
 
RNA and cDNA from transfected NRK-52E cells was prepared as before.  Samples 
were assayed separately for OAS-1 (Assay ID: Rn00594390_m1) and β-actin 
expression.  A 5µl reaction was set up in a 384 well plate consisting of:  
• 0.25µl OAS-1 FAM labelled probe or 0.25µl β-actin VIC labelled probe 
• 0.25µl nuclease free water 
• 2µl of template cDNA 
• 2.5µl of TaqMan Universal PCR master mix 
Each sample was analysed with the ABI PRISM 7900ht Sequence Detection System 
and results generated as before. 
 
 
3.3.7 Fiber-modified Adenovirus Vector Production 
 
Vector production was carried out in human embryonic kidney 293T cells that 
express the adenovirus E1A gene necessary for viral replication.   
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Figure 3.1 Ad19p-HTT plasmid construct and genome structure of the 
Ad5.βgal.∆F vector 
A: The plasmid for the expression of the modified Ad19p-HTT fiber protein (185).  
The plasmid contains the CMV promoter, Ad5 tripartite leader (to improve fiber 
gene expression) and the modified Ad19p-HTT fiber sequence (for renal 
selectivity). 
B: The genome structure of the Ad5.βgal.∆F vector.  This vector has E1, E3 and 
L5 (fiber gene) regions deleted with a β-galacotsidase reporter gene (LacZ) 
inserted in place of the E1 region (182).  Arrows indicate direction of 
transcription.  Adapted from (192) 
TPL: tripartite leader, ITR: inverted terminal repeat, ψ: packaging signal, E1-E4: 
adenoviral early genes, L1-L5: adenoviral late genes 
CMV Ad5 TPL Ad19pHTT 
∆L5 
∆E3 ∆E1 
LacZ 
E2 E4 
L1  L2  L3  L4 
ψ 
ITR ITR 
I II III 
A 
B 
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Cells were maintained in Eagle’s modified medium (MEM) supplemented with 
10% (v/v) FCS, 2mM L-Glutamine, 1mM sodium pyruvate, 100 U/ml penicillin and 
0.1 mg/ml streptomycin.  To passage cells, citric saline (0.13M KCl, 0.017M 
sodium citrate in PBS) was used instead of trypsin.  Transfections were carried 
out in 70% confluent 293T cells cultured in 10cm2 tissue culture plates (Nunc). 
 
293T cells were transfected with HTT modified fiber expressing plasmid (Figure 
3.1) using a calcium chloride (CaCl2) differential pH method.  Culture medium 
was removed from each plate and cells were washed twice in sterile PBS.  To 
each plate, 4.5 ml of low glucose (1000 mg/L) DMEM supplemented with 10% 
(v/v) FCS and 25mM HEPES, pH 7.9 was added.  A solution containing 960 µl low 
glucose DMEM (supplemented with 25mM HEPES pH 7.1), 48 µl CaCl2 and 21 µg 
plasmid DNA was prepared and added drop-wise to each plate and gently mixed.  
Cells were incubated at 37°C overnight. 
 
Following overnight incubation, cells were washed in sterile PBS and infected 
with Ad5.βgal.∆F (a fiber gene deleted vector that expresses the reporter gene 
LacZ, see Figure 3.1) at 2000 virus particles per cell.  The volume of virus 
required was calculated and added to the standard 293T culture medium and 15 
ml of this mix was added to each plate.  After the cytopathic effect was 
observed (the majority of cells will have detached from the plate) cells were 
harvested in sterile PBS and centrifuged at 850 g for 10 minutes.  The 
supernatant was discarded and the cell pellet was re-suspended in 6 ml of sterile 
PBS.  Cells were lysed by freeze/thawing four times and cell debris was removed 
by centrifugation at 850 g for 10 minutes.  The adenovirus containing 
supernatant was stored at -80°C until purification by caesium chloride (CsCl) 
density gradient centrifugation. 
 
3.3.7.1 Adenovirus Purification   
 
Virus particles were purified by CsCl density gradient centrifugation.  Fourteen 
ml ultra clear centrifuge tubes (Beckman Coulter) were sterilised by rinsing with 
70% ethanol followed by sterile water.  A CsCl gradient was prepared in the 
centrifuge tube by adding 2 ml 1.45 g/cm3 CsCl followed by a layer of 1.32 
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g/cm3 CsCl added drop-wise then a layer of 2 ml 40% glycerol.  To the top of this 
gradient, the adenovirus supernatant was added and the rest of the tube was 
filled with sterile water.  The tube was loaded into a Sorvall Discovery 90 rotor 
container and centrifuged at 90000 g for 1.5 hours with maximum acceleration 
and free deceleration.  Following centrifugation a white band containing virus 
could be seen.  The virus was removed by piercing the centrifuge tube just 
below the virus layer with a syringe and a 22 gauge needle.  The virus was 
carefully drawn up into the syringe without disturbing any of the other layers.   
 
A 10000 molecular weight cut-off Slide-A-Lyzer dialysis cassette (Pierce) was 
prepared by soaking in 0.01M Tris pH 8, 0.001M EDTA (TE buffer) for 30 minutes.  
Extracted virus was then transferred to the cassette and any excess air was 
removed.  The virus was dialysed against 2 L 0.01M TE buffer pH 8 for 2 hours 
then the TE buffer was replaced and dialysis was continued overnight.  The next 
day, the TE buffer was changed and supplemented with 10% (v/v) glycerol and 
dialysis was continued for a further 2 hours.  After this time, the virus was 
carefully removed from the cassette and stored in 50 µl aliquots at -80°C.  
 
3.3.7.2 Calculating Virus Particle Titres 
 
Virus particle titres were calculated using a Micro-BCA assay kit (Pierce).  Eight 
BSA standards (from 0.5 µg/ml to 200 µg/ml) and PBS blanks were prepared and 
150 µl of each was added, in duplicate, to a 96 well plate.  Three volumes of 
virus preparation (1 µl, 3 µl and 5 µl) were diluted to 150 µl with PBS and 
assayed in duplicate.  The BCA working reagent was prepared by mixing 25 parts 
Solution A, 24 parts Solution B and 1 part Solution C and 150 µl of the working 
reagent was added to each well.  The plate was covered to protect it from the 
light and incubated at 37°C for 2 hours.  The absorbance at 570nm was 
measured for each standard and sample and duplicate readings were averaged 
and the blank measurements were subtracted.  A standard curve was generated 
and used to calculate the protein concentration in each virus sample.  The virus 
particle titre was then calculated using the formula: 1 µg protein = 1 x 109 virus 
particles. 
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3.3.8 Animal Models 
 
Inbred colonies of SHRSP and WKY rat strains have been maintained by our group 
since 1991.  Animals were housed in a temperature and humidity controlled 
environment with 12 hour light/dark cycles.  Rats were fed standard rat chow 
and water provided ad libitum.  All experimental animal procedures were 
performed in accordance with the UK Home Office Animals (Scientific 
Procedures) Act 1986 under the project licence number 60/3618. 
 
 
3.3.9 Local Delivery to a Single Kidney 
 
WKY rats were anaesthetised by inhalation of isofluorane.  A laparotomy was 
performed and the intestines were exteriorised and wrapped carefully in 
moistened swabs. The left kidney and renal artery/vein were exposed by blunt 
dissection. Ties were placed on the renal artery and vein to control blood flow 
to and from the kidney. The artery was clamped briefly during administration 
(injection into artery) of Ad5/19p virus (1x1011 virus particles).  A maximum 
volume of 500 µl was infused over a maximum of 20 seconds.  The blood flow 
was re-established and haemorrhage from the injection site was prevented by 
cauterisation.  The intestines were returned to the abdominal cavity and the 
laparotomy incision was closed.  Kidneys were removed and used for histological 
analysis.  
 
 
3.3.10 In Vivo Virus Administration 
 
To investigate targeting of Ad19pHTT 8-week old male SHRSP rats were infused 
with 3.5x1011 virus particles per rat, via the femoral vein.  After 5 days rats were 
sacrificed and organs removed.  Expression of LacZ in the kidney was determined 
by IHC as described in section 2.9. 
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3.4 Results 
 
3.4.1 Transfection Efficiency of NRK-52E Cells 
 
In order to carry out in vitro RNAi experiments in NRK-52E cells, it was 
important to evaluate the transfection efficiency of these cells.  To do this, 
NRK-52E cells were transfected with a Cy3 labelled scrambled siRNA control.  
This siRNA has no known homology to any expressed genes and as such should 
not generate a silencing effect.  Figure 3.2 shows a representative transfection 
experiment.  Panel C demonstrates that there was no background fluorescence 
generated when cells were subjected to a mock transfection (treated with 
transfection reagent only).  However when cells were transfected with 100nM 
Cy3 labelled siRNA, fluorescence was detectable throughout indicating 
successful transfection of these cells (panel B).  This control transfection was 
carried out in all subsequent Gstm1 RNAi experiments and in each experiment, 
greater than 70% transfection efficiency was achieved. 
 
3.4.2 Glutathione S-Transferase Mu Type 1 mRNA Expression 
 
TaqMan quantitative real-time PCR was carried out to investigate silencing of 
Gstm1 mRNA expression following transfection of NRK-52E cells with 100nM 
siRNA.  The ability of each siRNA to knock-down Gstm1 is shown in Figure 3.3.  
Figure 3.3 is representative of 8 individual experiments carried out in triplicate.  
All 3 siRNA sequences resulted in significantly reduced Gstm1 mRNA expression. 
At 100nM, siRNA A produced knock-down of between 65 and 79%, siRNA B 
between 78 and 93% and siRNA C achieved between 63 and 69% knock-down 
when compared to the scrambled siRNA control.  In each experiment, siRNA B 
appeared to be the most effective as knock-down from this sequence was 
consistently higher as illustrated in Figure 3.3 (85% knock-down, p<0.01 v siCTL 
compared to 79% and 68% knock-down with siRNA A and C respectively, p<0.01 v 
siCTL). 
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Figure 3.2 Transfection efficiency of NRK-52E cells with 100nM siRNA  
A: Transmitted light image of NRK-52E cells. B: Cells transfected with 100nM Cy3 
labelled siRNA.  Comparison with transmitted light image of the same field (A) 
suggests high transfection efficiency. C: Mock transfected cells showing no 
background fluorescence.  Scale bar: 50µm 
 
A 
B 
C 
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3.4.2.1 Glutathione S-Transferase Mu Family mRNA Expression 
 
The mu family of glutathione transferases is highly homologous and as such, a 
sequence designed to target Gstm1 may inadvertently have a non-specific effect 
on other Gstm isoforms.  To check the specificity of each siRNA sequence, NRK-
52E cells were transfected as before and RNA extracted for TaqMan analysis of 
Gstm2, 3, 5 and 7.  The mRNA expression levels of each isoform following knock-
down of Gstm1 are shown in Figure 3.4.  Figure 3.4 is representative of 6 
individual experiments carried out in triplicate.  Both siRNA A and C were found 
to be specific for Gstm1 as no significant effect on the mRNA levels of other 
isoforms was detected. Table 3.1 shows the range of knock-down of each 
isoform in response to each siRNA at 100nM.  However, siRNA B was found to be 
less specific, resulting in reduced expression of all four isoforms as shown in 
Figure 3.4.  Expression of Gstm2, 3, 5 and 7 was reduced by 63, 93, 31 and 49% 
in this example (Gstm2, 3 and 7, p<0.01 and Gstm5, p<0.05 when compared to 
siRNA control). 
 
To investigate if the non-specific effect of siRNA B on the other Gstm family 
members was possibly due to transfection of an excess of siRNA into cells, 
transfections were repeated using a reduced concentration of siRNA.  Following 
transfection of NRK-52E cells with 30nM siRNA, RNA and protein were extracted 
for TaqMan and western analysis respectively.  Firstly Gstm1 expression levels 
were evaluated to ensure that by reducing the concentration of siRNA, the 
silencing potency was not diminished.  Figure 3.5 is representative of 4 
individual experiments carried out in triplicate and shows that each siRNA, at 
30nM, was still capable of significantly reducing Gstm1 expression.  In the 
example shown in Figure 3.5, Gstm1 expression was reduced by 71% by siRNA A, 
61% by siRNA B and 66% by siRNA C when compared to control siRNA, p<0.05.  
Across the 4 experiments, levels of knock-down varied between 56 and 71% 
(siRNA A), 61 and 76% (siRNA B) and 46 and 66% (siRNA C).  As before with siRNA 
used at 100nM, siRNAs A and C did not significantly knock-down expression of 
Gstm2, 3, 5 and 7 and by reducing the concentration to 30nM, siRNA B no longer 
had a non-specific effect on any other Gstm isoform (Figure 3.6). 
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Figure 3.3 Gstm1 mRNA expression following Gstm1 RNA interference in NRK-
52E cells 
NRK-52E cells were transfected with 100nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  TaqMan qRT-PCR was performed to assess Gstm1 expression. 
In this example, 79% knock-down was achieved by siRNA A, sequence B achieved 
85% and sequence C achieved 68% compared to siCTL (n=1 experiment performed 
in triplicate and is representative of 8 experiments in total) ** p<0.01 vs siCTL 
(ANOVA + Dunnett’s post-hoc test). 
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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Figure 3.4 Gstm family mRNA expression following Gstm1 RNA interference in 
NRK-52E cells 
NRK-52E cells were transfected with 100nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  TaqMan qRT-PCR was performed to assess expression levels of 
Gstm2, 3, 5 & 7.  No significant knock-down of any Gstm isoforms was observed 
with siRNA A and C.  However, siRNA B significantly reduced each of the 4 
isoforms.  In this example, Gstm2 and Gstm3 were reduced by 63% and 93% 
respectively compared to siCTL (n=1 experiment performed in triplicate and is 
representative of 6 experiments in total), ** p<0.01 vs siCTL (ANOVA + Dunnett’s 
post-hoc test).  Gstm5 and Gstm7 were reduced by 31% and 49% respectively 
compared to siCTL (n=1 experiment performed in triplicate and is representative 
of 6 experiments in total) *p<0.05 vs siCTL (ANOVA + Dunnett’s post-hoc test).  
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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Table 3.1 Percentage knock-down of expression of Gstm isoforms in response to 
each siRNA at 100nM 
 
RANGE OF KNOCK-DOWN (%) 
Gene siRNA A siRNA B siRNA C 
Gstm2 1 to 30 48 to 87 7 to 42 
Gstm3 7 to 33 77 to 93 2 to 49 
Gstm5 3 to 36 31 to 56 7 to 43 
Gstm7 24 21 to 55 21 to 42 
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3.4.3 Glutathione S-Transferase Mu Type 1 Western Blot Analysis 
 
The sensitivity of the anti-rat GSTM1 antibody was initially evaluated against a 
range of NRK-52E protein dilutions.  It was important that the antibody could 
detect different levels of GSTM1 protein in order to determine if effective 
knock-down of GSTM1 had taken place.  Figure 3.7 indicates that the antibody 
was sensitive to a range of concentrations of GSTM1 (Panel A).  Due to the 
homologous nature of GSTM1 and other members of the GSTM family, detecting 
GSTM1 selectively can be problematic. To ensure GSTM1 specificity, the 
antibody was evaluated against GSTM1 (M1) and GSTM2 (M2) protein standards.  
The antibody was found to be specific to GSTM1 and did not detect GSTM2 
(Panel A in Figure 3.7). 
 
To determine whether transfection with any of the three siRNA sequences 
resulted in efficient knock-down of GSTM1, western blot analysis was performed.  
A representative blot following transfection of NRK-52E cells with 100nM siRNA is 
shown in Figure 3.7 (Panel B).  Each band (~26kD) corresponds with the purified 
GSTM1 protein standard.  Each siRNA sequence caused a reduction in GSTM1 
protein (bands A, B and C) when compared with the scrambled siRNA control 
(siCTL).  This was confirmed by normalising each band to the housekeeper β-
actin by densitometry.  A representative β-actin blot and the corresponding 
densitometry results are shown in Figure 3.7 (Panels B and C).  The densitometry 
results show a 93% reduction in GSTM1 protein by siRNA A and knock-down of 87 
and 88% with siRNA B and C respectively.  Western blot analysis and 
densitometry was also performed to assess the ability of each siRNA to knock-
down GSTM1 protein levels when used at 30nM, as shown in Figure 3.8.  As 
before, GSTM1 protein was lower in siRNA treated samples.  At 30nM siRNA, 
protein expression was reduced by 60% with siRNA A and by 59 and 77% with 
siRNA B and C respectively. 
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Figure 3.5 Knock-down of Gstm1 expression is preserved with reduced 
concentrations of siRNA 
NRK-52E cells were transfected with 30nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  TaqMan qRT-PCR was performed to assess Gstm1 expression. 
In this example, 71% knock-down was achieved by siRNA A, sequence B achieved 
61% and sequence C achieved 66% compared to siCTL (n=1 experiment performed 
in triplicate and is representative of 4 experiments in total) * p<0.05 vs siCTL 
(ANOVA + Dunnett’s post-hoc test) 
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
UTF TFC siCTL A B C 
RQ 
* * * 
 103 
 
 
 
Figure 3.6 Gstm family mRNA expression is unaffected by reduced 
concentrations of Gstm1 siRNA 
NRK-52E cells were transfected with 30nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  TaqMan qRT-PCR was performed to assess expression of 
Gstm2, 3, 5 & 7. No significant reduction of mRNA expression was observed for 
any of the other Gstm isoforms following transfection with 30nM siRNA (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total).  
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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Figure 3.7 Western blot analysis of GSTM1 protein expression  
A: Total protein was extracted from NRK-52E cells and resolved by gel 
electrophoresis.  Western blotting confirmed the anti-rat GSTM1 antibody was 
sensitive to a range of GSTM1 concentrations.  Anti-rat GSTM1 was tested against 
GSTM1 (M1) and GSTM2 (M2) protein standards and was found to be specific for 
GSTM1.  B: NRK-52E cells were transfected with 100nM control (siCTL) or Gstm1 
specific siRNA (A, B or C).  Western blotting indicated GSTM1 protein levels were 
lower in cells transfected with Gstm1 specific siRNA compared to siCTL.  C: 
Reduced GSTM1 was confirmed by densitometry with each band normalised to β-
actin (n=1 experiment performed in duplicate and is representative of 8 
experiments in total). 
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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Figure 3.8 Western blot analysis of GSTM1 protein expression (30nM siRNA) 
A: NRK-52E cells were transfected with 30nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  Total protein was extracted and resolved by gel 
electrophoresis.  Western blotting was performed and bands indicated GSTM1 
protein levels were lower in cells transfected with Gstm1 specific siRNA 
compared to siRNA control.  B: Reduced GSTM1 was confirmed by densitometry 
with each band normalised to β-actin (n=1 experiment performed in duplicate 
and is representative of 3 experiments in total). 
UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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3.4.4 Interferon Response 
 
As well as the potential for non-specific silencing of other genes by siRNAs, it 
was also possible that introduction of siRNA to cells may induce off target 
effects through induction of an interferon response.  To investigate the 
likelihood of each Gstm1 specific siRNA to induce an interferon response in NRK-
52E cells, the expression level of oligoadenylate synthetase-1 was quantified.  
Following transfection with 100nM siRNA, OAS-1 expression was significantly 
increased with the greatest increase observed in response to siRNA sequences A 
and B, as shown in the top panel of Figure 3.9.  In this example, siRNA A induced 
OAS-1 expression 245.8 fold when compared to siCTL and siRNA resulted in 489.5 
fold induction of OAS-1, p<0.01.  The induction of OAS-1 by siRNA C was much 
less, with only a 4.6 fold increase.  Expression of OAS-1 varied between 
experiments; siRNA A caused a 17.5 to 245.8 fold increase, siRNA B caused a 
330.5 to 628.3 fold increase and siRNA C caused a 4.2 to 14.3 fold increase in 
OAS-1 expression.  This effect was diminished by reducing siRNA concentration 
to 30nM, as shown in the bottom panel of Figure 3.9.  When reduced to 30nM, no 
significant induction of OAS-1 expression was observed.  
 
3.4.5 Assessment of Local Delivery to Kidney 
 
Local delivery to the kidney was assessed by injecting modified Ad5/19p into the 
renal artery.  Haematoxylin and eosin staining was performed on kidney sections 
to assess what effect direct administration through the renal artery had on 
kidney structure.  Figure 3.10 shows sections from infused and contralateral 
kidney.  Extensive damage was observed in kidney infused with virus.  In the 
contralateral kidney, the tubules can be observed as discrete structures but in 
the infused kidney, these defined structures are lost indicating tubular necrosis. 
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Figure 3.9 Oligoadenylate synthetase expression levels 
Top panel: NRK-52E cells were transfected with 100nM control (siCTL) or Gstm1 
specific siRNA (A, B or C).  TaqMan qRT-PCR was performed to assess expression 
levels of oligoadenylate synthetase (OAS-1).  A large, significant increase in 
oligoadenylate synthetase expression was observed in response to siRNA A and B 
(n=1 experiment performed in triplicate and is representative of 6 experiments 
in total) **p<0.01 vs siCTL.  Bottom panel: NRK-52E cells were transfected with 
30nM control (siCTL) or Gstm1 specific siRNA (A, B or C).  Induction of OAS-1 
expression was diminished by reducing siRNA concentration to 30nM (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total).  UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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3.4.6 Ad19pHTT Targeting in SHRSP Kidney 
 
The adenoviral vector Ad19pHTT has been shown to target the kidney tubular 
epithelium of WKY rats following peripheral intravenous injection.  To be able to 
use this vector for in vivo modulation of Gstm1 expression in the congenic 2c* 
(entirely SHRSP apart from region of chromosome 2 which is from WKY) targeting 
in SHRSP had to be determined.  Figure 3.11 shows representative images of the 
staining observed in sections of the same kidney region treated with either 
negative control IgG antibody (right panel) or β-galactosidase antibody (left 
panel).  β-galactosidase staining was observed specifically in tubules, as had 
been shown previously in WKY with little or no staining in control sections.  
 
3.4.7 Evaluation of shRNA Expressing Plasmids 
 
Gstm1 targeting shRNA expression vectors were generated by cloning 
oligonucleotides encoding shRNA into the multiple cloning site (MCS) of the 
pShuttle-CMV vector backbone.  The shRNA sequences used were based on the 
Gstm1 siRNA and scrambled siRNA control sequences tested previously.  An 
outline of the pShuttle-CMV vector map and shRNA sequences are shown in 
Figure 2.1.  The plasmid region encompassing the MCS was amplified and 
subjected to gel electrophoresis to check if the shRNA insert was present.  
Plasmid vector containing insert generated a band of ~200 bp and vector without 
insert generated a band of ~150 bp.  Samples that generated a band at 200 bp 
were then sequenced to check that the orientation and sequence of the shRNA 
insert was correct.  An example gel and sequencing results are shown in Figure 
3.12. 
 
To assess the transfection efficiency of NRK-52E cells for transfection of plasmid 
DNA, cells were transfected with a pShuttle-CMV vector that expresses the β-
galactosidase reporter gene, LacZ (pShuttle-CMV-LacZ).   
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Figure 3.10 Haematoxylin and eosin staining of WKY kidney sections 
Top panel: Ad5/19p virus (1 x 1011 virus particles) was administered directly to 
male WKY rat kidney via the renal artery.  Renal artery infusion leads to 
significant kidney damage.  Bottom panel: Undamaged contralateral kidney with 
normal appearance. Scale bar = 100µm. 
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Figure 3.11 Analysis of kidney targeting in SHRSP  
Eight week old male SHRSP were infused with Ad19pHTT (3.5x1011 virus particles 
per rat) via the femoral vein.  Immunohistochemistry performed on kidney 
sections confirmed β-galactosidase expression (grey-black staining) in the 
tubules with no non-specific staining in the control sections treated with a 
negative control IgG antibody. Sections were counter-stained with haematoxylin 
to stain nuclei blue.  Representative sections are shown (n=3).  Scale bar = 100 
µm (x10 magnification).  Scale bar = 50 µm (x20 magnification). 
CD: collecting ducts, PT: proximal tubules, DT: distal tubules 
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Plasmid DNA transfection of NRK-52E cells was optimised using two different 
transfection reagents and by altering the ratio of DNA to transfection reagent 
used.  Using 2 µg of plasmid DNA was found to be most effective in combination 
with 5 µl of transfection reagent (Lipofectamine™ 2000).  However, transfection 
of NRK-52E cells with plasmid DNA was very low as shown by the low level of 
blue stained cells (Figure 3.12).  Approximately 5-10% transfection efficiency 
was achieved.   
 
The ability of the pShuttle-CMV-shRNA plasmids to knock-down Gstm1 expression 
in vitro was assessed by transfecting the plasmids into NRK-52E cells.  TaqMan 
RT-PCR was carried out to assess changes in expression.  The top panel in Figure 
3.13 indicates that Gstm1 mRNA expression is reduced in cells transfected with a 
plasmid expressing Gstm1 shRNA.  When compared to cells transfected with a 
scrambled control shRNA (SCR), Gstm1 expression was 58% lower, p<0.05.  
However this result was not reproducible, of 8 experiments only 1 demonstrated 
successful knock-down of Gstm1.  The remaining 7 experiments did not show any 
significant knock-down as demonstrated in the bottom panel of Figure 3.13.   
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Figure 3.12 Transfection efficiency of NRK-52E cells and shRNA vector 
sequencing analysis 
A: NRK-52E cells were transfected with pShuttle-CMV at Lipofectamine:DNA ratio 
of 5:2 (µl:µg).  β-galactosidase staining demonstrated 5-10% transfection 
efficiency.  Scale bar = 100µm.  B: PCR gel of amplified vector to check for 
insert.  Samples that generated a band at ~200bp were selected for sequencing 
(circled in yellow). C: DNA sequencing electropherogram showing correct 
insertion of each shRNA sequence.  
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Figure 3.13 Gstm1 mRNA expression levels in cells transfected with Gstm1 
shRNA expressing vector 
TaqMan qRT-PCR analysis of Gstm1 mRNA expression following transfection of 
NRK-52E cells with Gstm1 shRNA expressing pShuttle-CMV.  Top panel: Gstm1 
mRNA expression was reduced by 58% in cells transfected with Gstm1 shRNA 
compared to scrambled shRNA control (SCR) (n=1 experiment performed in 
triplicate) *p<0.05 vs SCR (ANOVA + Dunnett’s post-hoc test).  Bottom panel: no 
change in Gstm1 expression was observed in shRNA treated cells (n=1 
experiment performed in triplicate and is representative of 7 experiments in 
total). 
UTF: untransfected, TFC: mock transfection, SCR: control vector transfection  
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3.5 Discussion 
 
The in vitro experiments described so far indicate that NRK-52E cells are 
amenable to transfection with siRNA allowing for accurate measurement of 
reduced gene expression.  Using available RNA interference technology, three 
siRNA sequences have been identified that can successfully and reproducibly 
knock-down Gstm1 expression in vitro.  The level of knock-down achievable can 
be quantified at both protein and mRNA expression level by western blot and 
quantitative real-time PCR analysis respectively.  Although significant silencing 
could be achieved with each siRNA, sequence B was consistently more effective 
at reducing Gstm1 mRNA expression than either siRNA A or C.  As well as 
measuring Gstm1 expression, levels of Gstm2, 3, 5 and 7 were also quantified to 
ensure that no non-specific silencing occurred.  The genes that encode the Gstm 
family are all highly homologous and because of this, a sequence targeted 
against Gstm1 may result in non-specific knock-down of other members of the 
family, especially at high siRNA concentrations.  Gstm1 shares 84% homology 
with Gstm2, 85% with Gstm3, 71% with Gstm5 and 82% homology with Gstm7.  At 
100nM siRNA, all isoforms were affected by siRNA B but not siRNA A or siRNA C.  
To minimise this effect, the concentration of siRNA was reduced to 30nM.  
Lowering the concentration of siRNA used from 100nM to 30nM still resulted in 
significant reduction of Gstm1 expression but the level of knock-down 
achievable from each siRNA was slightly reduced.  At 30nM, the non-specific 
effect on other Gstm isoforms was lost.  This demonstrates that by reducing 
siRNA concentration the selectivity of the siRNA for Gstm1 can be increased.    
 
This is also the case when trying to limit the risk of inducing an interferon 
response following the introduction of double stranded RNA (dsRNA) molecules.  
Double stranded RNA of greater than 30bp has been shown to induce an 
interferon response in mammalian cells (152).  By using shorter RNA molecules it 
is thought that this effect can be avoided as it has been suggested that at least 
40 to 60 bp of dsRNA are required for the activation of 2'-5'OAS (191). However, 
OAS-1 expression was significantly increased in NRK-52E cells following the 
introduction of short (21 nt) siRNA molecules against Gstm1.  This effect was 
removed by lowering the siRNA concentration from 100nM to 30nM, indicating 
that as well as dsRNA length, concentration is also important.  This was found to 
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be the case in studies with IFN treated HeLa cells, where higher concentrations 
of dsRNA were able to activate 2'-5'OAS more effectively (193).  Therefore, to 
achieve successful and specific RNA interference, the lowest effective 
concentration of siRNA should be used to limit off-target effects. 
 
To be able to take investigation of the function of Gstm1 into an in vivo setting, 
local delivery to the kidney was evaluated as a potential means of introducing 
Gstm1 targeting siRNA directly to the kidney.  Direct administration of siRNA 
would maintain a high concentration of siRNA at the target site without having 
to deliver a large dose and so would also help to limit systemic side effects.  
Local delivery of siRNA has proved successful for delivery to the eye in mouse 
models of ocular neovascularisation (167;168).  However, delivery of siRNA 
throughout the kidney has been found to be more difficult (194).  Various 
methods have been employed to deliver siRNA/shRNA to the kidney.  An adeno-
associated virus vector expressing shRNA targeted against the mineralocorticoid 
receptor (MR) was introduced to Sprague Dawley rats by IV injection to the 
jugular vein.  Renal MR expression was reduced and cold induced hypertension 
and renal damage were subsequently inhibited (162).  The jugular vein was also 
used as a delivery route for a liposomal siRNA complex targeting V2 receptors in 
mouse kidney (195).  The method investigated in this study for potential in vivo 
knock-down of Gstm1 involved direct delivery to the kidney via the renal artery.  
However, following injection of Ad5/19p to the kidney, extensive damage was 
observed.  Successful kidney delivery via renal artery injection has been 
described previously.  Renal artery injection of a shRNA expression plasmid 
effectively inhibited TGF-β1 expression in mouse kidney (196).  Direct delivery 
to rat kidney has also been shown using an electroporation mediated gene 
transfer system (197).  Synthetic siRNA was introduced to the kidney by injection 
via the renal artery, the renal vein was then clamped and the kidney was 
subjected to electrical pulses.  This method resulted in efficient transduction of 
glomeruli and significant silencing of gene expression (198).  The silencing effect 
was restricted to the glomeruli with limited transduction of tubules observed.  
This method would not be appropriate for investigation of Gstm1 silencing as 
expression of Gstm1 has been found in kidney tubular epithelium.  Neither study 
mentioned kidney damage sustained as a result of renal artery infusion. 
 
 116 
To overcome the damage induced by direct kidney injection, a kidney targeting 
adenoviral vector that can be delivered systemically was evaluated.  Kidney 
targeted Ad5 vectors have been generated as described previously (185) and 
targeting was evaluated in SHRSP.  This testing in SHRSP was necessary as 
previous work had been carried out in WKY animals.  The 2c* congenic strain is 
entirely SHRSP apart from a region of chromosome 2 encompassing Gstm1 which 
has been transferred from WKY.  The 2c* was found to have a greater level of 
Gstm1 expression than SHRSP.  Knocking down expression of Gstm1 in the kidney 
of 2c* may re-establish the SHRSP phenotype and a greater understanding of the 
role of reduced expression observed in the SHRSP would be gained.  Selective 
staining of the tubules has been shown which is important for in vivo Gstm1 
studies as differential expression of Gstm1 was previously localised to kidney 
tubular epithelium (77).   
 
Plasmid vectors that express short hairpin forms of the siRNA sequences already 
tested in vitro have been generated and could be incorporated into the kidney 
targeted Ad5 vector system.  However, when assessing the activity of Gstm1 
shRNA in vitro, knock-down of Gstm1 expression could not be achieved.  Various 
studies have investigated optimal shRNA design for efficient knock-down of gene 
expression.  In a study performed by Siolas et al, shRNAs with a 29 nt long stem 
and 3' nt overhang were found to be more efficient inducers of RNAi than shRNAs 
with 19 nt long stems.  It has been suggested that Dicer substrates are 
incorporated into RISC more effectively.  The 29-mer shRNAs with 3' overhangs 
were efficiently converted to 22 nt products (mediators of RNAi) by incubation 
with Dicer however, this was not the case for 19-mer shRNAs suggesting that 
Dicer requires a minimum stem length for successful cleavage.  The presence of 
3' overhangs was also found to be important for Dicer activity as 29-mer shRNAs 
without the overhang generated very little 22 nt product.  Both 29-mer and 19-
mer stems were connected by a 4 nt loop in this study (199).  This would suggest 
that for efficient Dicer activity and subsequent incorporation into RISC, shRNAs 
should be designed with 29-mer stems and a 3' nt overhang.  The shRNAs 
designed for knock-down of Gstm1 in this study are composed of 19 nt stems 
with a 3' nt overhang and a 9 nt loop sequence.   However, experiments carried 
out by Li and colleagues found that only when a 4 nt loop was incorporated into 
the shRNA design were 29-mer stem shRNAs more effective than 19-mer shRNA.  
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When combined with a 9 nt loop, shRNA with 19-mer stems were more efficient 
than 29-mer shRNA (200).  They also found that 19 nt stems with a 9 nt loop 
provide an appropriate substrate for Dicer.  This would suggest that the shRNA 
design used in our study should be processed by Dicer and result in the 
production of small RNAs capable of knocking down Gstm1.   
 
Another factor that could affect the production of shRNA is the promoter used to 
drive shRNA expression.  The p-Shuttle vector used to generate the Gstm1 
specific shRNA in this study utilises a CMV promoter.  Many viral vectors use CMV 
to drive shRNA expression and a recent study involving plasmid generated shRNA 
found no significant differences in the silencing response generated from H1, U6 
and CMV promoters (201).  However, another group found that CMV was not 
suitable for expression of shRNA and that CMV-driven shRNA constructs were far 
less efficient than other promoter driven constructs (200).  It may be that the 
pShuttle-CMV vector is not suitable for efficient production of shRNA and that 
perhaps another vector should be used in the future.  As well as the various 
hairpin RNA design and expression considerations, a major factor contributing to 
in vitro gene silencing is transfection efficiency.  It seems most likely that the 
reason the pShuttle-CMV-shRNA constructs failed to successfully knock-down 
Gstm1 was due to the poor transfection efficiency of NRK-52E cells with plasmid 
DNA.  At most, 20% of cells were successfully transfected with the Gstm1 
pShuttle-CMV-shRNA expression vectors as determined by LacZ expression.  NRK-
52E cells have proved to be very difficult to transfect with plasmid DNA as 
observed in this study and by other colleagues in the laboratory.  Even if the 
cells that have taken up the shRNA constructs can generate a complete knockout 
of Gstm1 expression, still only 20% knock-down would be observed for the entire 
cell population.  Thus, the pShuttle-CMV-shRNA construct may generate 
effective Gstm1 targeting shRNA but to fully evaluate their potency, a cell line 
more amenable to plasmid transfection would need to be used in any future 
studies. 
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Chapter 4: Investigating the Impact of Altered Gstm1 Expression 
on Markers of Oxidative Stress
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4.1. Introduction 
 
As described in detail in Chapter 1, Gstm1 is part of a large family of antioxidant 
enzymes involved in the detoxification of the by-products of oxidative stress 
such as the break-down products of lipid peroxidation and oxidative DNA damage 
(118).  The results of Chapter 3 demonstrated that expression of Gstm1 can be 
successfully and consistently knocked down at both protein and mRNA level by 
siRNA mediated RNA interference.  The effect of reduced Gstm1 expression on 
markers of oxidative stress was investigated to assess the antioxidant role of 
Gstm1. 
 
4.1.1. Lipid Peroxidation 
 
Lipid peroxidation is a common feature of free radical induced damage to 
membranes (202).  Cell membranes containing polyunsaturated fatty acids are 
highly susceptible to peroxidation and the lipid radicals produced lead to 
propagation of free radical reactions, further contributing to lipid damage.  
Increased lipid peroxidation has been described as a significant contributor to 
the development of atherosclerosis (203).  The production of lipid radicals and 
their intermediates can affect cell function, lead to inflammation and vascular 
damage and may contribute to endothelial dysfunction (204). 
 
Isoprostanes are commonly used markers of lipid peroxidation and oxidative 
stress.  The prostaglandin like F2 isoprostanes are derived from the peroxidation 
of arachidonic acid and can be measured in blood and urine to assess lipid 
peroxidation in vivo (204;205).  The most commonly used biomarker of lipid 
peroxidation is 8-isoprostane (204).  Levels of 8-isoprostane have been shown to 
be higher in subjects with cardiovascular risk factors than in healthy subjects 
and were also found to be elevated in smokers (206;207).  Studies in 
hypertensive individuals have shown that plasma 8-isoprostane concentration is 
higher in salt sensitive subjects during salt loading (208) and that angiotensin II 
infusion also leads to increased 8-isoprostane in plasma of hypertensive subjects 
with high salt intake (209).  Measurement of 8-isoprostane has also been 
performed in vitro (210) and was used as an indicator of oxidative stress in NRK-
52E cells (211).  
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4.1.2. DNA Damage 
 
Increased levels of oxidative stress can also lead to DNA modification and 
damage.  Free radicals, such as the hydroxyl radical can cause DNA base 
oxidation (212).  8-hydroxy-2-deoxyguanosine (8-OH-dG) is a product of such free 
radical induced damage resulting from hydroxylation of the guanosine base.  It is 
frequently measured as an indicator of oxidative stress in vivo (213).  Studies 
measuring 8-OH-dG have shown that increased DNA damage is present in 
patients with type 2 diabetes compared to non-diabetic subjects (214) and 
plasma levels of 8-OH-dG are higher in hypertensive patients compared to 
normotensive subjects (215).  
 
The comet assay or single cell gel electrophoresis is commonly used to assess 
levels of DNA damage in response to oxidative stress (216).  It is frequently used 
to measure and analyse DNA breakage in individual cells and is sensitive to low 
levels of DNA damage (217).  Damaged DNA when subjected to an electric 
current, following unwinding under alkaline conditions, will migrate out of the 
nucleoid and when stained can be visualised as a comet (218).  The length of the 
comet tail generated is proportional to the level of damage, so that a longer 
comet tail indicates greater damage to DNA.  The comet assay has been used to 
investigate the protective effects of antioxidant treatment in various 
intervention studies and to assess oxidative stress both in vitro and in vivo (219).      
      
 
4.2 Aims  
 
• To assess GST activity following modification of Gstm1 expression 
 
• To measure levels of reduced glutathione, by high performance liquid 
chromatography (HPLC) 
 
• To assess the contribution of Gstm1 to oxidative stress, using 8-
isoprostane and 8-OH-dG assays and the comet assay  
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4.3 Methods 
 
4.3.1 Transfection of NRK52E Cells with siRNA 
 
NRK-52E cells were transfected with anti-Gstm1 siRNA (30 to 100nM) as outlined 
in section 2.3. 
 
4.3.2 Cell Culture 
 
HeLa cells were cultured in Eagle’s minimum essential medium supplemented 
with 10% FCS, 100 I.U/ml of penicillin and 100 µg/ml of streptomycin.  A10 and 
H9C2 cells were cultured in Dulbecco’s modified Eagle’s medium plus GlutaMAX 
supplemented with 10% FCS, 100 I.U/ml of penicillin and 100 µg/ml of 
streptomycin.  All cells were maintained in a 5% CO2 atmosphere at 37°C. 
  
4.3.3 HeLa Cell Infection 
 
To examine the effect of over-expression of Gstm1 on GST activity, HeLa cells 
were infected with an adenovirus engineered to express the WKY version of 
Gstm1 (RAd WKY Gstm1) (220).  As a negative control, cells were also infected 
with a non-expressing vector (RAd60).  Twenty four hours prior to infection, 
HeLa cells were plated out in 6 well plates and infected once approximately 90% 
confluent.  The number of cells in each well was determined by collecting and 
counting the cells from a control well as described in section 2.2.  The number 
of cells/well was then used to calculate the number of virus particles required 
for a multiplicity of infection (MOI) of 10, 50 and 100 and the volume of virus 
required per well was determined by virus titre.  The virus stocks were diluted in 
sterile PBS and added to cell culture medium in each well.  Following overnight 
incubation at 37°C, the virus containing medium was removed and replaced with 
fresh medium.  Forty eight hours after infection, protein was harvested from 
cells as described in section 2.4.  
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4.3.4 Total GST Activity 
 
Total GST activity was determined by the rate at which glutathione is 
conjugated to 1-Chloro-2,4-Dinitrobenzene (CDNB) by glutathione transferases 
present in each sample (GST Activity kit from Sigma).  Protein samples were 
prepared as described in section 2.4.  Assays were carried out in 96 well plates 
as per manufacturer instructions.  The substrate solution was prepared as 
follows: 2µl of 100mM CDNB, 2µl of 200mM reduced GSH and 196µl of DPBS (per 
well).  Control GST was diluted to a final concentration of 25µg/ml.  20µl of 
each sample and 4µl of diluted control GST was added to substrate solution to a 
final volume of 200µl per well and run in duplicate.  Immediately after preparing 
reaction samples, the absorbance from each well was read at 340nm and then at 
1 minute intervals until 10 readings had been obtained.  The increase in 
absorbance is directly proportional to total GST activity in the sample.  The 
change in absorbance per minute was used to calculate specific GST activity. 
 
4.3.5 Glutathione Measurement 
 
High performance liquid chromatography (HPLC) (221) was utilised to measure 
levels of reduced GSH in NRK-52E cells following knock-down of Gstm1 
expression. 
 
4.3.5.1 Cell Culture 
 
NRK-52E cells were cultured in 100mm plates until 70% confluent and then 
transfected with 30nM siRNA, as described before. 
4.3.5.2 Sample Preparation 
 
Culture medium was removed from each plate and cells were rinsed twice with 
PBS.  To detach cells, 3ml of 1X Trypsin-EDTA was added to each plate and 
incubated at 37°C for 5 minutes.  Once detached, 10ml of medium containing 
10% FCS was added to inactivate trypsin and cells were transferred to a 50ml 
falcon tube.  Cells were centrifuged at 1000rpm for 5 minutes to pellet cells and 
medium was removed.  200µl of cold 10% metaphosphoric acid was added to 
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each NRK-52E sample and incubated for 10 minutes at 4°C.  Samples were 
transferred to 1.5ml centrifuge tubes and centrifuged at 16,000g for 25 minutes 
at 4°C.  The supernatants were transferred into fresh 1.5ml tubes and 
immediately stored at -80°C. 
 
4.3.5.3 Derivatisation of GSH 
 
To 50µl of each sample, 1ml of 0.1% EDTA in 0.1M sodium hydrogenphosphate 
(pH 8.0) was added.  After mixing well, a 20µl aliquot was removed and to this, 
300µl of 0.1% EDTA in 0.1M sodium hydrogenphosphate and 20µl of 0.1% ortho-
phthalaldehyde (OPA) in methanol was added.  Each sample was briefly vortexed 
to mix and incubated, in the dark, for 25 minutes at 25°C.  Glutathione 
standards were prepared in the same way and used to generate a calibration 
curve. 
 
4.3.5.4 Chromatography 
  
Following derivatisation of GSH with OPA, chromatography was performed using 
a Shimadzu LC-10AT HPLC pump with a SIL-9A auto-injector and a reverse phase 
column.  The mobile phase consisted of 12% methanol in 25mM sodium 
hydrogenphosphate, pH 6.0 and the flow rate was held at a constant 
0.8ml/minute.  Fluorescence was detected using the Perkin Elmer Series 200 
fluorescence detector and excitation and emission wavelengths were set to 350 
and 420nm respectively.  Data was collected and analysed using the JCL6000 for 
Windows 2.0 Chromatography Data System.  The concentration of GSH in each 
sample was determined from the calibration curve. 
 
4.3.6 Lipid Peroxidation: 8-Isoprostane Assay 
 
Levels of 8-isoprostane in the culture medium of cells transfected with Gstm1 
specific siRNA were measured using an 8-isoprostane ELISA kit according to 
manufacturer’s instructions (Cayman Chemical).   
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4.3.6.1 Sample Preparation 
 
Culture medium samples were collected from cells 48 hours post transfection 
with siRNA (as described before) and assayed immediately.  Each sample was run 
in duplicate alongside 8-isoprostane standards in a 96 well plate.  All standard 
dilutions were prepared with fresh culture medium.  All assay reagents were 
prepared with UltraPure water (Cayman Chemical).  The EIA buffer used in the 
assay was diluted by adding 90ml of UltraPure water to the buffer concentrate 
supplied with the kit.  The 8-isoprostane tracer and 8-isoprostane antiserum 
were reconstituted with 6ml EIA buffer.  Wash buffer was prepared by diluting 
the Wash Buffer concentrate 1:400 and adding Tween 20 (0.5 ml/litre of wash 
buffer).   
 
4.3.6.2 8-isoprostane Assay 
 
Each 96 well plate was set up to include 2 blanks, 2 non-specific binding (NSB) 
wells, 2 maximum binding (Bmax) wells and an 8 point standard curve run in 
duplicate.  To each NSB well, 50µl of culture medium, 50µl EIA buffer and 50µl 
of tracer was added.  To each Bmax well, 50µl of culture medium, 50µl of tracer 
and 50µl of antiserum was added.  Antiserum and tracer (50µl) was also added to 
each well containing standard or sample (50µl).  Once all reagents were added, 
the plate was covered with plastic film and incubated for 18 hours at 4°C.  To 
develop the plate, Ellman’s reagent was reconstituted with 20ml UltraPure 
water and kept in the dark until ready to use.  Each well was emptied and rinsed 
5 times with wash buffer then 200µl of Ellman’s reagent was added to each well.  
The plate was left in the dark on a shaker for at least 90 minutes to allow the 
plate to develop.  The absorbance was measured at 405nm and readings were 
taken when the Bmax wells reached 0.3 A.U. after the blank wells had been 
subtracted.   
 
4.3.6.3 Analysis 
 
Each absorbance reading was blank corrected and then the average reading from 
the NSB wells was subtracted from the average reading from the Bmax wells to 
 125 
give the corrected maximum binding.  The % sample or standard bound / 
maximum bound (%B/Bmax) was calculated by subtracting the average NSB 
absorbance from the average standard or sample absorbance and dividing this by 
the corrected Bmax absorbance. This was then multiplied by 100 to give the 
%B/Bmax.  A standard curve was generated by plotting the %B/Bmax of each of 
the standards against 8-isoprostane concentration and used to calculate the 
concentration of 8-isoprostane in each sample. 
 
4.3.7 DNA Damage: Comet Assay  
 
The Trevigen comet assay kit was used to assess damage to DNA following knock-
down of Gstm1 expression.  This assay works on the basis of single cell gel 
electrophoresis on a pre-treated slide provided with the kit.  
 
4.3.7.1 Cell Preparation 
 
NRK52E cells were transfected with 100nM siRNA as before and cells were 
examined for DNA damage.  As a control, cells were treated with 100µM H2O2 in 
normal cell culture medium for 20 minutes at 4°C.  Cells were collected using a 
cell scraper and centrifuged at 1500 rpm for 5 minutes to form a pellet.  The 
cell pellet was washed in ice cold PBS, centrifuged again and then re-suspended 
in ice cold PBS to 1 x 105 cells/ml. 
 
4.3.7.2 Single Cell Gel Electrophoresis 
 
The electrophoresis step was carried out according to kit instructions.  Briefly, 
50µl of each cell suspension was combined with 500µl agarose (pre-warmed to 
37°C) and spread evenly over the CometSlide™ area.  Slides were kept in the 
dark at 4°C for 10 minutes and then placed in lysis solution at 4°C for 40 
minutes.  The slides were then placed in alkaline solution and incubated in the 
dark at room temperature for 40 minutes.  Slides were washed twice for 5 
minutes in 1X TBE buffer and then placed in the middle an electrophoresis tank 
containing 1X TBE, so that the slides were just covered with buffer.  
Electrophoresis was carried out at 14 volts for 10 minutes.  After 
 126 
electrophoresis, slides were removed from the tank and placed in 70% ethanol 
for 5 minutes.  The samples were then left to air dry.    
 
4.3.7.3 Staining 
 
To visualise the DNA, samples were stained with 50µl of diluted SYBR® Green I 
nucleic acid gel stain (supplied with comet assay kit) and examined under a 
fluorescence microscope.  To evaluate DNA damage, comet tail length was 
measured.  For each slide, up to 60 measurements were taken resulting in a 
maximum of 180 measurements per triplicate group. 
  
4.3.8 DNA Damage: 8-hydroxy-2-deoxy Guanosine Assay 
 
Levels of 8-hydroxy-2-deoxy guanosine (8-OH-dG) were measured in NRK-52E 
cells following transfection with Gstm1 specific siRNA using an 8-OH-dG ELISA kit 
(Cayman Chemical) according to the manufacturer’s instructions.  
 
4.3.8.1 Sample Preparation 
 
NRK-52E cells were cultured and transfected using serum free medium as foetal 
calf serum.  Cell culture medium was collected from NRK-52E cells 48 hours 
after transfection with siRNA (as described before) and immediately stored at -
80°C until ready to be assayed.  All assay reagents were prepared in UltraPure 
water (Cayman Chemical).  The EIA Buffer was prepared by adding 90ml of 
UltraPure water to the buffer concentrate supplied.  The 8-OH-dG tracer and 
antiserum were reconstituted with 6ml EIA buffer.  The wash buffer was 
prepared by diluting the Wash Buffer concentrate 1:400 and adding Tween 20 
(0.5ml/litre of wash buffer).  All standard dilutions were prepared in fresh, 
serum free culture medium. 
 
4.3.8.2 8-hydroxy-2-deoxy Guanosine Assay 
 
Each sample was run in duplicate alongside 8-OH-dG standards in a 96 well 
plate.  Each plate also contained 2 NSB wells and 2 Bmax wells.  The plate was 
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set up and assayed as described in section 4.3.5.2 using 8-OH-dG tracer and 
antiserum. The 8-OH-2dG concentration was calculated as described for 8-
isoprostane in section 4.3.5.3.  
 
 
4.4 Results 
 
4.4.1 GST Activity Assay 
 
Prior to investigating the effect of Gstm1 silencing in NRK-52E cells on total GST 
activity, protein samples were extracted from 3 different rat cell lines and 
tested for their basal levels of GST activity.  The following cell lines were used: 
A10 cells (aortic smooth muscle) H9C2 cells (cardiomyocytes) and NRK-52E cells 
(renal tubular).  Figure 4.1 demonstrates that a measureable level of GST 
activity was present in NRK-52E cells (n=1 experiment performed in duplicate 
and is representative of 3 experiments in total).  In this example, the highest 
level of total GST activity was measured in NRK-52E cells. 
 
Following confirmation that total GST activity was readily detectable in NRK-52E 
cells, the assay was repeated with protein from cells transfected with 100nM 
siRNA to knock-down Gstm1.  From the initial experiment carried out it seemed 
that lowering Gstm1 expression resulted in reduced total GST activity as shown 
in the top panel of Figure 4.2.  In this experiment, total GST activity was 
reduced by 53% in siRNA A treated cells when compared to control siRNA treated 
cells (siCTL) (p<0.05).  In cells transfected with siRNA B, activity was reduced by 
72% compared to siCTL (p<0.05) but no significant change was observed in siRNA 
C treated cells.  However, this result was not reproducible.  Instead, upon 
repeated experiments (n=6), total GST activity levels were unaffected by 
reduced Gstm1 expression, with no significant difference between cells 
transfected with Gstm1 siRNA and those transfected with control siRNA as shown 
in the bottom panel of Figure 4.2.   
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Figure 4.1 Total GST activity in rat cell lines 
Top panel: GST activity increases over time.  Bottom panel: Total GST activity 
observed in 3 rat cell lines.  Basal activity was highest in NRK-52E cells and 
lowest in H9C2 cells (n=1 experiment performed in duplicate and is 
representative of 3 experiments in total).  
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Figure 4.2 GST activity following Gstm1 RNAi 
NRK-52E cells were transfected with 100nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  Total protein was extracted and GST activity was measured.  
Top panel: Reduced GST activity was observed in response to siRNA A and B (n=1 
experiment performed in triplicate) *p<0.05 vs siCTL (ANOVA + Dunnett’s post-
hoc test).  Bottom panel: No change in GST activity was observed following 
knock-down of Gstm1 in NRK-52E cells (n=1 experiment performed in triplicate 
and is representative of 6 experiments in total). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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As total activity could not be modulated by reducing Gstm1 expression, it was 
then investigated if over-expression of Gstm1 could alter GST activity levels.  
For the purposes of this experiment, HeLa cells were used instead of NRK-52E 
cells.  Previous experiments carried out in the laboratory found that NRK-52E 
cells were not amenable to infection with a recombinant adenoviral vector 
engineered to express Gstm1.  HeLa cells were infected with the empty vector 
RAd60 as a negative control and a recombinant Ad vector expressing Gstm1 
(RAd_Gstm1) at MOI of 10, 50 and 100.  Figure 4.3 shows a dose dependent 
increase in total GST activity following the over-expression of Gstm1, compared 
to cells infected with an empty vector (n=3).  The RAd60 control vector had no 
significant effect on GST activity.  No significant increase in GST activity was 
observed between RAd_Gstm1 infected cells and RAd60 infected cells at MOI 10.  
At MOI 50, a significant 30% increase in activity was observed between control 
cells and Gstm1 over-expressing cells, p<0.05 and at MOI 100, activity in 
RAd_Gstm1 infected cells was 63% higher than control cells, p<0.01. 
 
4.4.2 Glutathione Measurement  
 
High performance liquid chromatography (HPLC) was performed to measure 
reduced glutathione concentration in NRK-52E cells to assess whether levels 
were affected by reduced Gstm1 expression.  A representative trace is shown in 
Figure 4.4.  The top panel is a representative HPLC chromatogram generated 
from the samples assayed and the bottom panel is a blank control chromatogram 
where only 10% metaphosphoric acid was assayed.  The top panel shows a peak 
representing GSH at a retention time of 2.36 minutes and this was the same for 
all samples, no peak was observed in the blank trace (bottom panel).  A 
calibration curve was generated using GSH standards from 2 to 10 µM (Figure 
4.5, top panel).  The relative fluorescence generated from each standard was 
plotted against concentration and this was used to calculate the concentration 
of GSH in each unknown sample.  The bottom panel in Figure 4.5 shows the GSH 
concentration measured in each NRK-52E sample.  No significant difference in 
GSH concentration was observed between control and siRNA treated groups.  The 
concentration of glutathione was found to be similar in all groups; 13.36µM in 
the untransfected group, 9.98µM in the mock transfected group, 11.98µM in the 
control siRNA group and 13.68µM in the siRNA B treated group.   
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Figure 4.3 Total GST activity following over-expression of Gstm1 in HeLa cells 
Total GST activity in uninfected (UI) HeLa cells and following infection with a 
non-expressing vector (RAd60) or vector expressing Gstm1 (AdGstm1) at MOI of 
10, 50 and 100.  GST activity shows a dose dependent increase in response to 
over-expression of Gstm1 compared to RAd 60 infected cells at equivalent MOI 
(n=1 experiment performed in triplicate and is representative of 3 experiments 
in total) *p<0.05 vs Rad60, **p<0.01 vs Rad60 (ANOVA + Dunnett’s post-hoc test).  
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Figure 4.4 HPLC analysis of glutathione  
Top panel: Representative HPLC chromatogram of glutathione present in NRK-
52E cells.  Bottom panel: Blank control HPLC chromatogram with no peak 
detected. 
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Figure 4.5 Glutathione measurement 
Top panel: Glutathione calibration curve showing linear relationship in low µM 
range.  Bottom panel: Glutathione concentration in NRK-52E cells transfected 
with 30 nM control (siCTL) or Gstm1 specific siRNA (B).  No difference in GSH 
concentration was observed in cells transfected with Gstm1 specific siRNA B 
when compared to control groups (n=1 experiment performed in triplicate). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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4.4.3 Lipid Peroxidation 
 
In an attempt to examine what affect reducing Gstm1 expression would have on 
oxidative stress, an ELISA based assay that measures levels of 8-isoprostane was 
used.  Initially the assay was tested on the culture medium from NRK-52E cells 
treated with H2O2 to ensure that a change in 8-isoprostane could be detected 
following induction of oxidative stress.  As indicated in Figure 4.6 (Panel B), 8-
isoprostane levels show a dose and time dependent increase in response to H2O2 
(n=1 experiment performed in duplicate and is representative of 3 experiments 
in total).  This indicates that 8-isprostane can be measured in the culture 
medium from NRK-52E cells. 
 
The assay was then performed with culture medium from NRK-52E cells 
transfected with each of the Gstm1 specific siRNA sequences. In the initial 
experiment, 8-isoprostane concentration appeared to be significantly increased 
in response to knock-down of Gstm1 as shown in the bottom panel of Figure 4.6.  
In this experiment, treatment of NRK-52E cells with siRNA A and C had no 
significant effect on 8-isoprostane concentration but transfection of NRK-52E 
cells with siRNA B resulted in a 96% increase in 8-isoprostane concentration and 
was significant, p<0.05.  However, no significant change in 8-isoprostane was 
observed following knock-down of Gstm1 in any other experiments (n=6) as 
shown in Figure 4.7.  Western blot analysis was performed to ensure that GSTM1 
was still being effectively knocked down in each experiment and this is shown in 
a representative blot in Figure 4.7.  Each band was normalised to β-actin and the 
densitometry results indicated that GSTM1 was successfully knocked down by 
65%, 79% and 40% by siRNA A, B and C respectively when compared to the 
scrambled siRNA control bands. 
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Figure 4.6 8-Isoprostane measurement 
A: 8-isoprostane standard curve.  B: 8-isoprostane concentration in NRK-52E cells 
following treatment with H2O2.  8-isoprostane concentration is increased in 
response to increasing concentrations of H2O2 (n=1 experiment performed in 
duplicate and is representative of 3 experiments in total).  C: NRK-52E cells 
were transfected with 30nM control (siCTL) or Gstm1 specific siRNA (A, B or C).  
8-isoprostane concentration was significantly increased in NRK-52E cells 
transfected with siRNA B compared to control siRNA transfected cells (n=1 
experiment performed in triplicate) *p<0.05 vs siCTL (ANOVA + Dunnett’s post-
hoc test). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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Figure 4.7 8-Isoprostane measurement and Gstm1 western blot analysis 
NRK-52E cells were transfected with 30nM control (siCTL) or Gstm1 specific 
siRNA (A, B or C).  A: No significant change in 8-isoprostane concentration was 
observed in cells transfected any Gstm1 specific siRNA (n=1 experiment 
performed in triplicate and is representative of 6 experiments in total).  B: 
GSTM1 and β-actin western blots indicating that GSTM1 protein levels were 
reduced in cells transfected with Gstm1 siRNA.  C: Reduced GSTM1 protein was 
confirmed by densitometry with each band normalised to β-actin (n=1 
experiment performed in duplicate). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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4.4.4 DNA Damage 
 
To examine whether reduced Gstm1 contributes to increased DNA damage, 
single cell gel electrophoresis was carried out using a comet assay kit.   
 
To ensure that comet tails could be easily detected using our available 
resources, NRK-52E cells were treated with increasing concentrations of H2O2 to 
induce oxidative stress before being assessed.  Representative images of the 
cells examined are shown in Figure 4.8.  As shown in the top panel of Figure 4.8 
no visible tail was detected in untreated control cells or those that had been 
treated with 10µM H2O2.   However, when the concentration of H2O2 was 
increased to 100µM, a pronounced tail was clearly visible indicating that an 
increased level of DNA damage was present in this cell.  At 300µM, a similar 
level of DNA damage was observed. 
 
Following knock-down of Gstm1, a significant increase in tail length was 
observed in cells transfected with either siRNA B or C indicating increased DNA 
damage in these cells (n=3).  Tail length measurements are shown in the chart in 
Figure 4.8.  In this example, when compared to cells transfected with control 
siRNA, tail length increased by 20% in response to siRNA B and 33% in response to 
siRNA C, p<0.05.  No significant increase in tail length was observed in response 
to siRNA A in this example.  Representative comet images obtained from each of 
the groups are shown in Figure 4.9.  As demonstrated in this Figure, no 
substantial comet tails were detected in any of the control groups when 
compared to the H2O2 induced tails as a reference.  In each of the siRNA treated 
groups, comet tails were readily detectable but with variation in length between 
cells and groups. 
 
4.4.5. 8-Hydroxy-2-Deoxyguanosine Measurement 
 
Levels of 8-OH-dG were measured in the culture medium of NRK-52E cells 
following knock-down of Gstm1 expression.  Figure 4.10 is representative of 4 
experiments.  As shown in Figure 4.10, no significant difference in 8-OH-dG 
concentration was observed between NRK-52E cells treated with Gstm1 specific 
siRNA B and control siRNA.   
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Figure 4.8 Analysis of DNA damage by comet assay  
Top panel: Representative comet images from NRK-52E cells stimulated with 
increasing concentrations of H2O2.  Bottom panel: NRK-52E cells were 
transfected with 30nM control (siCTL) or Gstm1 specific siRNA (A, B or C).  
Following knock-down of Gstm1 expression by RNAi, increased comet tail length 
was observed compared to the siRNA control indicating increased damage to DNA 
(n=1 experiment performed in triplicate and is representative of 3 experiments 
in total) **p<0.01 vs siCTL (ANOVA + Dunnett’s post-hoc test). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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Figure 4.9 Comet assay analysis 
Representative images obtained from NRK-52E cells transfected with 30nM 
control (siRNA CONTROL) or Gstm1 specific siRNA (A, B or C).  No clearly visible 
tails were present in any of the control groups (top 3 panels).  Comet tails of 
varying lengths were observed in cells treated with Gstm1 specific siRNA.  
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Figure 4.10 Measurement of 8-hydroxy-2-deoxyguanosine  
8-OH-dG was measured in NRK-52E cells following transfection with 30nM control 
(siCTL) or Gstm1 specific siRNA (B and C).  No significant change in 
concentration was observed in response to knock-down of Gstm1 expression (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total). 
UTF: untransfected cells, TFC: mock transfection, siCTL: control siRNA 
transfected cells 
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4.5 Discussion 
 
The results of the previous chapter show that Gstm1 expression can be 
selectively knocked down using RNA interference.  In an attempt to translate the 
expression data into a change in Gstm1 activity, a GST assay kit was evaluated.  
At present, there are no selective substrates for Gstm1; instead the kit used 
measures total GST activity by measuring the rate at which glutathione is 
conjugated to CDNB, a substrate for a broad range of GST isozymes.  After a 
number of attempts, no significant change in GST activity could be measured in 
response to reduced Gstm1 expression.  Therefore, one obvious conclusion from 
these experiments is that a kit measuring total GST activity is not sensitive 
enough to detect changes when only one member of a large class of enzymes is 
reduced, as reduction of Gstm1 enzyme activity may be masked by other GSTs in 
the sample.  In contrast, total GST activity was increased when Gstm1 was over-
expressed.  This suggests that total GST activity can indeed be modulated when 
a single GST (Gstm1 in this case) is over-expressed to a high enough level.  
 
Glutathione transferases detoxify the products of oxidative stress by catalysing 
the conjugation of reduced glutathione (GSH) to such products.  Therefore, 
lower levels of GST expression may lead to increased levels of GSH.  The 
concentration of GSH in NRK-52E cells with lower expression of Gstm1 was 
evaluated but no difference in GSH concentration was found.  Again, this is likely 
due to the presence and activity of other GST in the sample.  It is unlikely that 
total GSH levels would be greatly affected by the reduction of one GST when 
other GST isozymes and other enzyme systems such as glutathione peroxidase 
utilise glutathione as a substrate.   
 
As previously mentioned, oxidative stress has been implicated in development of 
hypertension.  Following knock-down of Gstm1 by RNA interference, DNA 
damage and lipid peroxidation were investigated as both are markers of 
oxidative stress.  Lipid peroxidation showed no change in any of the siRNA 
treated cells demonstrated by the levels of 8-isoprostane in the culture medium.  
This data suggests that Gstm1 does not play a role in protection from lipid 
peroxides; however, it could be that other members of the GST super-family are 
compensating for reduced Gstm1 expression.  Treatment of primary cultured rat 
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cerebral cortical cells with valproate (a mood stabilising drug) inhibited lipid 
peroxidation and also increased Gstm1 and Gsta4 levels (222;223).  This may 
suggest a role for Gstm1 in lipid peroxidation protection.  Previous studies have 
shown a role for alpha class GSTs in reduction of lipid hydroperoxides (224).  
Therefore, the increase in Gsta4 may have contributed more to lipid 
peroxidation inhibition.  Although 8-isoprostane is a commonly used biomarker 
for lipid peroxidation in vivo, it may not be the best way to assess oxidative 
stress as such products are quite often only minor end products of peroxidation 
and may not give a reliable indication of oxidative stress status (225).   
 
As well as lipid peroxidation, DNA damage was investigated using the comet 
assay and by assessing levels of the oxidative DNA damage marker 8-OH-dG.  The 
data collected from comet assay analysis show that reduced Gstm1 expression 
was associated with a small but significant increase in comet tail length, 
suggesting greater DNA damage in these cells compared to cells transfected with 
control siRNA.  However, this result did not correlate with the results from the 
8-OH-dG assay.  No change in 8-OH-dG concentration was observed when Gstm1 
expression was reduced, suggesting that lowering Gstm1 expression does not 
contribute to oxidative stress mediated DNA damage.  The comet assay detects 
strand breaks and as such may not represent damage resulting solely from 
oxidative stress.  In order to enhance evaluation of oxidative DNA damage in 
NRK-52E cells, the comet assay could be used in combination with 
formamidopyrimidine DNA glycosylase (FPG).  This enzyme recognizes and 
removes oxidative DNA base modifications including 8-OH-dG and generates a 
strand break.  By measuring comet tails after incubation with FPG and then 
subtracting the score obtained from cells without enzyme an indication of 
oxidative damage could be obtained (216;226).  However, it has been suggested 
that 8-OH-dG may not be a particularly reliable marker of oxidative damage to 
DNA.  The initial products generated from free radical attack on DNA bases are 
converted into end products such as 8-OH-dG and relative amounts will depend 
on various reaction rates and conditions leading to variation between samples 
(213).  This may be important when measuring 8-OH-dG in vivo but in the 
current study, all assays were performed in medium from cultured cells where 
sample to sample variation is less likely.  It has also been suggested that it is 
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unreliable to measure one single reaction product and use this alone as an 
indicator of oxidative stress (227).   
 
The current study has assessed various markers of oxidative stress and results 
demonstrated that reduction of Gstm1 alone was not sufficient to cause 
increased oxidative damage.  It may be that expression of other GSTs in NRK-52E 
cells compensate for reduced Gstm1 expression and in doing so, mask any 
functional significance resulting from Gstm1 knock-down.  However, it could be 
the case that Gstm1 is not important for protection against oxidative stress in 
NRK-52E cells.  Previous studies have shown that Gstm1 expression is localised to 
kidney tubular epithelium, particularly the collecting ducts (77).  Perhaps 
investigating Gstm1 in primary cells isolated from the collecting ducts of SHRSP 
and WKY rats would provide a better model for assessment of the role of Gstm1 
in oxidative stress.  However, it may be that the only way to actually assess the 
function of Gstm1 is to modulate expression in specific cells of interest in vivo.    
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Chapter 5: MicroRNA Analysis in Rat Congenic Strains 
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5.1 Introduction 
 
The previous chapters have demonstrated knock-down of gene expression via 
siRNA mediated RNAi.  Analogous to siRNA, microRNAs (miRNA) are a class of 
endogenous short RNA that drive post-transcriptional inhibition of gene 
expression.  These short regulatory RNAs were first described in C.elegans with 
the discovery of lin-4 and let-7, short transcripts that were found to be 
complementary to regions in the 3' UTR of genes involved in larval development 
(228;229).  MicroRNA induced gene silencing can result from translational 
repression like that observed in studies with C.elegans or from mRNA 
degradation (230;231).  Unlike siRNAs, miRNAs are generated from endogenous 
transcripts that produce long hairpin structures.  These hairpins are further 
processed to generate 21-22 nt mature miRNAs (147-149).  For efficient siRNA 
mediated gene knock-down, near perfect complementary base pairing is 
required between the siRNA and target mRNA.  However for efficient miRNA 
activity, it has been suggested that complementary base pairing is most 
important between the miRNA seed region (6-7nt consecutive nucleotides at 5' 
end of miRNA) and the 3' UTR of the target gene, with binding at multiple sites 
(232;233). 
 
 
5.1.1 MicroRNA Target Prediction 
 
Various computational programs have been developed to improve miRNA target 
gene identification, including TargetScan, MiRanda and PicTar.  Each program 
uses specific base pairing rules to identify miRNA targets and also take into 
account cross species conservation of the target site (234).  Target sites can be 
classified according to miRNA interaction.  Those target sites that have perfect 
complementarity with at least the miRNA seed region and substantial pairing at 
the 3' end can be described as 5' dominant canonical sites.  Where perfect base 
pairing is limited to the 5' seed region, target sites are described as 5' dominant 
seed only.  Targets where there is imperfect pairing to the seed region but 
considerable pairing to the 3' end of the miRNA are described as 3' compensatory 
target sites (234;235).  Following on from target identification it is important 
then to try and validate the miRNA/mRNA target pair (236). 
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5.1.2 Microarray Analysis of Gene Expression     
   
It may be possible to further enhance miRNA target identification by combining 
the computational systems described with microarray analysis of gene 
expression.  Microarray analysis of rat parental and congenic strains was utilised 
previously by our group, leading to the identification of Gstm1 as a positional 
and potentially functional target in blood pressure regulation (69).  This work 
was performed in 16 week old animals, since then microarrays have been carried 
out in kidney tissue from SHRSP, WKY and congenic animals at 5 weeks and 21 
weeks of age, allowing for examination of changes in gene expression over time.   
 
As well as the 2c* congenic strain, other chromosome 2 congenic strains have 
been generated.  The SP.WKYGla2a (2a) strain is of SHRSP background with a 
region of chromosome 2 incorporating 2 BP QTLs transferred from WKY (70).  The 
SP.WKYGla2k (2k) strain is of SHRSP background with a 10 cM region of 
chromosome 2 transferred from WKY (237).  The 2a congenic encompasses both 
2c* and 2k congenic regions and the 2c* and 2k regions partially overlap as shown 
in Figure 5.1.  The 2a and 2k strains demonstrate significantly lower baseline and 
salt-loaded blood pressure, however the 2c* retains salt sensitivity (237).  Thus 
the region that differs between the 2c* and 2k likely contains genes responsible 
for salt sensitivity. The genes encoding miR-9-1 (rno-miR-9-1) and miR-137 (rno-
miR-137) map to the 2c* and 2k congenic regions respectively and may play a 
role in baseline blood pressure regulation (miR-9-1) and salt-sensitive 
hypertension (miR-137).   
 
Ingenuity Pathway Analysis (IPA) is a web-based data analysis tool and 
knowledge database that can be used to investigate relationships between gene 
expression data generated from microarray and other high throughput analyses.  
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Figure 5.1 Rat chromosome 2 congenic sub-strains 
Chromosome 2 congenic strains were generated by transferring chromosomal 
regions from WKY onto the SHRSP background.  Yellow bars represent regions of 
WKY homozygosity.  Blue bars represent regions of SHRSP homozygosity. 
 
Adapted from (237). 
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Ingenuity Pathway Analysis was combined with microarray analysis of salt-loaded 
21 week SHRSP, WKY and 2a strains to identify genes involved in salt sensitivity 
(237).  Using IPA, microarray data can potentially be integrated with results 
from miRNA target prediction to identify genes which may be differentially 
expressed as a result of miRNA targeting.   
 
 
5.2 Aims 
 
• To investigate the expression of miR-9-1 and miR-137 in kidneys from 
SHRSP, WKY and congenic rat strains at 5 weeks (post weaning), 16 weeks 
(adult) and 21 weeks (post salt challenge) 
 
• To identify potential miRNA gene targets and assess differential 
expression of these targets in the microarray datasets previously 
generated 
 
• To evaluate the ability of precursor miRNA molecules and miRNA 
inhibitors to drive up and knock-down miRNA expression in NRK-52E cells  
 
• To assess expression of predicted miRNA gene targets in rat kidney tissue 
and in NRK-52E cells following modulation of miRNA expression 
 
 
5.3 Materials and Methods 
 
5.3.1 Transfection of NRK-52E Cells 
 
NRK-52E cells were transfected with Pre-miR™ miRNA precursors and Anti-miR™ 
miRNA inhibitors for rno-miR-9 and rno-miR-137 (Applied Biosystems) using the 
siPORT™ Amine transfection protocol outlined in section 2.3.  All reagent 
volumes and incubation times were the same as those described in section 2.3, 
replacing siRNA with 30nM to 50nM of Pre-miR™ or Anti-miR™.  To assess 
transfection efficiency, cells were transfected with Cy™3 dye-labelled Pre-miR™ 
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or Anti-miR™ negative control sequences and transfection levels were assessed 
by fluorescence microscopy.  All transfection experiments were performed in 
triplicate and included the following controls: untransfected cells (UTF), cells 
treated with transfection reagent only (TFC) and cells treated with either Pre-
miR™ negative control (Pre-CTL) or Anti-miR™ negative control (Anti-CTL).  
 
 
5.3.2 MicroRNA Extraction 
 
The miRNeasy Mini Kit (Qiagen) was used for the purification of total RNA 
(including miRNA) from NRK-52E cells and frozen rat kidney tissue.  Cultured 
cells and tissues were first homogenized in QIAzol® lysis reagent (phenol and 
guanidine thiocyanate solution).  Each frozen kidney section was transferred into 
5 ml of cold QIAzol® lysis reagent and homogenised with a Polytron 2100 rotor 
homogeniser at full speed.  The homogenate was split into 700 µl aliquots.   
NRK-52E cells (cultured in 6 well plates) were rinsed twice with PBS and then 
700 µl QIAzol® lysis reagent was added to each well.  Cells were homogenized by 
scraping with a pipette tip, transferred to a 1.5 ml centrifuge tube and vortexed 
briefly. 
 
Cell/tissue homogenates were incubated at room temperature for 5 minutes, 
followed by the addition of 140 µl chloroform to each sample.  Samples were 
mixed by shaking vigorously for 15 seconds and incubated at room temperature 
for 2-3 minutes.  This was followed by centrifugation at 12000 g for 15 minutes 
at 4°C to separate the homogenate into aqueous and organic phases.  The upper 
aqueous layer was transferred to a fresh 1.5 ml centrifuge tube and 1.5 volumes 
of 100% ethanol was added and mixed by pipetting.  A maximum of 700 µl was 
then applied to the RNeasy Mini spin column and centrifuged at 8000 g for 15 
seconds.  The flow-through was discarded and the remaining sample was applied 
to the column and centrifuged as before.  The column was washed with 700 µl 
buffer RWT, centrifuged at 8000 g for 15 seconds and the flow-through 
discarded.  The column was then washed with 500 µl buffer RPE and centrifuged 
at 8000 g for 15 seconds.  This wash step was repeated but with centrifugation 
at 8000 g for 2 minutes.  The flow-through was discarded and columns were 
centrifuged again for 1 minute to dry the column membrane.   
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To elute RNA, nuclease-free water was added to the column membrane.  For 
tissue RNA samples, 40 µl of nuclease-free water was added to the column 
membrane and centrifuged for 1 minute at 8000 g.  This elution step was 
repeated with 40 µl nuclease-free water and centrifuged again at 8000 g for 1 
minute.   For cell RNA samples, 40 µl of nuclease-free water was added to the 
column membrane and centrifuged at 8000 g for 1 minute.  The flow-through 
(containing RNA) was applied to the column membrane again and centrifuged at 
8000 g for 1 minute.  All RNA samples were subjected to DNase treatment as 
described in section 2.6.1 and quantified as described in section 2.6.2. 
 
 
5.3.3 MicroRNA Reverse Transcription  
 
The TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) was used 
to generate cDNA for analysis of miRNA expression with miRNA specific primers 
and TaqMan® MicroRNA Assays.  Each RNA sample was diluted in nuclease-free 
water to 2 ng/µl and 5 µl of this was used in each reverse transcription reaction.  
The reverse transcription reaction mix was prepared as follows: 
• 1.5 µl 10X RT Buffer 
• 0.15 µl dNTP mix 
• 1 µl MultiScribe reverse transcriptase (50 U/µl) 
• 0.19 µl RNase inhibitor (20 U/µl) 
• 4.16 µl nuclease-free water 
 
This was added to 5 µl of the diluted RNA sample and 3 µl of the specific miRNA 
primer (supplied with the TaqMan® MicroRNA Assay, Applied Biosystems) to give 
a final reaction volume of 15 µl.  Reverse transcription was carried out in a 96 
well plate using the following thermal cycling parameters: 
• 30 minutes at 16°C 
• 30 minutes at 42°C 
• 5 minutes at 85°C 
 
cDNA samples were stored at -20°C. 
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5.3.3.1 TaqMan® MicroRNA Assays 
 
Quantitative real-time PCR was performed using TaqMan® MicroRNA Assays 
(Applied Biosystems) for quantification of rat miR-9-1 (Assay ID: 000583, hsa-
miR-9) and rat miR-137 (Assay ID: 001129, mmu-miR-137).  Expression of each 
miRNA was normalised to U87 (control miRNA, Assay ID: 001712) and expression 
levels were determined using the comparative CT method (2
-∆∆Ct) (171).  For each 
miRNA assay, a 20 µl simplex reaction was prepared in a 96 well plate as follows: 
• 10 µl 2X TaqMan® Universal PCR master mix 
• 1 µl 20X TaqMan® MicroRNA Assay 
• 7.6 µl nuclease-free water 
• 1.2 µl RT product 
 
Each reaction was performed in duplicate and subjected to the thermal cycling 
parameters described in section 2.7.1. 
 
 
5.3.4 miR-9 Target Genes: mRNA Expression 
 
Quantitative RT-PCR was performed on cDNA using TaqMan Gene Expression 
Assays (Applied Biosystems) for the following genes:   
 
 
Gene ID Gene Name Assay ID 
Adamts1 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
Rn01646120_m1 
Comt Catechol-O-methyltransferase Rn00561037_m1 
Ctsb Cathepsin B Rn00575030_m1 
Igfbp3 Insulin-like growth factor binding protein 3 Rn01401281_m1 
Igsf11 Immunoglobulin superfamily, member 11 Rn01439426_m1 
Scly Selenocysteine lyase Rn01427211_m1 
Trim35 Tripartite motif-containing 35 Rn01534954_m1 
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The expression of each gene of interest was normalised to β-actin expression 
and all assays were performed in simplex as described in section 2.7.1. 
 
 
5.4 Results 
 
5.4.1 Rat Kidney Expression of miR-9-1 and miR-137 
 
The expression levels of miR-9-1 and miR-137 were examined in kidney tissue 
from SHRSP, WKY and congenic strains at various time-points to assess whether 
miRNA expression differs between strains.  Figure 5.2 shows the levels of miR-9 
expression in SHRSP, 2c* and WKY kidney at 5, 16 and 21 weeks of age (n=4).  No 
significant change in miR-9 levels was observed at any time-point in SHRSP.  
However, a significant decrease in miR-9 expression was observed between 5 
and 16 weeks of age in 2c* and WKY animals, p<0.05.  Figure 5.3 shows the 
levels of miR-137 expression in SHRSP, WKY and 2k kidney at 5, 16 and 21 weeks 
of age and at 21 weeks with salt (n=4).  No significant change in miR-137 
expression was observed in 2k or WKY strains regardless of time-point or salt 
loading.  However, a significant increase in miR-137 expression was observed in 
21 week old salt loaded SHRSP compared to 21 week old SHRSP animals without 
salt, p<0.05. 
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Figure 5.2 Kidney miR-9-1 expression levels 
TaqMan® qRT-PCR analysis of miR-9-1 expression in rat kidney shows that 
expression of miR-9-1 was unchanged across all time-points in SHRSP.  Expression 
of miR-9-1 was significantly reduced in 16 week 2c* and WKY kidney compared to 
5 week, n=4, *p<0.05. 
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Figure 5.3 Kidney miR-137 expression levels 
TaqMan® qRT-PCR analysis of miR-137 expression in rat kidney shows that 
expression of miR-137 was unchanged across all time-points in 2k and WKY 
kidney.  Expression of miR-137 was significantly increased in 21 week salt loaded 
SHRSP compared to 21 week SHRSP without salt, n=4, *p<0.05. 
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5.4.2 In Vitro Modulation of miR-9-1 and miR-137 Expression 
 
To modulate expression of miR-9-1 and miR-137 in vitro, Pre-miR™ miRNA 
precursors or Anti-miR™ miRNA inhibitors were used.  The transfection efficiency 
of NRK-52E cells for transfection of Pre-miR™ and Anti-miR™ molecules was 
assessed using Cy™3 labelled control versions of both.  Figure 5.4 shows a 
representative Cy™3 labelled control Pre-miR™ transfection experiment.  Panel B 
demonstrates that no fluorescence is generated when NRK-52E cells are 
subjected to a mock transfection (treated with transfection reagent only).  
However, when cells are treated with 30nM Cy™3 labelled control Pre-miR™, 
fluorescence is detected throughout (panel C).  The level of fluorescence 
observed indicates that at least 70% transfection efficiency was achieved.  
Figure 5.5 shows a representative Cy™3 labelled control Anti-miR™ transfection 
experiment.  As before, cells subjected to a mock transfection do not generate 
fluorescence (Figure 5.5, panel B).  Initial experiments performed with 30nM 
Cy™3 labelled control Anti-miR™ did not achieve the levels of transfection 
observed with the Pre-miR™.  However, when increased to 50nM, similar levels 
of transfection efficiency were achieved, as shown in Figure 5.5, panel C. 
 
Following confirmation of efficient transfection of NRK-52E cells with control 
Pre-miR™ and Anti-miR™, transfections were repeated with miR-9-1 and miR-137 
Pre-miR™ and Anti-miR™ molecules.  The ability to over-express each miRNA was 
evaluated first.  Figure 5.6 is representative of 4 individual experiments 
performed in triplicate.  The top panel of Figure 5.6 shows the results obtained 
from transfection of NRK-52E cells with 30nM Pre-miR-9.  In this example, 
transfection with Pre-miR-9 resulted in a 1928 fold increase in miR-9-1 
expression compared to cells transfected with control Pre-miR (Pre-CTL), 
p<0.0001.  Across the 4 experiments, expression of miR-9 was increased up to 
2629 fold.  The bottom panel of Figure 5.6 shows the results obtained from 
transfection of NRK-52E cells with 30nM Pre-miR-137.  In this example, miR-137 
expression was increased 2278 fold in cells transfected with Pre-miR-137 
compared to Pre-CTL cells, p<0.0001. 
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Figure 5.4 Pre-miR transfection efficiency of NRK-52E cells 
Panel A: Transmitted light image of NRK-52E cells.  B: Mock transfected cells 
showing no background fluorescence.  C: Cells transfected with 30nM Cy™3 
labelled Pre-miR.  Comparison with transmitted light image of the same field (A) 
suggests high transfection efficiency.  Scale bar: 50µm  
 
 
A 
B 
C 
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Figure 5.5 Anti-miR transfection efficiency of NRK-52E cells 
Panel A: Transmitted light image of NRK-52E cells.  B: Mock transfected cells 
showing no background fluorescence.  C: Cells transfected with 50nM Cy™3 
labelled Anti-miR.  Comparison with transmitted light image of the same field 
(A) suggests high transfection efficiency.  Scale bar: 50µm 
 
 
A 
B 
C 
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The ability to inhibit miR-9-1 and miR-137 expression was then assessed by 
transfecting NRK-52E cells with 50nM of each miRNA inhibitor.  Figure 5.7 is 
representative of 4 individual experiments performed in triplicate.  The top 
panel indicates that miR-9-1 expression was not reduced in cells transfected 
with Anti-miR-9 as no significant change in expression was detected.  The 
bottom panel of Figure 5.7 shows the results obtained from transfection of NRK-
52E cells with Anti-miR-137.  Expression of miR-137 was not inhibited although 
expression levels were found to be highly variable. 
 
 
5.4.3 Target Identification and Ingenuity Pathway Analysis 
 
Target genes were identified by searching for perfect complementarity between 
miR seed regions (miR-9-1 and miR-137) and the 3' UTR of genes represented on 
the microarray chips used previously.  The seed region was designated as a 
consecutive stretch of 6 nucleotides starting from the second nucleotide at the 
5' end of the mature miRNA.   
 
 
The sequence marked in red was used to search through 3' UTRs for regions that 
would base pair with each miRNA.  A list of predicted gene targets for miR-9-1 
and miR-137 was generated (see Table A1 and A2 in the appendix for full list of 
genes) and uploaded to the Ingenuity Pathway Analysis (IPA) website.
5' CCAAAG 3' 
3' AGUAUGUCGAUCUAUUGGUUUCU 5' miR-9-1 
3' GAUGCGCAUAAGAAUUCGUUAUU 5' 
5' GCAATA 3' 
miR-137 
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Figure 5.6 Over-expression of microRNAs in NRK-52E cells 
TaqMan® qRT-PCR analysis of miRNA expression in NRK-52E cells following 
transfection with Pre-MiR.  Top panel: Following transfection of cells with 30nM 
Pre-miR-9, miR-9-1 expression was significantly increased (~1900 fold) compared 
to Pre-CTL (n=1 experiment performed in triplicate and is representative of 4 
experiments in total) *p<0.0001 vs Pre-CTL (ANOVA + Dunnett’s post-hoc test).  
Bottom panel: Following transfection of cells with 30nM Pre-miR-137, miR-137 
expression was significantly increased (~2000 fold) compared to Pre-CTL (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total) *p<0.0001 vs Pre-CTL (ANOVA + Dunnett’s post-hoc test). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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Figure 5.7 Effect of Anti-miR transfection on miRNA expression in NRK52E 
cells 
TaqMan® qRT-PCR analysis of miRNA expression in NRK-52E cells following 
transfection with Anti-miR.  Top panel: Following transfection of cells with 50nM 
Anti-miR-9, no significant change in miR-9-1 expression was observed compared 
to Anti-CTL (n=1 experiment performed in triplicate and is representative of 4 
experiments in total).  Bottom panel: Following transfection of cells with 50nM 
Anti-miR-137, no significant change in miR-137 expression was observed 
compared to Anti-CTL (n=1 experiment performed in triplicate and is 
representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Anti-CTL: Control Anti-
miR transfected cells 
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Using IPA, the list of targets was combined with gene expression datasets 
generated from 5 week, 16 week, 21 week and 21 week plus salt kidney 
microarray analysis carried out previously.  The predicted targets identified for 
miR-9-1 were combined with SHRSP, WKY and congenic microarray datasets (16 
week versus 5 week) to identify genes that were up-regulated in both the 
congenic and WKY datasets but not in the SHRSP dataset (as kidney miR-9-1 
expression was lower in 16 week WKY and congenic but was unchanged in 
SHRSP).  The predicted targets identified for miR-137 were combined with 
SHRSP, WKY and congenic microarray datasets (21 week versus 21 week plus 
salt) to identify genes that were down-regulated in the SHRSP comparison but 
were unchanged in both WKY and congenic datasets (as SHRSP kidney miR-137 
expression was greater in 21 week old animals with salt than in 21 week old 
animals without but was unchanged in the congenic and WKY).  Table 5.1 
contains information regarding miR-9-1 seed/target interactions of gene targets 
identified by IPA.  Of the list of targets uploaded, 7 were found that were up-
regulated and common to both the congenic and WKY (Figure 5.8) but were 
unchanged in the SHRSP (Figure 5.9).  The following genes were identified: ADAM 
metallopeptidase with thrombospondin type 1 motif, 1 (Adamts1), Cathepsin B 
(Ctsb), Catechol-O-methyltransferase (Comt), Insulin like growth factor binding 
protein 3 (Igfbp3), Immunoglobulin superfamily, member 11 (Igsf11), 
Selenocysteine lyase (Scly) and Tripartite motif-containing 35 (Trim35). Table 
5.2 outlines the miR-9-1 gene targets identified by IPA.  However, analysis of the 
miR-137 targets failed to find any genes that were down-regulated in the SHRSP 
21 week/21 week salt dataset and unchanged in both congenic and WKY 
datasets.  
 
 
5.4.4 Expression of miR-9-1 Target Genes 
 
The mRNA expression levels of the gene targets identified by IPA were examined 
in kidney tissue from SHRSP, WKY and congenic strains at 5 weeks and 16 weeks 
of age (n=4 for each target gene) and in NRK-52E cells transfected with Pre-miR-
9-1 (each figure is representative of 4 individual experiments performed in 
triplicate).  
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Table 5.1 Seed site information for predicted miR-9-1 targets  
A1: nucleotide at first position downstream of the seed match, M8: nucleotide at 
first position upstream of the seed match  
 
RefSeq Gene 
No. of 
Seeds 
Position in 3' 
UTR 
A1 M8 
NM_024400 Adamts1 1 230 T C 
NM_012531 Comt 1 212 G G 
NM_022597 Ctsb 1 337 G T 
NM_012588 Igfbp3 1 209 T G 
NM_001013120 Igsf11 1 1197 A C 
NM_001007755 Scly 2 601 T G 
              756 G G 
NM_001025142 Trim35 1 106 T C 
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Congenic (16wk V 5wk) WKY (16wk V 5wk) SHRSP (16wk V 5wk) 
RefSeq Gene Location 
Mean 
Difference 
p-value 
Mean 
Difference 
p-value 
Mean 
Difference 
p-value 
NM_024400 Adamts1 11q11 1.031 0.0125 1.106 0.0054 1.695 0.2055 
NM_012531 Comt 11q23 1.141 0.0025 1.907 5.74E-6 1.056 0.0992 
NM_022597 Ctsb 15p12 1.823 0.0173 1.591 4.13E-6 1.474 0.1278 
NM_012588 Igfbp3 14q21 1.310 0.0515 3.002 7.63E-6 1.066 0.4538 
NM_001013120 Igsf11 11q21 1.037 0.0218 1.802 5.40E-6 0.751 0.2495 
NM_001007755 Scly 9q36 0.775 0.0124 1.107 2.10E-4 0.281 0.7195 
NM_001025142 Trim35 15p12 1.552 0.0090 2.172 0.0011 1.893 0.0803 
 
 
 
 
Table 5.2 Microarray expression data: predicted miR-9-1 targets 
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Figure 5.8 Ingenuity Pathway Analysis of congenic and WKY microarray 
datasets 
Data output from Ingenuity Pathway Analysis of predicted miR-9-1 target genes.  
Seven targets were identified that were up-regulated in 16 week versus 5 week 
datasets and common to both congenic and WKY strains.  Red represents up-
regulation of genes and colour intensity represents the significance of up-
regulation. 
 
 
Congenic 16wk V 5wk WKY 16wk V 5wk 
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Figure 5.9 Ingenuity Pathway Analysis of SHRSP microarray datasets 
Data output from Ingenuity Pathway Analysis of predicted miR-9-1 target genes.  
Data shows that predicted miR-9-1 targets are not differentially expressed in 16 
week versus 5 week SHRSP microarray dataset. 
 
 
SHRSP 16wk V 5wk 
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As miR-9-1 expression was found to be down-regulated in 16 week compared to 5 
week old 2c* and WKY strains, it would be expected that miR-9-1 target genes 
would be up-regulated in these strains at 16 weeks compared to 5 weeks.  
Conversely, target gene expression would be expected to go down in NRK-52E 
cells where miR-9-1 has been over-expressed.  The functions of each gene target 
are summarised in Table 5.3.    
 
 
5.4.4.1 Adamts1 
 
Kidney mRNA expression of Adamts1 showed no change between 5 and 16 week 
old 2c* but was significantly up-regulated by 6.5 fold in 16 week old WKY 
compared to 5 week, p<0.05 (Figure 5.10, top panel).  No significant change in 
expression was observed between 5 and 16 week old SHRSP.  The bottom panel 
of Figure 5.10 shows Adamts1 expression in NRK-52E cells following over-
expression of miR-9-1.  No significant change in Adamts1 expression was 
observed in NRK-52E cells treated with Pre-miR-9. 
 
5.4.4.2 Comt 
 
No significant difference in Comt expression was observed between 5 week and 
16 week time-points in SHRSP and WKY strains (Figure 5.11, top panel).  
However a significant 1.3 fold increase in expression was detected in 16 week 
2c* compared to 5 week, p<0.05.  Over-expression of miR-9-1 in NRK-52E cells 
had no significant effect on Comt expression (Figure 5.11, bottom panel). 
 
5.4.4.3 Ctsb 
 
No significant difference in Ctsb mRNA expression was observed between 5 and 
16 week time-points in any of the strains (Figure 5.12, top panel).  Expression of 
Ctsb in NRK-52E cells showed no significant difference following transfection 
with Pre-miR-9 (Figure 5.12, bottom panel).  
  
 
 
Table 5.3 Functional information of each miR-9-1 predicted target gene identified by 
IPA 
 
Gene Function Refs 
Adamts1 
Binds VEGF and inhibits VEGFR2 phosphorylation.  Inhibits 
endothelial cell proliferation.  Inhibits tumour growth and 
has anti-angiogenic function. 
(238-240) 
Comt 
Catalyses the methylation and inactivation of catecholamine 
neurotransmitters.  Possible role in BP regulation in SHR and 
Dahl S rats.  Decreased levels have been shown to associate 
with pre-eclampsia 
(241-243) 
Ctsb 
Role in cell proliferation, tumour development and tumour 
progression.  Possible target for cancer therapy. 
(244;245) 
Igfbp3 
Role in growth, proliferation and apoptosis.  Shown to have 
anti-proliferative and pro-apoptotic functions 
(246) 
Igsf11 
Preferentially expressed in brain and testes.  Regulates cell 
growth and is elevated in various cancers. 
(247;248) 
Scly Metabolism of L-selenocysteine (249) 
Trim35 
Member of the tripartite motif containing family with roles 
in cell growth, proliferation and apoptosis 
(250;251) 
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Figure 5.10 Adamts1 mRNA expression 
TaqMan® qRT-PCR analysis of Adamts1 mRNA expression.  Top panel: Expression 
of Adamts1 in kidney of SHRSP, congenic and WKY strains at different time-
points.  No significant change in expression was observed in SHRSP or congenic 
but was significantly increased in 16 week WKY compared to 5 week (n=4) 
*p<0.05 vs 5wk WKY (2 sample t-test).  Bottom panel: Adamts1 expression 
following transfection of NRK-52E cells with 30nM control (Pre-CTL) or miR-9 
precursor (Pre-miR-9).  No significant change in expression was observed (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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Figure 5.11 Comt mRNA expression 
TaqMan® qRT-PCR analysis of Comt mRNA expression.  Top panel: Expression of 
Comt in kidney of SHRSP, congenic and WKY strains at different time-points.  No 
significant change in expression was observed in SHRSP or WKY but was 
significantly increased in 16 week congenic compared to 5 week (n=4) *p<0.05 vs 
5wk 2c* (2 sample t-test).  Bottom panel: Comt expression following transfection 
of NRK-52E cells with 30nM control (Pre-CTL) or miR-9 precursor (Pre-miR-9).  No 
significant change in expression was observed (n=1 experiment performed in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells  
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Figure 5.12 Ctsb mRNA expression 
TaqMan® qRT-PCR analysis of Ctsb mRNA expression.  Top panel: Expression of 
Ctsb in kidney of SHRSP, congenic and WKY strains at different time-points.  No 
significant change in expression was observed in any of the strains, regardless of 
time-point (n=4).  Bottom panel: Ctsb expression following transfection of NRK-
52E cells with 30nM control (Pre-CTL) or miR-9 precursor (Pre-miR-9).  No 
significant change in expression was observed (n=1 experiment performed in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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5.4.4.4 Igfbp3 
 
No significant difference in Igfbp3 expression was observed between 5 and 16 
week time-points in any of the strains (Figure 5.13, top panel).  No significant 
change in Igfbp3 expression was observed in Pre-miR-9 transfected NRK-52E cells 
when compared to Pre-CTL transfected cells.  However, expression was 
markedly reduced, by approximately 10 fold in all cell groups treated with 
transfection reagent compared to untransfected cells, p<0.05 (Figure 5.13, 
bottom panel). 
 
5.4.4.5 Igsf11 
 
No significant change in expression of Igsf11 was observed in SP or WKY between 
5 week and 16 week.  A significant decrease in Igsf11 expression of 
approximately 2 fold was observed in 16 week 2c* compared to 5 week, p<0.05 
(Figure 5.14).  No detectable level of Igsf11 expression was found in NRK-52E 
cells. 
 
5.4.4.6 Scly 
 
No significant difference in Scly expression was observed between 5 and 16 week 
time-points in any of the strains (Figure 5.15, top panel).  No change in 
expression was observed in NRK-52E cells transfected with Pre-miR-9 compared 
to Pre-CTL transfected cells (Figure 5.15, bottom panel). 
 
5.4.4.7 Trim35 
 
No significant change in Trim35 expression was observed between 5 and 16 week 
time-points in any of the strains. (Figure 5.16, top panel).
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Figure 5.13 Igfbp3 mRNA expression 
TaqMan® qRT-PCR analysis of Igfbp3 mRNA expression.  Top panel: Expression of 
Igfbp3 in kidney of SHRSP, congenic and WKY strains at different time-points.  
No significant change in expression was observed in any of the strains, regardless 
of time-point (n=4).  Bottom panel: Igfbp3 expression following transfection of 
NRK-52E cells with 30nM control (Pre-CTL) or miR-9 precursor (Pre-miR-9).  No 
significant change in expression was observed compared to Pre-CTL, however 
when compared to UTF all other groups were significantly reduced (n=1 
experiment performed in triplicate and is representative of 4 experiments in 
total) *p<0.05 vs UTF (ANOVA + Dunnett’s post-hoc test). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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Figure 5.14 Igsf11 mRNA expression 
TaqMan® qRT-PCR analysis of Igsf11 mRNA expression in kidney of SHRSP, 
congenic and WKY strains at different time-points.  No significant change in 
expression was observed in SHRSP or WKY between 5 week and 16 week time 
points.  Igsf11 expression was significantly decreased in 16 week congenic 
compared to 5 week (n=4) *p<0.05 vs 16 wk 2c* (2 sample t-test).    
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Figure 5.15 Scly mRNA expression 
TaqMan® qRT-PCR analysis of Scly mRNA expression. Top panel: Expression of 
Scly in kidney of SHRSP, congenic and WKY strains at different time-points.  No 
significant change in expression was observed in any of the strains, regardless of 
time-point (n=4).  Bottom panel: Scly expression following transfection of NRK-
52E cells with 30nM control (Pre-CTL) or miR-9 precursor (Pre-miR-9).  No 
significant change in expression was observed (n=1 experiment performed in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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Figure 5.16 Trim35 mRNA expression 
TaqMan® qRT-PCR analysis of Trim35 mRNA expression. Top panel: Expression of 
Trim35 in kidney of SHRSP, congenic and WKY strains at different time-points.  
No significant change in expression was observed in any of the strains, regardless 
of time-point (n=4).  Bottom panel: Trim35 expression following transfection of 
NRK-52E cells with 30nM control (Pre-CTL) or miR-9 precursor (Pre-miR-9).  No 
significant change in expression was observed (n=1 experiment performed in 
triplicate and is representative of 4 experiments performed in triplicate). 
UTF: untransfected cells, TFC: mock transfected cells, Pre-CTL: Control Pre-miR 
transfected cells 
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No change in Trim35 expression was observed in NRK-52E cells following over-
expression of miR-9 (Figure 5.16, bottom panel).      
 
 
5.5 Discussion 
 
As previously mentioned, miR-9-1 and miR-137 map within the 2c* and 2k 
congenic regions.  Using commercially available TaqMan® probes designed to 
detect and quantify mature miRNAs, it has been possible to investigate 
expression of miR-9-1 and miR-137 in kidney tissue from SHRSP, congenic and 
WKY animals.  As the mature miRNA is the active species responsible for binding 
to the 3' UTR of target mRNA and subsequent inhibition of gene expression, 
quantification of mature miRNA is preferred (252).  Kidney expression of mature 
miR-9-1 was found to be higher in 5 week old than 16 week old congenic and 
WKY strains.  However, expression of miR-9-1 in SHRSP was unchanged over 
time.  Kidney expression of mature miR-137 was found to be higher in salt-
loaded 21 week old SHRSP than in 21 week old SHRSP without salt loading.  No 
significant change in miR-137 expression was observed in kidney from congenic 
and WKY strains at any time-point.  This suggests that miR-137 and its gene 
targets may be play a role in salt sensitivity in the SHRSP.   
 
To aid in the validation of miRNA/mRNA target pairs, ‘gain of function’ and/or 
‘loss of function’ experiments can be performed (236).  If a predicted 
miRNA/mRNA is valid then over-expression of a miRNA mimic (gain of function) 
would result in reduced target expression and inhibition of a miRNA by antisense 
oligonucleotides (loss of function) would result in increased target expression.  
NRK-52E cells were transfected with miRNA precursor and inhibitor molecules for 
miR-9-1 and miR-137 and the ability of each miRNA to be up-regulated or down-
regulated was assessed.  Using precursor miRNA molecules (designed to mimic 
mature miRNAs); expression of miR-137 and miR-9-1 was significantly up-
regulated.  However, when NRK-52E cells were transfected with miRNA 
inhibitors, no down-regulation of either miRNA was observed.  Anti-miRNA 
antisense oligonucleotides (ASO) have been used previously in attempts to 
modulate miRNA expression to improve target validation.  Antisense 
oligonucleotides are chemically modified single stranded RNA molecules and 
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have been used to target and inhibit mature miRNA (253).  However, measuring 
the level of miRNA inhibition can be difficult.  Neither miR-9-1 nor miR-137 
inhibition was detectable by qRT-PCR.  Other studies investigating the efficacy 
of miRNA inhibition by ASO have utilised reporter constructs to demonstrate 
reduced miRNA activity.  Cheng and colleagues used a luciferase reporter 
construct engineered so that the 3' UTR contained miRNA target sites.  The 
reporter constructs and miRNA inhibitors were then co-transfected into HeLa 
cells.  In those cells treated with miRNA inhibitor, luciferase activity was 
increased due to the inhibition of endogenous miRNA thus preventing miRNA 
mediated repression of reporter gene expression (254).  A luciferase reporter 
system was also used to assess the effect of different ASO chemical 
modifications on ASO activity after attempts to measure target expression by RT-
PCR were not sensitive enough to detect subtle changes following ASO treatment 
(255). An EGFP reporter construct containing a miR-21 complementary sequence 
in the 3' UTR was used to evaluate anti-miR-21 activity in HeLa cells.  Expression 
of EGFP was restored when cells were transfected with anti-miR-21 (256).  The 
expression data generated from TaqMan® analysis of miR-9-1 and miR-37 
suggests that expression is quite low in NRK-52E cells and may explain why it was 
not possible to detect reduced miRNA expression by qRT-PCR.  In future 
experiments involving analysis of miRNA activity a reporter construct method 
could be used in conjunction with qRT-PCR of mature miRNA to further enhance 
miRNA expression analysis. 
 
It has been shown that over-expression of miR-9-1 and miR-137 can be readily 
achieved in NRK-52E cells.  This over-expression was then used to try and 
validate predicted miRNA targets.  Target validation has proved to be 
problematic.  The targets of interest were identified using a computational 
method to find 3' UTR sequences complementary to the miRNA seed region 
combined with bioinformatic analysis to identify which targets were 
differentially expressed.  Analysis found 7 predicted target genes for miR-9-1 but 
none for miR-137.  The mRNA expression levels of each predicted target were 
assessed in kidney tissue and in NRK-52E cells over-expressing miR-9-1.  None of 
the predicted targets followed the pattern of expression expected in kidney 
tissue and no significant changes in target expression were observed in NRK-52E 
cells following over-expression of miR-9-1.   
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The lack of miR-9-1 induced changes to gene expression may be because binding 
of just one miRNA to the 3' UTR of these targets is not sufficient and that binding 
of multiple miRNAs may be required before a reduction in expression is 
observed.  Different miRNAs can affect the regulation of a single transcript by 
co-operative binding to the 3' UTR and binding of multiple identical miRNAs can 
also enhance down-regulation (257).  Each of the targets investigated were 
chosen according to complementarity between the 3' UTR and miRNA seed 
region.  All targets were found to contain only one seed apart from Scly which 
contained two.  The greater the number of seed regions in the 3' UTR that 
miRNA can bind to, the greater the miRNA activity (258;259).  Another factor 
contributing to miRNA ability to down-regulate expression is the distance 
between miRNA seed sites in 3' UTR.  It has been suggested that optimal activity 
of miRNAs occurs when 2 seed sites are separated between 13 and 35 nt (260).  
Our data shows a lack of seed sites in the 3' UTR of each predicted target and 
when more than one seed site was detected, the distance between sites was 
much larger than suggested for optimal activity.  MicroRNA specificity may also 
be affected by the nucleotide present in the A1 position of the seed site.  This 
corresponds to the first nucleotide of the miRNA, which is usually a uracil (this is 
the case for miR-9-1) such that an adenine in the position next to the seed site 
(3') may improve specificity (261).  However, Table 5.1 shows the nucleotide 
present at the A1 position for each predicted target; none contained an adenine 
at this position.  This may have contributed to reduced miRNA binding 
specificity.  The target identification method used here relied solely on 
complementarity between the 3' UTR and the miRNA seed region.  However, it 
has been suggested that complementarity to the seed region is not the only 
factor important for target recognition (230).  
 
Various computational approaches have been used to identify miRNA targets.  
These approaches also use seed binding as an indicator of potential targets.  
TargetScan requires perfect complementary base pairing with the miRNA seed 
(261) but other resources, such as MiRanda, consider seed binding as important 
but do not require perfect complementarity (234;262).  However, as a second 
criterion for target prediction, these programs also require cross species 
conservation.  Both TargetScan and PicTar require that the portion of the 3' UTR 
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that interacts with the miRNA seed be conserved between at least five species.  
MiRanda also requires cross species conservation but only between human and 
rodent (234).  In order to improve miRNA target prediction in future 
experiments, it may be better to assess cross species conservation and to also 
consider genes that have multiple predicted sites even if complementarity to the 
seed is not perfect.  Target sites could also be 3' compensatory so the ability to 
detect targets may be reduced by focusing solely on the seed region (5' dominant 
sites). 
 
MicroRNA mediated down-regulation of gene expression can result from either 
translational repression or mRNA degradation (262).  Potentially, the lack of 
target validation at mRNA observed in the present study may be a reflection of 
translational repression occurring further downstream.  It has been suggested 
that if the miRNA is sufficiently complementary to the mRNA target then mRNA 
cleavage would be the outcome; otherwise the miRNA would induce translational 
repression (263;264).  It may have been more appropriate to try and validate 
each target at the protein level, as it could be the case that target mRNA 
expression was unaffected by miR-9-1 over-expression and that miRNA activity 
was mediated through repression of translation. 
 
A recent study demonstrated successful identification and validation of hsa-miR-
193b and its target urokinase-type plasminogen activator (uPA).  Using anti-miR-
193b in human breast cancer cells lines resulted in increased uPA protein 
expression and increased cell invasion.  However, over-expression of miR-193b 
reduced protein expression and also reduced cell invasion (265).  The work 
performed here highlights the difficulties involved when trying to identify and 
validate predicted miRNA/mRNA target pairs.  The approach used in the present 
study attempted to increase the likelihood of identifying a valid miRNA/mRNA 
target pair by combining target identification methods with gene expression 
data from microarray analysis.  By looking at genes that were down-regulated in 
kidney tissue at time-points when miRNA expression was up-regulated and vice 
versa, it was hoped that a valid target would be found.  This was not the case in 
this study but the same strategy could be applied to miRNAs of interest in the 
future.  The application of proteomics could further enhance miRNA studies.  
Strategies such as pulsed SILAC (stable isotope labelling with amino acids in cell 
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culture) labelling of proteins allow for genome wide quantification of protein 
synthesis (258;266).  This method was utilised by Selbach and colleagues to 
measure changes in protein production in HeLa cells following modulation of 
miRNA expression.  By pulse labelling miRNA transfected cells and control 
transfected cells with different heavy stable isotopes it was possible to measure 
differences in protein production between the two samples.  This study found 
that a single miRNA could down-regulate production of hundreds of proteins 
(258).  By combining such methods for analysis of protein expression with mRNA 
expression analysis, the ability to detect and validate miRNA targets could be 
vastly improved. 
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Chapter 6: General Discussion 
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A combination of congenic breeding and microarray analysis to assess changes in 
gene expression led to the identification of Gstm1 as a positional and functional 
candidate gene for hypertension in the SHRSP (69).  As Gstm1 is part of a large 
family of antioxidant enzymes, it was proposed that depleted renal Gstm1 levels 
in the SHRSP may contribute to the development of hypertension by increasing 
the susceptibility of kidney tubular cells to the damaging effects of oxidative 
stress.  This in turn could impair the ability of the kidney to regulate the sodium 
and fluid balance and subsequently alter blood pressure.  This study has aimed 
to investigate the role of Gstm1 using an RNAi mediated approach and to 
develop molecular tools that could be used for targeted modulation of gene 
expression in vivo.  In addition to this, two microRNAs that mapped to the 
congenic region were investigated to assess their potential contribution to 
differences in gene expression observed between the SHRSP, WKY and congenic 
rat strains. 
   
The findings from chapter 3 indicate that expression of Gstm1 can be effectively 
and reproducibly knocked down in response to siRNA and can be quantified at 
both mRNA and protein level.  It has also been shown that by modulating the 
concentration of siRNA used any non-specific effects on the expression of other 
Gstm family members can be prevented and interferon response gene activation 
can be avoided.  To be able to take investigation of the function of Gstm1 into 
an in vivo setting the possibility of using local delivery to the kidney for in vivo 
gene knock-down was assessed but was found to be inappropriate as it resulted 
in significant renal damage.  However, successful targeting of renal tubules in 
SHRSP following systemic delivery was demonstrated using a previously 
identified kidney targeting modified adenoviral vector (185).  Furthermore, 
over-expression and RNAi sequences could be incorporated into these targeted 
adenoviral vectors allowing both approaches to be delivered to specific cells of 
interest.  Short-hairpin RNA expressing vectors have been generated and were 
evaluated in NRK-52E cells, however knock-down of Gstm1 was not confirmed in 
this cell line.  The integration of targeted vectors and modulation of Gstm1 
expression would allow the role of Gstm1 to be investigated more fully in vivo.   
 
Following on from the optimisation of Gstm1 knock-down performed in chapter 
3, the experiments carried out in chapter 4 sought to investigate the 
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contribution of reduced Gstm1 expression to oxidative stress.  Reduced Gstm1 
expression was not sufficient to cause a change in glutathione levels and 
reduced activity could not be detected using a total GST activity kit.  Lipid 
peroxidation (as determined by 8-isoprostane level) and DNA damage (as 
determined by 8-OH-2OG level) were unaffected by reducing Gstm1 expression.  
However, when DNA damage was assessed by comet assay, a small but 
significant increase in tail length was observed in cells with reduced Gstm1 
expression, suggesting increased damage in these cells.  The results generated 
tend to suggest that Gstm1 alone is not responsible for cellular protection 
against products of oxidative stress such as lipid radicals, as suggested in the 
hypothesis of this study.  Rather Gstm1 may function as part of a larger pathway 
in the protection against oxidative stress.   
 
Two miRNAs (miR-9-1 and miR-137) were identified that map to the chromosome 
2 congenic region.  It was proposed that miRNA within this region may target 
genes expressed in the kidney and contribute to differential gene expression in 
parental and congenic strains.  Expression analysis of miR-9-1 and miR-137 found 
expression of miR-9-1 was lower in 16 week old congenic and WKY strains than in 
5 week animals of the same strain but was unchanged in SHRSP and that 
expression of miR-137 was unchanged across all time-points in congenic and WKY 
strains but was significantly higher in 21 week old, salt-loaded SHRSP than in 21 
week old SHRSP without salt.  By combining previously generated microarray 
data with predicted miRNA targets using IPA, 7 predicted targets for miR-9-1 
were identified.  However, none of the predicted targets were validated by qRT-
PCR in kidney tissue or in NRK-52E cells transfected with pre-miR-9.  Although no 
targets were validated in this instance, miR-9-1 may still have a role in 
contributing to the changes in gene expression observed in kidney from congenic 
and WKY strains. 
 
The combined congenic breeding and microarray strategy used to identify Gstm1 
has been used previously and led to the identification and confirmation of Cd36 
as a candidate gene for insulin resistance in the SHR (65;267).  This strategy was 
also used to identify Vcam1 and Edg1 as candidate genes for salt sensitivity in 
the SHRSP (237).  This study utilised IPA to generate a molecular network linking 
each gene and demonstrated how Edg1 could regulate Vcam1 expression.  
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Following on from identification of Gstm1 as a candidate gene for hypertension 
in SHRSP, this study sought to further investigate its function and role in 
oxidative stress.  Increased renal oxidative stress was identified in SHRSP (77).  
However, using RNAi to knock-down Gstm1 expression in a rat kidney cell line 
did not lead to identification of a specific role for Gstm1 in protection against 
products of oxidative stress.  This would suggest that the decreased expression 
of Gstm1 alone, as observed in SHRSP, is not responsible for reduced oxidative 
stress protection but instead may act as part of an oxidative stress pathway.  As 
described previously, Gstm1 is part of a large, highly homologous family of 
antioxidant enzymes.  A recent study observed a small reduction (less than 2-
fold) in expression of other Gstm isoforms in kidney from the SHRSP (268) but it 
may be that many small changes in the expression of genes participating in 
oxidative stress defence contribute to the overall phenotype observed.  Indeed it 
would seem that for analysis of complex traits, instead of investigating singular 
candidate genes, it would be more informative to assess candidate pathways 
encompassing such genes (269).   
 
This study has investigated the effects of reduced Gstm1 expression; conversely, 
a transgenic SHRSP expressing Gstm1 may provide greater information regarding 
a direct link between Gstm1 and blood pressure.  Our group has recently 
completed the generation of a Gstm1 transgenic rat and studies are underway to 
investigate the effect of Gstm1 over-expression on blood pressure.  If Gstm1 
does indeed have a significant contribution to blood pressure regulation then it 
would be expected that over-expression in the SHRSP would cause a reduction in 
blood pressure. 
 
RNA interference is now a commonly used method for knock-down of gene 
expression allowing for subsequent functional analysis and, as described in 
section 1.5.5, is a potential therapeutic for various human disorders.  Various 
routes of administration have been evaluated for in vivo delivery of siRNA 
(270;271).  Delivery vectors have also been used to drive expression of shRNA in 
vivo, such as adenoviral vectors (272), lentiviral vectors (273) and adeno-
associated viral vectors (AAV) (162;274).  However, in vivo expression of siRNA 
or shRNA can be problematic due to immune system activation (275;276).  Not 
only can immune system activation be detrimental but a study that used AAV 
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mediated shRNA expression in mice found that shRNA expression caused liver 
damage and in some cases was fatal.  They then discovered that this was due to 
saturation of the endogenous miRNA pathway machinery.  However, after 
careful optimisation of AAV vector dose and selection of shRNA with lower 
expression, the study was able to demonstrate efficient and persistent silencing 
of hepatitis B virus in mice (277;278).  Due to technical difficulties encountered 
by colleagues working on virus development it was not possible to generate the 
Gstm1 shRNA expressing targeted adenoviral vectors.  Given more time and 
optimisation, the completion of these vectors would provide an excellent tool 
for thorough in vivo investigation of Gstm1 function.  This system could also be 
applied to evaluate future renal expressed candidate genes in hypertension and 
oxidative stress.   
 
MicroRNAs are an endogenous class of short RNA that regulate gene expression 
by binding the 3’ UTR of target genes resulting in mRNA degradation (like siRNA) 
or translational repression.  MicroRNAs represent another level of complexity in 
the control of gene expression, as one miRNA can target many genes and one 
gene can be targeted by many miRNAs (279).  Genome wide profiling of miRNA 
expression in human heart disease found that in specific types of heart disease 
there was a distinct miRNA expression profile (280).  This also supports the idea 
that a single miRNA is not responsible for gene expression changes contributing 
to phenotype, instead many miRNAs together regulate gene expression.  This 
may account for the lack of significant change in predicted target gene 
expression following over-expression of miR-9-1 and also why targets for miR-137 
were not identified in this study.  As hypertension is a complex trait, it may be 
that many miRNAs regulate the expression of many genes, with each gene 
imparting a small effect and contributing to overall phenotype.  Our group is 
currently analysing data generated from miRNA microarrays performed on kidney 
from SHRSP, WKY and congenic strains at the various time-points described in 
chapter 5.  It is hoped that this in combination with IPA and molecular 
techniques to assess predicted targets will further elucidate the potential role of 
miRNAs in hypertension in the rat.  In chapter 5, IPA was employed to 
interrogate microarray data and combined with miRNA target prediction.  
Although the targets identified were not validated in this study, the combination 
of miRNA and microarray analysis of congenic and parental strains may further 
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contribute to identification of candidate genes and also provide important 
information on how such genes are regulated.  Ingenuity pathway analysis has 
been used to probe miRNA target lists and compare to genes known to have a 
role in cancer.  This allowed a large list of targets to be stratified according to a 
reported role in a specific type of cancer (281).  More recently, IPA has been 
used to build signalling networks using the predicted targets of 8 miRNAs found 
to be differentially expressed in heart failure (282). 
 
It is hoped that by combining strategies to identify candidate genes with in vitro 
and in vivo functional analysis using techniques such as RNAi will lead to a better 
understanding of genes involved in oxidative stress and hypertension.  Although 
the experiments performed here have not identified a specific role for Gstm1, 
the same approach could be used to evaluate future candidates.  MicroRNA 
expression profiling adds another level of complexity and may provide important 
information regarding the differential expression of genes.  The utilisation of 
microarray analysis of mRNA and miRNA expression may lead to identification of 
candidate miRNA that contribute to regulation of functionally important genes.  
The integration of such data using Ingenuity Pathway Analysis would allow for 
specific targets to be identified depending on whether they are part of a 
pathway of interest.  Using such technologies may lead to the identification of 
pathways that directly contribute to oxidative stress or blood pressure regulation 
in the rat.  It may then be possible to find similar regulatory mechanisms in 
human that could be translated to generate therapeutic measures for the 
treatment of essential hypertension.  
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RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID 
NM_001001508 Prg1 NM_001017376 Phyhip NM_017162 Gif NM_053584 Gosr1 
NM_001002016 Lmna NM_001017377 Paqr4 NM_017164 Capza3 NM_053598 Nudt4 
NM_001003401 Enc1 NM_001017382 Frs3 NM_017214 Rgs4 NM_053603 Clic5 
NM_001003404 Il22ra2 NM_001017386 Tmem10 NM_017224 Slc22a6 NM_053605 Smpd3 
NM_001003957 Dnmt3a NM_001017445 Ubxd8 NM_017226 Padi2 NM_053610 Prdx5 
NM_001004084 RT1-Bb NM_001017446 RGD1310199 NM_017230 Padi3 NM_053621 Magi2 
NM_001004090 Tspan5 NM_001017451 RGD1309228 NM_017238 Vipr2 NM_053622 Pom121 
NM_001004107 Tacc1 NM_001017453 RGD1311203 NM_017244 Crabp2 NM_053623 Acsl4 
NM_001004210 Xbp1 NM_001017454 RGD1307799 NM_017249 Mbc2 NM_053624 Pitx1 
NM_001004222 Arfip2 NM_001017482 LOC498033 NM_017255 P2ry2 NM_053635 St14 
NM_001004266 RGD1303144 NM_001017499 LOC498353 NM_017259 Btg2 NM_053638 Idh3a 
NM_001004269 Jam3 NM_001017504 LOC498425 NM_017261 Gria2 NM_053667 Lepre1 
NM_001004271 Ugt2b4 NM_001017508 LOC498664 NM_017265 Hsd3b6 NM_053670 Crcp 
NM_001004274 Igfbp4 NM_001017988 LOC303566 NM_017289 Gabrd NM_053679 Dffa 
NM_001004444 Zbtb1 NM_001024262 RGD1305424 NM_017291 Gabrr1 NM_053690 Dnajc14 
NM_001004445 Znf183 NM_001024275 Rassf4 NM_017302 Slc16a7 NM_053693 Dmtf1 
NM_001005547 Tspan3 NM_001024292 LOC499330 NM_017303 Kcnab1 NM_053700 Ccl28 
NM_001005560 Pla2g6 NM_001024298 LOC499516 NM_017309 Ppp3r1 NM_053714 Ank 
NM_001005872 Htatip NM_001024303 LOC499677 NM_017313 Rab3ip NM_053733 Bcl2l10 
NM_001005886 Nsddr NM_001024305 LOC499691 NM_017317 Rab27a NM_053734 Ncf1 
NM_001005889 Rdx NM_001024307 LOC499732 NM_017321 Aco1 NM_053742 Pitpnb 
NM_001006963 Itm2b NM_001024313 LOC499900 NM_017325 Runx1 NM_053743 Cdc37 
NM_001006973 mrpl11 NM_001024327 LOC500110 NM_017355 Rab4b NM_053754 Abcg5 
NM_001006981 Dlst NM_001024338 LOC500348 NM_017356 Hpcal1 NM_053756 Atp5g3 
NM_001006990 LOC304000 NM_001024343 LOC500445 NM_017361 Nup54 NM_053756 Atp5g3 
NM_001006993 Sgcg NM_001024344 LOC500449 NM_019123 St6galnac3 NM_053758 Plce1 
Table A1 continued overleaf 
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RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID 
NM_001007005 Arhgdia NM_001024349 LOC500598 NM_019124 Rabep1 NM_053765 Gne 
NM_001007009 MGC94915 NM_001024741 Chaf1b NM_019126 Cgm3 NM_053778 Ipo13 
NM_001007607 Pigq NM_001024763 Nif3l1 NM_019135 Tnfrsf8 NM_053779 Serpini1 
NM_001007609 Mfap3 NM_001024779 Cyp2u1 NM_019146 Bsn NM_053788 Stx1a 
NM_001007611 F101B_RAT NM_001024780 Prkra NM_019152 Capn1 NM_053798 Sacm1l 
NM_001007626 Ggps1 NM_001024795 Rnf44 NM_019158 Aqp8 NM_053801 Sec14l2 
NM_001007628 Cxxc5 NM_001024799 RGD1306302 NM_019172 Galr2 NM_053810 Snap29 
NM_001007629 NTF2 NM_001024865 LOC684557 NM_019187 Coq3 NM_053812 Bak1 
NM_001007636 S100a1 NM_001024991 Fahd1 NM_019191 Smad2 NM_053818 Slc6a9 
NM_001007637 mrpl24 NM_001024992 LOC303332 NM_019202 Pla2g2c NM_053837 Ap2m1 
NM_001007641 Rnd3 NM_001025008 LOC314996 NM_019214 Slc26a4 NM_053843 FCGR3_RAT 
NM_001007645 MGC95152 NM_001025009 Josd1 NM_019219 Rbbp9 NM_053847 Map3k8 
NM_001007653 Mrps15 NM_001025014 Tmem50b NM_019225 Slc1a3 NM_053848 Opcml 
NM_001007662 Arcn1 NM_001025016 RGD1309120 NM_019230 Slc22a3 NM_053851 Cacnb2 
NM_001007667 Sat NM_001025019 RGD1306582 NM_019232 Sgk NM_053878 Cplx2 
NM_001007669 Zfp672 NM_001025020 RGD1310753 NM_019238 Fdft1 NM_053879 Cntn4 
NM_001007679 RGD1359339 NM_001025022 RGD1308059 NM_019243 Ptgfrn NM_053883 Dusp6 
NM_001007682 Thtpa NM_001025025 LOC363267 NM_019250 Ralgds NM_053893 Sdc3 
NM_001007688 RGD1359600 NM_001025027 Fundc1 NM_019256 P2rx7 NM_053912 Pscd3 
NM_001007689 Ciapin1 NM_001025033 LOC498154 NM_019261 Klrc2 NM_053921 Pex12 
NM_001007701 Tram1 NM_001025034 LOC498796 NM_019262 C1qb NM_053923 Pik3c2g 
NM_001007705 RGD1359144 NM_001025051 LOC500638 NM_019272 Sema4f NM_053929 Slc7a9 
NM_001007706 RGD1359191 NM_001025142 Trim35 NM_019280 Gja5 NM_053931 Gp1bb 
NM_001007713 Tmbim1 NM_001025143 LOC498606 NM_019289 Arpc1b NM_053936 Edg2 
NM_001007714 Morf4l2 NM_001025151 LOC500625 NM_019304 Dgkb NM_053945 Rims2 
NM_001007727 Lypd1 NM_001025271 Sfpq NM_019306 Flt1 NM_053959 Bin1 
Table A1 continued overleaf 
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RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID 
NM_001007730 Cabp7 NM_001025402 Umps NM_019326 Neurod2 NM_053965 Slc25a20 
NM_001007732 MGC94010 NM_001025412 RGD1305651 NM_019329 Cntn3 NM_053967 Spam 
NM_001007737 RGD1359158 NM_001025418 Ppp2r1b NM_019331 Pcsk3 NM_053972 RragB 
NM_001007738 RGD1359349 NM_001025419 Tax1bp3 NM_019344 Rgs8 NM_053974 Eif4e 
NM_001007742 Ubadc1 NM_001025635 Nars NM_019345 Slc12a3 NM_053988 Calb2 
NM_001007747 Pomgnt1 NM_001025648 Snapap NM_019347 Slc14a2_v1 NM_053997 Kcnc3 
NM_001007751 MGC94207 NM_001025684 Pex11b NM_019351 Timm17a NM_053998 Rab8a 
NM_001007754 Rassf1 NM_001025688 Palmd NM_019358 Pdpn NM_057097 Vamp3 
NM_001007755 Scly NM_001025693 Cdca7 NM_019365 Rassf5 NM_057122 Psmc4 
NM_001007759 Mar-03 NM_001025711 Atg4b NM_019371 Egln3 NM_057124 P2ry6 
NM_001008278 RGD1308696 NM_001025721 Colec12 NM_019378 Snip NM_057133 Nr0b2 
NM_001008279 Fliih NM_001025726 Srpk1 NM_019623 Cyp4f1 NM_057148 Sep-02 
NM_001008280 Lrrc59 NM_001025739 Rpl11 NM_019630 Gip NM_057155 Xpnpep2 
NM_001008287 Donson NM_001025752 Ccrk NM_019905 Anxa2 NM_057185 Folh1 
NM_001008292 Diablo NM_001025760 MGC116363 NM_020075 Eif5 NM_057192 Waspip 
NM_001008307 RGD1311257 NM_001025769 C20orf165 NM_020076 Haao NM_078620 Slc8a3 
NM_001008319 Maea NM_001029909 CPG2 NM_021266 Fzd1 NM_080477 Pfkfb2 
NM_001008320 Rhoj NM_001029920 RGD1310423 NM_021579 Nxf1 NM_080480 Pip5k2c 
NM_001008334 Tmem97 NM_001029927 LOC502774 NM_021583 Ptges NM_080576 Apoa5 
NM_001008336 LOC682784 NM_001031646 Stoml2 NM_021587 Ltbp1 NM_080580 Rab3d 
NM_001008339 Whsc2 NM_001031647 Dnali1 NM_021594 Slc9a3r1 NM_080581 Abcc3 
NM_001008353 Mkks NM_001031652 St6galnac2 NM_021653 Dio1 NM_080582 Abcb6 
NM_001008354 Mrrf NM_001031655 Manba NM_021676 Shank3 NM_080583 Ap2b1 
NM_001008356 Slc39a3 NM_001033683 Vat1 NM_021698 F13a1 NM_080585 Napa 
NM_001008363 Zfand2a NM_001033693 Slc31a2 NM_021702 Atxn3 NM_080688 Plcd4 
NM_001008370 MGC105830 NM_001033704 Xylb NM_021740 Ptma NM_080689 Dnm1 
Table A1 continued overleaf 
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RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID RefSeq Gene ID 
NM_001008376 Trappc3 NM_001033862 Ceacam1 NM_021744 Cd14 NM_080780 P2rx5 
NM_001008378 Tspan31 NM_001033864 Cflar NM_021766 Pgrmc1 NM_080782 Cdkn1a 
NM_001008384 Rac2 NM_001033866 Surf2 NM_021776 Ecel1 NM_080783 Gale 
NM_001008386 LOC493574 NM_001033870 Csnk1g2 NM_021850 Bcl2l2 NM_080786 Slco2b1 
NM_001008517 RGD1310553 NM_001033883 Cxcl12 NM_021868 Cttn NM_080906 Ddit4 
NM_001008518 MGC105649 NM_001033890 RGD1311072 NM_021997 Cyln2 NM_080907 Ppp4r1 
NM_001008521 Ptk9 NM_001033891 LOC690779 NM_022179 Hk3 NM_130403 Ppp1r14a 
NM_001008557 Mip1 NM_001033951 Npuk68 NM_022198 Clcn4-2 NM_130426 Tnfrsf1b 
NM_001008560 Prss35 NM_001033998 Itgal NM_022215 Gpd1 NM_130779 Adcy3 
NM_001008561 Rnase9 NM_001034006 Centb2 NM_022218 Cmklr1 NM_130812 Cdkn2b 
NM_001008767 Txnip NM_001034032 Dnajc12 NM_022224 Pter NM_133290 Zfp36 
NM_001008768 Prim1 NM_001034079 Thrap4 NM_022240 A4galt NM_133296 Xtrp3 
NM_001008771 Wdr77 NM_001034112 Mlx NM_022254 Gpr85 NM_133306 Oldlr1 
NM_001008861 Usp11 NM_001034149 RGD1311815 NM_022257 Masp1 NM_133310 Icmt 
NM_001008880 Scn4b NM_001034163 Blmh NM_022280 Lrat NM_133380 Il4ra 
NM_001008891 Ssr1 NM_001034835 RGD1309220 NM_022281 LOC688339 NM_133393 Lfng 
NM_001009176 Trim10 NM_001034932 C1qtnf6 NM_022289 Snx16 NM_133394 Zdhhc7 
NM_001009264 RGD1306635_predicted NM_001034934 Arid5a NM_022294 Eltd1 NM_133395 Tpo1 
NM_001009357 Rqcd1 NM_001037158 Pcdhga9 NM_022388 Fxyd4 NM_133396 Tesk2 
NM_001009424 Eps15 NM_001037187 LOC302680 NM_022392 Insig1 NM_133397 Erg 
NM_001009478 Saa4 NM_001037191 RGD1306873 NM_022396 Gng11 NM_133402 Nap1l3 
NM_001009490 Oas1f NM_001037209 Mterfd2 NM_022400 Bcat2 NM_133406 Agpat4 
NM_001009494 NP_001009494.1 NM_001037556 Nmnat1 NM_022404 Gbl NM_133542 Igsf6 
NM_001009540 Tacstd2 NM_001037649 RGD1306676 NM_022441 Acvrl1 NM_133553 B3galt4 
NM_001009599 RGD1307679 NM_001037654 Dixdc1 NM_022498 Ppp1cc NM_133560 Trak2 
NM_001009600 Arhgdib NM_001037774 Cldn8 NM_022513 Sult1b1 NM_133567 Centa1 
Table A1 continued overleaf 
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NM_001009605 Brms1 NM_001037797 LOC500354 NM_022516 Ptbp1 NM_133568 Rasd2 
NM_001009674 Itm2c NM_001039002 RGD1304790 NM_022523 Cd151 NM_133571 Cdc25a 
NM_001009675 Tceal1 NM_001039003 Mtrr NM_022525 Gpx3 NM_133580 Rab26 
NM_001009677 Plekhm1 NM_001039005 Mcoln2 NM_022534 Tcn2 NM_133583 Ndrg2 
NM_001009683 Tor3a NM_001039016 Zdhhc9 NM_022548 Wig1 NM_133593 Ap3m1 
NM_001009687 Riok2 NM_001039017 RGD1309718 NM_022589 Tspan2 NM_133597 Chrnb3 
NM_001009691 Dclk2_predicted NM_001039021 Zdhhc8 NM_022596 Golga2 NM_133601 Cblb 
NM_001009701 ITFG3_RAT NM_001039044 Cdc42se1 NM_022597 Ctsb NM_133610 Kcnh5 
NM_001009705 MGC109149 NM_001039196 Slc39a13 NM_022598 Cnbp1 NM_133620 Zhx1 
NM_001009708 Lmo4 NM_001039207 Narf NM_022599 Synj2bp NM_133651 Cav1 
NM_001009713 Slc17a5 NM_001039455 RGD1309570 NM_022600 Adcy5 NM_134327 Cd69 
NM_001009825 Ppp1r7 NM_001039505 Irx2 NM_022614 Inhbc NM_134329 Adh7 
NM_001009965 Eiih NM_001040156 Aste1 NM_022639 Chrna10 NM_134334 Ctsd 
NM_001010945 RGD1311474 NM_001042619 Hsd3b1 NM_022643 Hist1h2ba NM_134363 Slc12a5 
NM_001011557 RGD1305677 NM_001042621 Pip5k1a_predicted NM_022671 Onecut1 NM_134371 Trpm8 
NM_001011665 Trim26 NM_001044228 LOC289740 NM_022676 Ppp1r1a NM_134373 Avpi1 
NM_001011890 Rnps1 NM_001044237 LOC689500 NM_022697 Rpl28 NM_134379 UST4r 
NM_001011893 Sep-04 NM_001044246 Mageb18_predicted NM_022700 Arl3 NM_134413 Btbd14b 
NM_001011893 Sep-04 NM_001044251 MGC112790 NM_022710 Pde1b NM_134414 Exoc2 
NM_001011902 Rabl5 NM_001044255 Coq2 NM_022853 Slc30a1 NM_134459 Mic2l1 
NM_001011906 Acbd6 NM_001044267 MGC112775 NM_022860 B4galnt1 NM_138505 Adra2b 
NM_001011914 Dr1 NM_001044274 Apin NM_022864 Cplx1 NM_138530 Mawbp 
NM_001011918 Anxa11 NM_001044297 LOC689907 NM_022936 Ephx2 NM_138613 Zfp179 
NM_001011919 Gtpbp3 NM_001047110 LOC499770 NM_022944 Inppl1 NM_138833 Snrk 
NM_001011923 Prpf4b NM_001047743 MGC112883 NM_022953 Slit1 NM_138836 Prss8 
NM_001011924 Mbd1 NM_001048184 Rragc_predicted NM_022962 Lphn1 NM_138840 Tgoln2 
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NM_001011942 Cnnm2 NM_001048215 Kirrel3_predicted NM_023023 Dpysl5 NM_138842 Sftpb 
NM_001011947 Rai14 NM_001077641 Plcb1 NM_023092 Myo1c NM_138848 Podxl 
NM_001011952 Slc39a8 NM_001077648 Prdm2 NM_023969 Edg7 NM_138849 Bk 
NM_001011954 Cybrd1 NM_001079700 Cdc42ep1_predicted NM_023977 Golph3 NM_138858 Slc9a5 
NM_001011961 Srms NM_001080783 RGD1311552_predicted NM_024000 Camkv NM_138864 Ccdc5 
NM_001011962 Ceecam1 NM_001080789 Arhgap9 NM_024002 Secisbp2 NM_138866 Eif2b5 
NM_001011963 Asb6 NM_012498 Akr1b4 NM_024132 Faah NM_138873 Nbn 
NM_001011965 LOC652927 NM_012505 Atp1a2 NM_024133 Hap1 NM_138879 Sele 
NM_001011969 Strap NM_012517 Cacna1c NM_024134 Ddit3 NM_138884 Akr1d1 
NM_001011974 Akap2 NM_012521 S100g NM_024135 Limk2 NM_138889 Cdh13 
NM_001011983 Coq6 NM_012523 Cd53 NM_024138 Gng7 NM_138891 Gpr149 
NM_001011985 Mknk2 NM_012526 Chgb NM_024144 Pigm NM_138893 Myo16 
NM_001011999 LOC366923 NM_012527 Chrm3 NM_024155 Anxa4 NM_138894 Grasp 
NM_001012012 Snx11 NM_012531 Comt NM_024162 Fabp3 NM_138896 Pja2 
NM_001012013 Acbd4 NM_012538 Cyp11b2 NM_024163 Begain NM_138908 Slc22a9 
NM_001012015 Lamp3 NM_012545 Ddc NM_024379 Grid2 NM_138909 Foxe1 
NM_001012032 Arhgap24 NM_012547 Drd2 NM_024385 Hhex NM_138915 Drd1ip 
NM_001012038 Mtmr3 NM_012548 Edn1 NM_024396 Abca2 NM_139036 Lhx5 
NM_001012039 Efemp1 NM_012550 Ednra NM_024400 Adamts1 NM_139040 RGD621098 
NM_001012041 Isgf3g NM_012555 Ets1 NM_024483 Adra1d NM_139060 Csnk1d 
NM_001012044 Lcp1 NM_012557 Fancc NM_030586 Cyb5b NM_139084 Magi3 
NM_001012051 Zfp367 NM_012571 Got1 NM_030830 Luzp1 NM_139090 Acvr1c 
NM_001012055 Cdh16 NM_012574 Grin2b NM_030834 Slc16a3 NM_139094 Rbm16 
NM_001012061 Cnksr3 NM_012576 Nr3c1 NM_030836 Arts1 NM_139097 Scn3b 
NM_001012062 Map3k7ip2 NM_012579 Hist1h1t NM_030838 Slco1a5 NM_139183 Crhbp 
NM_001012064 Pvrl2 NM_012588 Igfbp3 NM_030841 Nptxr NM_139188 Otos 
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NM_001012065 ADCK4_RAT NM_012591 Irf1 NM_030842 Itga7 NM_139190 Calcoco1 
NM_001012066 Sphk2 NM_012599 Mbl1 NM_030854 Lect1 NM_139192 Scd1 
NM_001012067 Grwd1 NM_012607 Nefh NM_030861 Mgat1 NM_139194 Fas 
NM_001012079 Arhgef2 NM_012608 Mme NM_030864 Mtr NM_139252 Ppap2c 
NM_001012080 Hfe2 NM_012610 Ngfr NM_030990 Plp NM_139255 LOC246120 
NM_001012083 Snx7 NM_012615 Odc1 NM_030991 Snap25 NM_139324 Ehd4 
NM_001012092 Xkr7 NM_012620 Serpine1 NM_030992 Pld1 NM_139331 Lrrc21 
NM_001012119 Nptxr NM_012631 Prnp NM_030993 Ddn NM_144730 Gata4 
NM_001012120 Naga NM_012634 Prps2 NM_030995 Mtap1a NM_144747 Slc45a1 
NM_001012122 Ecgf1 NM_012642 Ren1 NM_030996 Oprs1 NM_144748 LOC246263 
NM_001012139 Plscr3 NM_012643 Ret NM_031012 Anpep NM_144752 Oas1b 
NM_001012140 Rab34 NM_012648 Scnn1b NM_031022 Cspg4 NM_144757 Zfp180 
NM_001012147 Pxn NM_012651 Slc4a1 NM_031026 Dncli2 NM_145081 Optn 
NM_001012148 Ankrd13 NM_012652 Slc9a1 NM_031035 Gnai2 NM_145085 Pcyox1 
NM_001012166 Abcb10 NM_012653 Slc9a2 NM_031047 Jup NM_145088 Rmt1 
NM_001012167 Pld3 NM_012654 Slc9a3 NM_031050 Lum NM_145093 Aard 
NM_001012169 Zfp143 NM_012655 Sp1 NM_031062 Mvd NM_145677 Slc25a25 
NM_001012170 Nap1l4 NM_012663 Vamp2 NM_031069 Nell1 NM_145682 Filip1 
NM_001012174 Fkbp5 NM_012664 Syp NM_031083 Pik4cb NM_145723 Stx17 
NM_001012188 Creb3l2 NM_012665 Syt2 NM_031094 Rbl2 NM_145724 ZN394_RAT 
NM_001012189 Mboat5 NM_012666 Tac1 NM_031123 Stc1 NM_145767 Prrxl1 
NM_001012195 Rnf41 NM_012681 Ttr NM_031127 Suox NM_145774 Rab38 
NM_001012195 Rnf41 NM_012682 Ucp1 NM_031132 Tgfbr2 NM_145785 Hdgfrp3 
NM_001012206 Phlda3 NM_012693 Cyp2a2 NM_031153 Sharpin NM_145877 Kif1c 
NM_001012213 Sfxn1 NM_012700 Stx1b2 NM_031241 Cyp8b1 NM_147205 St6gal1 
NM_001012218 Rnf29 NM_012706 Grpr NM_031320 Celsr3 NM_147211 Cr16 
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NM_001012469 Il21r NM_012715 Adm NM_031322 Lrp4 NM_152242 Gpr56 
NM_001012476 Rnase11 NM_012719 Sstr1 NM_031332 Slc22a8 NM_152847 Snx27 
NM_001012740 Cbln2 NM_012721 P2rxl1 NM_031334 Cdh1 NM_152935 Tomm20 
NM_001013043 Sectm1a NM_012725 Klkb1 NM_031337 St3gal5 NM_152938 Slc4a9 
NM_001013066 Sipa1l3 NM_012728 Glp1r NM_031339 Parg NM_153311 Tmprss5 
NM_001013070 Tspan4 NM_012732 Lip1 NM_031351 Atrn NM_153467 Gsbs 
NM_001013072 Sfxn2 NM_012735 Hk2 NM_031355 Vdac3 NM_153470 Lzts1 
NM_001013077 Plekha3 NM_012740 Th NM_001034942 Btbd15 NM_153722 Mrgprf 
NM_001013079 Osbpl2 NM_012743 Foxa2 NM_001034998 Ctps2 NM_153724 Dscr1 
NM_001013099 Slc38a6 NM_012747 Stat3 NM_031503 Ascl2 NM_153725 Slc17a8 
NM_001013101 Moap1 NM_012756 Igf2r NM_031511 Igf2 NM_153735 Nptx1 
NM_001013103 Cdc34_predicted NM_012758 Syk NM_031525 Pdgfrb NM_153740 Sap1 
NM_001013120 Igsf11 NM_012761 Sp4 NM_031544 Ampd3 NM_170789 Cd3z 
NM_001013124 Ung NM_012764 Gata1 NM_031548 Scnn1a NM_171992 Ccnd1 
NM_001013135 Sdccag3 NM_012775 Tgfbr1 NM_031559 Cpt1a NM_172008 Canx 
NM_001013149 Mesdc1 NM_012778 Aqp1 NM_031568 Clcn7 NM_172021 Tbkbp1 
NM_001013154 Pcgf6 NM_012779 Aqp5 NM_031588 Nrg1 NM_172066 Slc30a4 
NM_001013156 Zcchc9 NM_012781 Arnt2 NM_031590 Wisp2 NM_172067 Spon1 
NM_001013165 Lrrc23 NM_012789 Dpp4 NM_031597 Kcnq3 NM_172157 Arid1b 
NM_001013171 Gulp1 NM_012798 Mal NM_031600 Ptprn2 NM_172243 Ppif 
NM_001013174 Laptm4b NM_012800 P2ry1 NM_031612 Apln NM_172327 Aip 
NM_001013182 RGD1305117 NM_012813 St8sia1 NM_031614 Txnrd1 NM_172333 Cthrc1 
NM_001013191 Cbfb NM_012818 Aanat NM_031639 Dlgh3 NM_172335 Gm2a 
NM_001013211 Prp2_predicted NM_012820 Acsl1 NM_031642 Klf6 NM_173105 Aqp11 
NM_001013231 Pea15 NM_012821 Adcy6 NM_031658 Msln NM_173126 Nid67 
NM_001013238 Pttg1ip NM_012828 Cacnb3 NM_031662 Camkk1 NM_173147 Vps54 
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NM_001013241 Lzic NM_012843 Emp1 NM_031664 LOC691960 NM_173309 Elavl2 
NM_001013243 Slc30a3 NM_012845 Ms4a2 NM_031675 Actn4 NM_173324 RGD708449 
NM_001013250 Mageh1 NM_012863 Bhlhb8 NM_031678 Per2 NM_173337 Camk2n1 
NM_001013429 Cldn14 NM_012869 Npy5r NM_031693 Syt4 NM_175578 Dscr1l1 
NM_001013434 Rras2 NM_012874 Ros1 NM_031696 Gpr88 NM_175579 Wnk4 
NM_001013860 RGD1306819 NM_012879 Slc2a2 NM_031699 Cldn1 NM_175597 Ssx2ip 
NM_001013869 RGD1306108 NM_012884 Cntn2 NM_031711 Arl2 NM_175755 Ppm1f 
NM_001013878 RGD1359592 NM_012888 Tshr NM_031713 Pirb NM_175869 Plod2 
NM_001013880 LOC290651 NM_012894 Adarb1 NM_031716 Wisp1 NM_176076 S100vp 
NM_001013894 Gp49b NM_012896 Adora3 NM_031727 Limk1 NM_176077 G6pc3 
NM_001013898 RGD1311703 NM_012900 Ambn NM_031735 Stk3 NM_176080 Naglt1 
NM_001013905 RGD1307648 NM_012916 Bcan NM_031740 B4galt6 NM_176856 Sep-09 
NM_001013906 Lhfpl5 NM_012923 Ccng1 NM_031743 Slc24a2 NM_177421 Slc22a17 
NM_001013907 LOC294513 NM_012924 Cd44 NM_031753 Alcam NM_178092 Slc4a10 
NM_001013911 Ift80 NM_012928 Cnga2 NM_031781 Apba3 NM_178093 Mtus1 
NM_001013914 RGD1305808 NM_012929 Col2a1 NM_031784 Pias3 NM_178094 Itpkc 
NM_001013919 Galk2 NM_012953 Fosl1 NM_031789 Nfe2l2 NM_178097 Sla 
NM_001013922 RGD1307752 NM_012971 Kcna4 NM_031793 Ppig NM_178102 Mapkapk2 
NM_001013927 RGD1308734 NM_012980 Mmp11 NM_031802 Gabbr2 NM_178106 Entpd3 
NM_001013930 LOC298139 NM_012981 Mras NM_031803 Gmeb2 NM_181081 Myst2 
NM_001013931 RGD1311249 NM_012983 Myo1d NM_031816 Rbbp7 NM_181090 Slc38a2 
NM_001013938 Vwa1 NM_012991 Npap60 NM_031819 Fath NM_181377 Rtn4rl1 
NM_001013939 Raver1h NM_012999 Pcsk6 NM_031820 Dvl1 NM_181386 Tmem23 
NM_001013954 RGD1308555 NM_013001 Pax6 NM_031976 Prkab1 NM_181474 Tfb1m 
NM_001013976 RGD1305007 NM_013015 Ptgds NM_031977 Src NM_181637 Cdc91l1 
NM_001013979 LOC304131 NM_013016 Ptpns1 NM_031979 Csda NM_181687 Nnat 
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NM_001013980 LOC304138 NM_013026 Sdc1 NM_031983 Smarcd2 NM_182667 Myocd 
NM_001013981 LOC304396 NM_013031 Slc18a2 NM_032061 Cntnap1 NM_182814 Cct4 
NM_001013984 LOC304860 NM_013045 Tnr NM_032066 Hsd17b12 NM_182816 Amigo2 
NM_001013986 LOC305076 NM_013055 Map3k12 NM_032073 Kcnq1 NM_182824 Cd276 
NM_001013997 RGD1309522 NM_013059 Alpl NM_032074 Irs3 NM_182950 Tnfaip1 
NM_001013999 RGD1311738 NM_013064 Hcrtr1 NM_032416 Aldh2 NM_182952 Cxcl11 
NM_001014010 RGD1308147 NM_013068 Fabp2 NM_032613 Lasp1 NM_183052 Ube2v2 
NM_001014011 Gramd3 NM_013070 Utrn NM_033021 Sec31l1 NM_183054 Rhbg 
NM_001014012 Zmat2 NM_013075 Hoxa1 NM_033352 Abcd2 NM_183326 Gabra1 
NM_001014015 Rbm34 NM_013082 Sdc2 NM_033376 Kcnk3 NM_183329 Sra1 
NM_001014018 RGD1309326 NM_013090 Vamp1 NM_052798 Zfp354a NM_183332 Myadm 
NM_001014022 Btbd10 NM_013095 Smad3 NM_052804 Fmr1 NM_198731 Chdh 
NM_001014023 RGD1304579 NM_013100 Ptger1 NM_052983 Slc5a5 NM_198739 Ly6g5c 
NM_001014030 RGD1309313 NM_013111 Slc7a1 NM_053301 Hfe NM_198744 Tpd52l2 
NM_001014041 LOC310721 NM_013113 Atp1b1 NM_053302 Admr NM_198746 Klra5 
NM_001014043 RGD1305778 NM_013114 Selp NM_053323 Degs1 NM_198749 Rab15 
NM_001014047 NP_001014069.1 NM_013121 Cd28 NM_053328 Bhlhb2 NM_198755 LHR2A_RAT 
NM_001014051 LOC311548 NM_013125 Scn5a NM_053329 Igfals NM_198757 Srr 
NM_001014064 Pars2 NM_013132 Anxa5 NM_053343 Dclk1 NM_198758 Rap2ip 
NM_001014069 Snip1 NM_013136 Mak NM_053355 Ikbkb NM_198770 Zmynd19 
NM_001014070 LOC313672 NM_013141 Ppard NM_053360 Sh3kbp1 NM_198771 Fam3c 
NM_001014072 RGD1311517 NM_013143 Mep1a NM_053362 Dffb NM_198777 MGC73003 
NM_001014076 Nol10 NM_013151 Plat NM_053380 Slc34a2 NM_198778 C11orf8h 
NM_001014077 Clec14a NM_013152 Slc18a1 NM_053381 Atp1b4 NM_198790 Rgsl2h 
NM_001014087 Ccdc67 NM_013153 Has2 NM_053385 Prelp NM_198791 NP_942086.1 
NM_001014091 LOC315712 NM_013159 Ide NM_053390 Il12a NM_199096 Necap2 
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NM_001014093 Parp16 NM_013168 Hmbs NM_053394 Klf5 NM_199110 Mfng 
NM_001014095 Dzip1l NM_013174 Tgfb3 NM_053403 Grb7 NM_199113 Popdc2 
NM_001014100 LOC316326 NM_013187 Plcg1 NM_053427 Slc17a6 NM_199208 Rdh2 
NM_001014130 RGD1309106 NM_013192 Kcnj6 NM_053429 Fgfr3 NM_199253 Pcsk9 
NM_001014133 LOC360910 NM_013214 Acot7 NM_053437 Dgat1 NM_199267 Rela 
NM_001014147 RGD1310571 NM_013222 Gfer NM_053442 Slc7a8 NM_199269 Mamdc1 
NM_001014162 RGD1309578 NM_016987 Acly NM_053445 Fads1 NM_199391 RGD735112 
NM_001014164 Cybasc3 NM_016993 Bcl2 NM_053455 Fgl2 NM_199407 Unc5c 
NM_001014166 RGD1311155 NM_017006 G6pdx NM_053457 Cldn11 NM_199463 Ripk5 
NM_001014176 RGD1312003 NM_017007 Gad1 NM_053463 Nucb1 NM_199491 Fut7 
NM_001014182 Mall NM_017009 Gfap NM_053484 Gas7 NM_199493 RGD735029 
NM_001014202 RGD1311835 NM_017011 Grm1 NM_053491 Plg NM_199495 Ndufa10 
NM_001014209 LOC363060 NM_017020 Il6ra NM_053502 Abcg1 NM_199501 Cdk2 
NM_001014211 LOC363091 NM_017023 Kcnj1 NM_053503 Jub NM_199502 Chrdl1 
NM_001014216 RGD1306658 NM_017027 Mpz NM_053511 Fbxo2 NM_201988 Pgpep1 
NM_001014219 RGD1359242 NM_017037 Pmp22 NM_053516 Nol3 NM_203336 Esrrg 
NM_001014232 RGD1308373 NM_017052 Sord NM_053517 Shc1 NM_207610 Ube4a 
NM_001014247 Lzts2 NM_017058 Vdr NM_053520 Elf1 NM_207617 Iqsec3 
NM_001014248 RGD1308127 NM_017061 Lox NM_053521 Slc5a7 NM_212490 Atp6v1g2 
NM_001014256 LOC365972 NM_017064 Stat5a NM_053522 Rhoq NM_212498 RGD1303066 
NM_001014269 Lrrfip1 NM_017065 Gabrb3 NM_053524 Nox4 NM_212499 G7c 
NM_001015009 Zadh1 NM_017070 Srd5a1 NM_053536 Klf15 NM_212505 Ier3 
NM_001015010 Cib2 NM_017076 PVR NM_053550 Pip5k2b NM_212508 Nrm 
NM_001015013 Mtvr2 NM_017079 Cd1d1 NM_053558 Trpc1 NM_212549 Ring1 
NM_001015014 Surf6_predicted NM_017107 Ogt NM_053560 Chi3l1 NM_213562 Trim39 
NM_001015026 Tm4sf12 NM_017110 Cart NM_053561 Nap1l1 NM_213629 Arhgap20 
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NM_001015027 Crebl2 NM_017115 Myog NM_053563 Ddx39 NM_001015034 Tnfrsf14 
NM_001015028 Anks6 NM_017130 Neu2 NM_053568 Pcyt2 NM_017161 Adora2b 
NM_001015032 Galnt3 NM_017156 CP2BC_RAT NM_053569 Mbtps1 NM_053582 Lcn7 
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NM_001001508 Prg1 NM_001024795 Rnf44 NM_019232 Sgk NM_053811 Slc9a3r2 
NM_001001510 Klhl10 NM_001024865 LOC684557 NM_019243 Ptgfrn NM_053818 Slc6a9 
NM_001002279 Rnf166 NM_001024874 Rhox9 NM_019250 Ralgds NM_053851 Cacnb2 
NM_001002798 Top1mt NM_001024876 RGD1305156 NM_019253 Ptpn5 NM_053880 Dncic2 
NM_001002819 Gfpt2 NM_001024885 RGD1308637 NM_019261 Klrc2 NM_053883 Dusp6 
NM_001003957 Dnmt3a NM_001024890 MGC114520 NM_019282 Grem1 NM_053896 Aldh1a2 
NM_001003975 G4 NM_001024965 RGD1306925 NM_019331 Pcsk3 NM_053917 Inpp4b 
NM_001003978 Gspt1 NM_001024968 RGD1307594 NM_019336 Rgs1 NM_053923 Pik3c2g 
NM_001004228 Emcn NM_001025000 RGD1309288 NM_019344 Rgs8 NM_053947 Mark1 
NM_001004244 RGD1303127 NM_001025009 Josd1 NM_019362 Stk39 NM_053949 Kcnh2 
NM_001004253 Syap1 NM_001025020 RGD1310753 NM_020089 LOC56764 NM_053978 Rab28 
NM_001004255 Dek NM_001025022 RGD1308059 NM_021653 Dio1 NM_053981 Kcnj12 
NM_001004260 Slc22a18 NM_001025027 Fundc1 NM_021671 Tmem33 NM_053985 H3f3b 
NM_001004277 Lypla3 NM_001025035 Thnsl1 NM_021682 Negr1 NM_053997 Kcnc3 
NM_001004418 Tacc2 NM_001025685 Cd5l NM_021693 Snf1lk NM_053998 Rab8a 
NM_001005538 MGC94288 NM_001025701 MGC116373 NM_021702 Atxn3 NM_054000 Kcnb2 
NM_001005539 Smpdl3a NM_001025756 MGC114379 NM_021766 Pgrmc1 NM_054002 Zbtb7a 
NM_001005544 Morn1 NM_001029909 CPG2 NM_021776 Ecel1 NM_054011 Sh3bp5 
NM_001005902 Abtb1 NM_001029914 LOC291823 NM_021835 Jun NM_057139 Hnrpu 
NM_001006991 Nudt9 NM_001029919 RGD1306053 NM_022198 Clcn4-2 NM_057141 Hnrpk 
NM_001006993 Sgcg NM_001030025 Upp1 NM_022224 Pter NM_057148 Sep-02 
NM_001006994 MGC94555 NM_001031663 LOC500419 NM_022254 Gpr85 NM_057210 Sv2a 
NM_001007020 Hmgn3 NM_001033653 Akap12 NM_022257 Masp1 NM_080394 Reln 
NM_001007145 Catna1 NM_001033680 Syt1 NM_022280 Lrat NM_080397 Chst10 
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NM_001007235 Itpr1 NM_001033693 Slc31a2 NM_022296 Xylt2 NM_080411 Gpr83 
NM_001007606 Sars1 NM_001033715 Cast NM_022392 Insig1 NM_080480 Pip5k2c 
NM_001007629 NTF2 NM_001033867 Crkrs NM_022400 Bcat2 NM_080775 Smgb 
NM_001007646 Fkbp9 NM_001033896 RGD1309886 NM_022403 Tdo2 NM_080888 Bnip3l 
NM_001007660 MGC94183 NM_001033958 Obp3 NM_022407 Aldh1a1 NM_080902 Higd1a 
NM_001007669 Zfp672 NM_001034006 Centb2 NM_022498 Ppp1cc NM_080906 Ddit4 
NM_001007681 Zfp219 NM_001034010 RGD1310827 NM_022585 Azin1 NM_130739 Acsl6 
NM_001007688 RGD1359600 NM_001034110 Ctsf NM_022589 Tspan2 NM_130749 Mark3 
NM_001007694 Ifit3 NM_001034830 Zfp384 NM_022631 Wnt5a NM_130779 Adcy3 
NM_001007698 RGD1560806_predicted NM_001034918 Iws1 NM_022690 Ube2g1 NM_130813 Kcnk15 
NM_001007706 RGD1359191 NM_001034950 Rup2 NM_022697 Rpl28 NM_133306 Oldlr1 
NM_001007720 Gorasp2 NM_001034994 Rwdd4a NM_022698 Bad_v2 NM_133317 Tob1 
NM_001007721 Emp2 NM_001035007 Mbtps2 NM_022853 Slc30a1 NM_133396 Tesk2 
NM_001007730 Cabp7 NM_001037184 RGD1307100 NM_022864 Cplx1 NM_133397 Erg 
NM_001007731 Golga7 NM_001037191 RGD1306873 NM_022939 Stx12 NM_133398 Mtdh 
NM_001007737 RGD1359158 NM_001037214 Cdca4 NM_022946 Dlgap1 NM_133423 Yt521 
NM_001007746 MGC94199 NM_001037336 Lrrc4 NM_022957 Serpina5 NM_133425 Ppp1r14c 
NM_001008287 Donson NM_001037772 LOC300963 NM_023025 Cyp2j3 NM_133427 Cyb5r4 
NM_001008305 RGD1304686 NM_001037774 Cldn8 NM_023092 Myo1c NM_133551 Pla2g4a 
NM_001008325 RGD1311364 NM_001039005 Mcoln2 NM_023955 Scamp2 NM_133560 Trak2 
NM_001008373 RGD1305356 NM_001039009 Zdhhc21 NM_023979 Apaf1 NM_133561 Brp44l 
NM_001008511 Esrra NM_001039010 Ppcs NM_023991 Prkaa2 NM_133578 Dusp5 
NM_001008521 Ptk9 NM_001039099 LOC291967 NM_024001 Mrs2l NM_133611 Slc2a13 
NM_001008557 Mip1 NM_001039196 Slc39a13 NM_024127 Gadd45a NM_134327 Cd69 
NM_001008694 LOC361571 NM_001039455 RGD1309570 NM_024151 Arf4 NM_134363 Slc12a5 
NM_001008802 Kb1 NM_001039686 RGD1311934_predicted NM_024361 Ndst1 NM_134371 Trpm8 
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NM_001008891 Ssr1 NM_001042619 Hsd3b1 NM_024371 Slc6a1 NM_134373 Avpi1 
NM_001009264 RGD1306635_predicted NM_001047110 LOC499770 NM_024379 Grid2 NM_134392 Spata6 
NM_001009413 RGD1306495 NM_001077641 Plcb1 NM_024398 Aco2 NM_138504 Okl38 
NM_001009622 Sar1b NM_001079884 Galntl4_predicted NM_024405 Axin1 NM_138515 Cyp2d4v1 
NM_001009636 RGD1308082 NM_001080149 Ptpn20_predicted NM_030829 Gprk5 NM_138519 Dkk3 
NM_001009665 Ebag9 NM_001080150 RGD1309969 NM_030830 Luzp1 NM_138535 Grip2_v3 
NM_001009677 Plekhm1 NM_012491 Add2 NM_030835 RAMP4 NM_138710 Dab2ip 
NM_001009691 Dclk2_predicted NM_012517 Cacna1c NM_030849 Bmpr1a NM_138710 Dab2ip 
NM_001009704 Sipa1l2 NM_012527 Chrm3 NM_030990 Plp NM_138833 Snrk 
NM_001009825 Ppp1r7 NM_012537 C11B1_RAT NM_031007 Adcy2 NM_138855 Spdy1 
NM_001009967 Pip5k1c NM_012538 Cyp11b2 NM_031011 Amd1 NM_138861 Prl2b1 
NM_001011557 RGD1305677 NM_012545 Ddc NM_031022 Cspg4 NM_138871 Tdrd7 
NM_001011900 Tssk1 NM_012587 Ibsp NM_031024 Dbn1 NM_138879 Sele 
NM_001011914 Dr1 NM_012588 Igfbp3 NM_031123 Stc1 NM_138886 Ick 
NM_001011941 Cdc37l1 NM_012589 Il6 NM_031139 Usf2 NM_138891 Gpr149 
NM_001011944 Slc37a1 NM_012604 Myh3 NM_031351 Atrn NM_139040 RGD621098 
NM_001011947 Rai14 NM_012607 Nefh NM_031541 Scarb1 NM_139097 Scn3b 
NM_001011971 XRG4 NM_012619 Pah NM_031561 LOC685953 NM_139190 Calcoco1 
NM_001011974 Akap2 NM_012651 Slc4a1 NM_031563 Ybx1 NM_139256 Man2c1 
NM_001011985 Mknk2 NM_012652 Slc9a1 NM_031597 Kcnq3 NM_139324 Ehd4 
NM_001012000 Plscr4 NM_012655 Sp1 NM_031601 Cacna1g NM_144748 LOC246263 
NM_001012010 Rhot1_predicted NM_012663 Vamp2 NM_031633 Foxm1 NM_144754 Cant1 
NM_001012015 Lamp3 NM_012699 Dnajb9 NM_031656 Stx8 NM_145767 Prrxl1 
NM_001012066 Sphk2 NM_012700 Stx1b2 NM_031657 Gprk6 NM_145774 Rab38 
NM_001012092 Xkr7 NM_012708 Psmb9 NM_031659 Tgm1 NM_145782 Cyp3a18 
NM_001012116 Spag1 NM_012724 Fcer1a NM_031665 Stx6 NM_147135 Sbk1 
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NM_001012147 Pxn NM_012765 Htr2c NM_031678 Per2 NM_147205 St6gal1 
NM_001012148 Ankrd13 NM_012781 Arnt2 NM_031685 Gosr2 NM_147215 Obp3 
NM_001012169 Zfp143 NM_012812 Cox6a2 NM_031696 Gpr88 NM_153297 Cops2 
NM_001012238 RGD1311980 NM_012815 Gclc NM_031705 Dpys NM_153310 St18 
NM_001012464 Terf1 NM_012843 Emp1 NM_031722 Tmed2 NM_153467 Gsbs 
NM_001012473 Polr2c NM_012864 Mmp7 NM_031729 Ppp5c NM_153629 Hspa4 
NM_001013033 Tspyl NM_012866 Nfyc NM_031730 Kcnd2 NM_153728 Soat2 
NM_001013040 Ptpn9 NM_012887 Tmpo NM_031743 Slc24a2 NM_153735 Nptx1 
NM_001013066 Sipa1l3 NM_012909 Aqp2 NM_031772 Rpo1-4 NM_153814 Cacna1h 
NM_001013082 Pon2 NM_012922 Casp3 NM_031785 Atp6ap1 NM_172019 Ifi47 
NM_001013084 Akr1b10 NM_012941 Cyp51 NM_031786 Trim3 NM_172045 Ppp1r14b 
NM_001013094 Ccnl2 NM_012942 Cyp7a1 NM_031795 Ugcg NM_172047 Eaf2 
NM_001013161 Cstf1 NM_012950 F2r NM_031798 Slc12a2 NM_172066 Slc30a4 
NM_001013171 Gulp1 NM_012983 Myo1d NM_031802 Gabbr2 NM_172157 Arid1b 
NM_001013172 Fhl4 NM_013026 Sdc1 NM_031821 Plk2 NM_172223 Pxmp4 
NM_001013192 Olfml1 NM_013037 Il1rl1 NM_031976 Prkab1 NM_172243 Ppif 
NM_001013196 Dnajc4 NM_013045 Tnr NM_031979 Csda NM_172321 Slc6a15 
NM_001013209 Dnajb6 NM_013049 Tnfrsf4 NM_032061 Cntnap1 NM_172328 Tac4 
NM_001013218 Reep6 NM_013051 Scgb1a1 NM_032067 Ralbp1 NM_173096 Mx1 
NM_001013224 Nmnat3 NM_013065 Ppp1cb NM_032077 Pon1 NM_173098 Slc9a4 
NM_001013228 Tcte1l NM_013081 Ptk2 NM_032614 Txnl2 NM_173130 LOC286914 
NM_001013907 LOC294513 NM_013102 Fkbp1a NM_032617 Rab11b NM_173141 Tfpi2 
NM_001013933 Ube2a NM_013113 Atp1b1 NM_033096 Ppm1b NM_173300 Olr1271 
NM_001013956 RGD1309049 NM_013127 Cd38 NM_033442 Gata2 NM_173328 Lgr4 
NM_001013980 LOC304138 NM_013131 Nr3c2 NM_052804 Fmr1 NM_173339 Ceacam10 
NM_001013992 LOC305691 NM_013133 Glra1 NM_053293 Gstt1 NM_175578 Dscr1l1 
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NM_001013994 Rcor2 NM_013159 Ide NM_053297 Pkm2 NM_175758 Slc1a5 
NM_001014011 Gramd3 NM_013179 Hcrt NM_053301 Hfe NM_177927 Serpinf1 
NM_001014045 RGD1311463 NM_013192 Kcnj6 NM_053343 Dclk1 NM_178093 Mtus1 
NM_001014064 Pars2 NM_017006 G6pdx NM_053356 Col1a2 NM_178102 Mapkapk2 
NM_001014073 RGD1305486 NM_017011 Grm1 NM_053358 Ssbp3 NM_178106 Entpd3 
NM_001014075 RGD1311648 NM_017025 Ldha NM_053394 Klf5 NM_178866 Igf1 
NM_001014082 Ncln NM_017029 Nef3 NM_053421 Arid4b NM_178866 Igf1 
NM_001014094 LOC315883 NM_017031 Pde4b NM_053427 Slc17a6 NM_181090 Slc38a2 
NM_001014109 LOC317379 NM_017044 Pth NM_053429 Fgfr3 NM_181626 Hbld2 
NM_001014122 Mif4gd NM_017066 Ptn NM_053455 Fgl2 NM_181631 Fbxo11 
NM_001014126 RGD1306410 NM_017067 Chm NM_053457 Cldn11 NM_181633 Gpr151 
NM_001014130 RGD1309106 NM_017097 Ctsc NM_053458 Rab9 NM_181636 Col23a1 
NM_001014133 LOC360910 NM_017116 Capn2 NM_053502 Abcg1 NM_182817 Smagp 
NM_001014149 RGD1305276 NM_017127 Chka NM_053503 Jub NM_183056 Lyk4 
NM_001014172 Rsrc1 NM_017131 Casq2 NM_053521 Slc5a7 NM_183326 Gabra1 
NM_001014175 LOC500378 NM_017156 CP2BC_RAT NM_053530 Twist1 NM_184051 Prkag2 
NM_001014177 LOC362056 NM_017159 Hal NM_053536 Klf15 NM_198735 Art2b 
NM_001014185 LOC362264 NM_017226 Padi2 NM_053549 Dnajc4 NM_198760 Slc16a6 
NM_001014190 RGD1307218 NM_017238 Vipr2 NM_053557 Hrmt1l3 NM_198771 Fam3c 
NM_001014231 RGD1308513 NM_017259 Btg2 NM_053577 SPP24_RAT NM_198779 RGD735140 
NM_001014245 RGD1305441 NM_017261 Gria2 NM_053591 Dpep1 NM_198783 Hrpap20 
NM_001014275 Tceal8 NM_017263 Gria4 NM_053603 Clic5 NM_198972 Gkn1 
NM_001015020 Tgif NM_017288 Scn1b NM_053610 Prdx5 NM_199237 Fshr 
NM_001015025 Stk38 NM_017290 Atp2a2 NM_053633 Egr2 NM_199267 Rela 
NM_001017485 LOC498145 NM_017298 Cacna1d_v3 NM_053650 Pdlim3 NM_199407 Unc5c 
NM_001017498 LOC498350 NM_017305 Gclm NM_053722 Clasp2 NM_199409 Panx2 
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NM_001024252 Pcaf NM_017336 Ptpro NM_053733 Bcl2l10 NM_199502 Chrdl1 
NM_001024252 Pcaf NM_017348 Slc6a8 NM_053736 Casp4 NM_201560 RGD1303142 
NM_001024252 Pcaf NM_019146 Bsn NM_053738 Wif1 NM_203334 Slc6a5 
NM_001024262 RGD1305424 NM_019147 Jag1 NM_053750 Nppc NM_203336 Esrrg 
NM_001024275 Rassf4 NM_019155 Cav3 NM_053769 Dusp1 NM_207586 Chia 
NM_001024278 LOC367171 NM_019157 Aqp7 NM_053779 Serpini1 NM_207595 Ankra2 
NM_001024296 LOC499418 NM_019194 Tef NM_053801 Sec14l2 NM_207603 Fcgr3a 
NM_001024305 LOC499691 NM_019207 Neurod3 NM_053805 Snai1 NM_207610 Ube4a 
NM_001024316 LOC499951 NM_019218 Neurod1 NM_053806 Kcnk6 NM_212498 RGD1303066 
NM_001024349 LOC500598 NM_019219 Rbbp9 NM_019221 Trp63 NM_212504 Hspa1b 
NM_001024355 LOC500909       
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